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Abstract 
Deficiency in fukutin-related protein (FKRP) or fukutin results in aberrant 
glycosylation of -dystroglycan, a key receptor for basement membrane proteins.  
There is a broad spectrum of disorders associated with FKRP and fukutin deficiency, 
ranging from limb-girdle muscular dystrophy to congenital disorders such as muscle 
eye brain disease and Walker-Warburg syndrome (WWS).  fkrp and fukutin were 
knocked down in the zebrafish with antisense morpholino oligonucleotides (MO).  
The fkrp, fukutin and dystroglycan MOs each produced a spectrum of comparable 
phenotypes.  With each MO producing a comparable morphant phenotype on 
morphological examination, it was hypothesised that inferences could be made 
about similarities and differences in the fkrp, fukutin dystroglycan axis during 
zebrafish development.  The morphants had abnormal muscle fibres, including 
disruptions of the vertical myosepta and sarcolemma.  Disorganised retinal layering 
in the eyes was found in both fukutin and fkrp morphants.  Dysplasia of the lens was 
observed in most fukutin morphants and some of the fkrp morphants with a severe 
phenotype.  Structural changes in basement membranes at 1-3 days post fertilisation 
(dpf) were investigated.  The perturbation observed across the inner limiting 
membranes may account for the lens dysplasia.  Cell density of the granular 
epithelium in the photoreceptor cell layer was found to be lower in both morphants 
with the least density in fukutin knock-downs, which may result from a disruption of 
the external limiting membrane.  This leads to the conclusion that fkrp and fukutin 
are essential for membrane integrity in the eye and muscle of developing zebrafish.  
A transgenic zebrafish line expressing enhanced green fluorescent protein (EGFP) in 
vascular endothelium from the fli-1 promoter was used to investigate early 
vascularisation.  In all morphants, including dystroglycan knock downs, the 
intersegmental vessels failed to reach the dorsal longitudinal anastomotic vessel at 
1dpf.  Additionally, in the fkrp and fukutin morphant the eye vasculature was 
abnormal.  Interestingly, no change was observed in the eye vasculature of the 
dystroglycan morphants suggesting that fkrp and fukutin may modify proteins other 
than α-dystroglycan in the eye.   
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1.1 Muscular Dystrophy 
The muscular dystrophies (MDs) are a heterogeneous group of inherited 
conditions characterised by progressive muscle weakness and wasting (Walton 
and Nattrass, 1954; Bushby, 1994).  The latter occurs as a consequence of 
degeneration, fatty infiltration and fibrosis of muscle tissue (Bushby, 1994; 
Kornegay et al., 2012).  Duchenne muscular dystrophy (DMD) is one of the 
most common forms of MD and in spite of better standards of care over recent 
times, it remains associated with a bleak prognosis with most patients dying in 
their early twenties due to cardio-respiratory complications (Sejerson and 
Bushby, 2009; Kuru, 2011; Kwon et al., 2012).  Nevertheless, there have 
recently been promising developments in new therapies such as exon skipping 
which is currently being trialled in several centres including Newcastle (Mann et 
al., 2001; Kinali et al., 2009; Foster et al., 2012).  One would hope that similar 
therapies will become available in other forms of MD, including the 
dystroglycanopathies, which like most MDs remain without treatment (Godfrey 
et al., 2011; Kuga et al., 2011; Muntoni et al., 2011).  The aim of this thesis is to 
gain a better insight into MD by investigating the pathology associated with 
dystroglycanopathy in zebrafish models (Bassett and Currie, 2003; Guyon et al., 
2003; Bassett and Currie, 2004; Guyon et al., 2007).  
It was hypothesised that by knocking down the secondary dystroglycanopathy 
genes fkrp fukutin and comparing to primary dystroglycanopathy, as modelled 
by dystroglycan knockdown, the function of these genes with respect to the 
primary function of dystroglycan could be delineated. 
1.1.1 Duchenne Muscular Dystrophy  
DMD is an X-linked recessive disorder, affecting 1/3600 male births (Cowan et 
al., 1980).  Frame shifting or nonsense mutations in the DMD gene (Hoffman et 
al., 1987) on the X-chromosome p21.2-21.1 result in absence of dystrophin 
expression and a DMD phenotype (OMIM: 310200), however mutations which 
preserve the open reading frame result in partial protein expression and a 
milder form of disease, Becker muscular dystrophy BMD (OMIM: 300376) 
(Nicholson et al., 1993).  DMD is named after the neurologist Guillaume 
Duchenne de Boulogne who was the first clinician to accurately describe the 
disease in a case report, in the 1861 edition of his book “Paraplegie 
hypertrophique de l'enfance de cause cerebrale” (Semmola, 1834; Conte G, 
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1836; Emery, 1993).  DMD is still characterised clinically based on these early 
descriptions that include progressive proximal weakness, pseudo-hypertrophy 
of the calves and elevated serum creatine kinase (CK) levels, a marker of 
skeletal and cardiac muscle breakdown (Bach, 2000; Manzur and Muntoni, 
2009). 
1.1.2 Limb Girdle Muscular Dystrophy (LGMD) 
Before genetic testing became available, myopathies were classified based on 
their clinical presentation (Broglio et al., 2010; Rocha and Hoffman, 2010).  The 
LGMDs were delineated from facioscapulohumeral muscular dystrophy (FSHD), 
myotonic dystrophy and metabolic myopathies based on the distinct proximal 
wasting and weakness observed around the shoulder and hip girdles (Walton 
and Nattrass, 1954; Deufel and Gerbitz, 1991; Reifer and Sobel, 1998; Tawil 
and Van Der Maarel, 2006).  Within the LGMD subgroup, there is a wide range 
of variation in terms of disease onset and progression (Rocha and Hoffman, 
2010).  LGMDs are classified into autosomal dominant (type 1) or recessive 
(type 2) forms, the former being much rarer (Walton and Nattrass, 1954).  There 
are at least eight forms of dominant LGMD, for some of which the gene has not 
yet been identified (Rocha and Hoffman, 2010; Kaplan, 2011; Reilich et al., 
2011).  Sixteen forms of autosomal recessive LGMD have been identified to 
date (Kaplan, 2011).  Mutations in FKRP and fukutin both have been associated 
with autosomal recessive limb-girdle forms (Table 1.1).  The sequence in which 
the disorders appear in the alphabetical list is based on the order in which they 
were discovered (Bushby, 2009; Kaplan, 2011).  
1.1.3 Congenital Muscular Dystrophy (CMD) 
Since infants born with hypotonia and weakness could have any one of a 
number of conditions, a muscle biopsy is helpful in reaching a diagnosis of CMD 
(Bertini et al., 2011).  CMD is differentiated from the clinically similar conditions 
such as the congenital myopathies by higher serum CK levels and evidence of 
degeneration/regeneration cycles in the myofibres, whereas the congenital 
myopathies have developmental defects in myofibre formation (North, 2011; 
Sparks and Escolar, 2011; Nance et al., 2012).  A final molecular diagnosis is 
important for refining the particular subtype of CMD.  All of the CMDs have an 
autosomal recessive pattern of inheritance and can be divided into three groups: 
disorders of post translational modification of α-dystroglycan (secondary 
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dystroglycanopathies), abnormality of endoplasmic reticulum proteins and 
disorders of the basal lamina (Mendell et al., 2006; Rocha and Hoffman, 2010). 
Protein  Gene 
Symbol 
Gene 
Location 
Disease IH OMIM Reference 
Cytoskeletal Proteins 
Dystrophin DMD Xp21.2 DMD 
BMD 
XR 
XR 
300377 
300376 
(Monaco et al., 1986) 
Basement Membrane Receptors 
Dystroglycan DAG1 3p21.31 LGMD AR 128239 (Hara et al., 2011) 
Integrin ITAG7 12q13.2 CMD AR 600536 (Mayer et al., 1997) 
Dystroglycan Post Translational Modifiers  
Fukutin FKTN 9q31 FCMD 
LGMD2M 
AR 
AR 
253800 
607440 
(Toda et al., 1993) 
(Godfrey et al., 2006) 
FKRP FKRP 19q13.3 LGMD2I 
MDC1C 
 
 
MEB 
WWS 
AR 
AR 
 
 
AR 
AR 
607155 
606612 
 
 
253280 
236670 
(Brockington et al., 
2001b) 
(Brockington et al., 
2001a) 
(Mercuri et al., 2006) 
POMT1 POMT1 9q34.1 WWS 
 
LGMD2K 
AR 
 
AR 
236670 
 
609308 
(Beltran-Valero de 
Bernabe et al., 2002) 
(Balci et al., 2005) 
POMT2 POMT2 14q24.3 WWS 
MEB 
AR 
AR 
236670 
253280 
(van Reeuwijk et al., 
2005) 
(Mercuri et al., 2006) 
POMGnT1 POMGn
T1 
1p34-p33 MEB AR 253280 (Hehr et al., 2007) 
LARGE LARGE 22q12-q13 MDC1D AR 608840 (Longman et al., 2003) 
ISPD ISPD 7p21.2 WWS AR 614631 (Roscioli et al., 2012; 
Willer et al., 2012) 
Extracellular Matrix Proteins 
Laminin LAMA2 6q22 MDC1A AR 156225 (Patton et al., 2008) 
 Table 1.1: Dystroglycan associated proteins and the diseases associated 
with mutations in the genes  
The table is divided into mutations in proteins of the cytoskeleton, basement membrane 
receptors, modifiers of dystroglycan post translational processing and extracellular 
matrix proteins, all of which have been associated with MD.  The table gives the protein, 
its gene symbol, genomic location, disease, mode of inheritance: (IH, AR: autosomal 
recessive, XR: X-linked recessive), OMIM and a reference describing the clinical 
phenotype.  DMD and BMD account for ~10% each of MD in the Northern Region of 
the United Kingdom with a prevalence of ~7-8/100,000.  There has only been one case 
in the world with a mutation in the DAG1 gene (Hara et al., 2011).  In the Northern 
region ~6%, 2.5/100,000 of patients were diagnosed with LGMD of total MD in the 
region interestingly 19% were diagnosed with LGMD2I.  2%, 0.8/100,000 of the 
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population in the North East with MD had CMD and the majority of these patients were 
diagnosed with MDC1A 1.6% 0.6/100,000 (Norwood et al., 2009).  
1.2 Dystrophin 
The disease causing gene in DMD was localized to Xp21 by genetic linkage 
analysis and cytologically through manifesting females with balanced 
translocations (Davies et al., 1983; Aldridge et al., 1984; Brown et al., 1985; 
Francke et al., 1985; Boyd and Buckle, 1986).  Subsequently, the DMD gene 
was identified from cloned cDNA (Monaco et al., 1985), the protein product was 
isolated shortly after by Hoffman et al. (Monaco et al., 1986; Hoffman et al., 
1987).  Campbell and Kahl purified a dystrophin associated membrane bound 
glycoprotein known today as dystroglycan and together the discovery of the two 
proteins allowed rapid progress in the field of MD, (Campbell and Kahl, 1989; 
Ervasti and Campbell, 1991).  These discoveries and subsequent 
characterisation of the dystrophin-associated glycoprotein complex (DGC) 
forms the basis of our current understanding of MD (Sciandra et al., 2003; 
Gumerson and Michele, 2011).  Dystrophin is a predominantly hydrophilic, rod 
shaped protein consisting of 3684 amino acids, with a molecular weight (MW) of 
427kDa and an approximate length of 150nm (Hoffman et al., 1987; Pons et al., 
1990).  The protein can be split into four domains: the actin binding domain at 
the N-terminus, the rod domain, the cysteine rich domain and the carboxy 
terminal domain (Koenig and Kunkel, 1990; Winder et al., 1995; Rybakova et al., 
1996; Sadoulet-Puccio et al., 1997; Norwood et al., 2000; Harper et al., 2002; 
Bohm and Roberts, 2009; Le Rumeur et al., 2010).   
While screening a batch of C57BL/10ScSn mice the spontaneously occurring 
mdx mouse was identified, initially studied as a biochemical variant at the PK 
locus (Bulfield et al., 1984).  Elevated pyruvate kinase and raised serum CK 
indicated the mice had muscle necrosis analogous to DMD patients (Banks and 
Chamberlain, 2008).  Breeding experiments showed an X-linked segregation.  
The mdx mouse carries a point mutation in exon 23 of the Dmd gene and is an 
effective null for dystrophin protein expression at birth (De la Porte et al., 1999).  
A feature of the model is that exon 23 is prone to skipping and over time many 
fibres revert, similar to the revertant fibres found in humans (Thanh et al., 1995; 
Yokota et al., 2006).  Utrophin upregulation, differences in mouse immune 
systems when compared to humans and longer telomerase length in mice, also 
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all account for the diminished phenotype severity compared to human DMD 
(Brockdorff et al., 1987; Kipling, 1997; Gillis, 2000). 
1.3 The Dystrophin Associated Glycoprotein Complex 
(DGC) 
Dystrophin forms an integral part of a stable protein complex at the muscle cell 
membrane: the dystrophin-associated glycoprotein complex (DGC; Haenggi 
and Fritschy, 2006).  The main function of the DGC in muscle is to form a link 
between cytoskeletal actin and laminin in the extracellular matrix (ECM; Ervasti 
and Campbell, 1991; Lapidos et al., 2004; Figure 1.1).  The DGC is essential for 
stabilising the sarcolemma i.e. the plasma membrane that encloses a muscle 
fibre, during muscle contraction (Ibraghimov-Beskrovnaya et al., 1992; Petrof et 
al., 1993).  Dystrophin binds to the actin cytoskeleton and to β-dystroglycan at 
the sarcolemma (Jung et al., 1995; Ishikawa-Sakurai et al., 2004).  
Dystroglycan spans the sarcolemma, anchoring the DGC complex to the 
muscle specific basement membrane and acts as a linker between internal and 
external components.  Dystroglycan stabilises the sarcoglycan complex within 
the sarcolemma (Lim and Campbell, 1998; Crosbie et al., 1999; Durbeej et al., 
2000).  In healthy muscle correctly glycosylated α-dystroglycan binds laminin-α2 
and various other ligands such as agrin, neurexin and perlecan (Noonan et al., 
1991; Campanelli et al., 1994; Gee et al., 1994; Sugiyama et al., 1994; Denzer 
et al., 1997; Hohenester et al., 1999; Sugita et al., 2001; Michele et al., 2002).  
Other intracellular components of the DGC include the syntrophins and 
dystrobrevin (Froehner et al., 1997; Sadoulet-Puccio et al., 1997; Adams et al., 
2004; Fuentes-Mera et al., 2006; Bohm and Roberts, 2009; Figure 1.1).  
Dystrophin and the DGC are also associated with nitric oxide synthase (nNOS; 
Crosbie, 2001).  Nitric oxide synthase catalyzes the synthesis of the potent 
signalling molecule nitric oxide from L-arginine (Thomas et al., 2003; Kobayashi 
et al., 2008).  Elevation of local calcium levels leads to calmodulin binding NOS 
and NO synthesis (Walsh, 1994).  NO has been shown to be important in 
muscle for metabolism, inflammation, vasodilatation and contractility (Reid, 
1998; Wang et al., 2001). 
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Figure 1.1: Schematic representation of the DGC  
Depicts dystroglycan and integrin interaction with ligands both within the DGC and the 
ECM.  The DGC forms a link between intracellular F-actin and laminin-211 in the 
extracellular matrix.  The black circles on dystroglycan represent the O-glycosylated 
mucin domain of α-dstroglycan and the black branched structures represent N-
glycosylation sitses also found on the sarcoglycans and β-dystroglycan (Cohn and 
Campbell, 2000; Barresi and Campbell, 2005).  
1.3.1 Dystroglycan 
Dystroglycan is the central component of the DGC (Ervasti and Campbell, 1991; 
Figure 1.1).  The dystroglycan gene (DAG1) on chromosome 9p21 has two 
exons split by a large intronic segment which contain an 895 codon open 
reading frame encoding both alpha and beta peptides (Ibraghimov-Beskrovnaya 
et al., 1993; Gorecki et al., 1994).  The propeptide is translated from a single 
mRNA and proteolytically cleaved into the core protein of the heavily 
glycosylated extracellular α-dystroglycan and the transmembrane β-
dystroglycan (Ibraghimov-Beskrovnaya et al., 1992; Holt et al., 2000).  After 
post translational cleavage of the precursor polypeptide the two subunits are 
independently targeted to either the plasma membrane or the extracellular 
space respectively, where they re-assemble into a complex held together by a 
relatively weak non-covalent interaction (Bozzi et al., 2006).  Mutating the 
cleavage site inhibits post-translational processing leading to dystrophic 
changes in a mouse model (Jayasinha et al., 2003).  
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The β-dystroglycan PPXY motif interacts with the WW domains of dystrophin 
(Rentschler et al., 1999).  Extracellularly the central O-glycosylated mucin 
domain of α-dystroglycan binds the LG domain of the extra-cellular matrix (ECM) 
protein laminin, linking the ECM to the intracellular cytoskeleton of the skeletal 
muscle syncytium (Figure 1.1; Jung et al., 1995).  α-Dystroglycan is extensively 
post-translationally modified by O- and N- linked glycosylation (Brancaccio et al., 
1995; Brancaccio et al., 1997) in the Golgi complex.  The glycosylation state of 
α-dystroglycan is tissue specific and variable, resulting in a range of α-
dystroglycan glycoforms, differing in molecular weight and glycan composition 
(Moukhles et al., 2000; McDearmon et al., 2001).  The first major glycoform 
(cranin) was identified in brain and has a molecular mass of 120kDa 
(Smalheiser and Schwartz, 1987).  In skeletal muscle the major glycoform is 
36kDa larger than that found in brain as a result of tissue specific O-
glycosylation (Ibraghimov-Beskrovnaya et al., 1993; Barresi and Campbell, 
2005). 
1.3.2 Glycosylation 
In eukaryotes many cellular proteins and almost all extracellular proteins are 
post-translationally modified to contain glycans (Spiro, 2002; Moremen et al., 
2012).  These carbohydrate moieties can have widely diverse functions, from 
altering protein stability and conformation to defining molecular recognition 
(Endo, 1999).  Glycosylation is generally considered to be the most complex 
post translational modification because of the large number of steps in the 
process, usually requiring a number of enzymes (Spiro, 1973).  The enzymes 
which drive glycosylation are segregated into different compartments including 
the rough endoplasmic reticulum, cristernae of the Golgi apparatus, cytoplasm 
and nucleus (Opat et al., 2001; Spiro, 2002).   
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Figure 1.2:  Schematic of the five types of sugar-peptide bond 
The schematic highlights how different types of glycosylation, O-glycosylation, N-
glycoslation phosphor-glycosylation, C-linked glycosylation and glypiation can produce 
a range glycotopes at the first glycosylation event, (Spiro, 2002).   
Sugar chains are classified into one of two major classes, O-glycans and N-
glycans.  There are three other less relevant classes of glycans: phosphor-
glycans, C-linked glycans and glypiation which will not be discussed here (Spiro, 
2002; Figure 1.2).  O-glycans are attached to the hydroxyl group of serine, 
threonine, tyrosine, hydroxylysine or hydroxyproline residues.  N-linked glycans 
attach to the amine group of asparagine or arginine residues.  O-linked 
glycosylation occurs predominantly in the Golgi whereas N-linked glycosylation 
occurs with greatest frequency in the lumen of the endoplasmic reticulum (ER) 
(Schwarz and Aebi, 2011; Stalnaker et al., 2011).  The secondary 
dystroglycanopathy genes are all involved in the O-glycosylation of α-
dystroglycan are found in the ER (POMT1, POMT2) and the Golgi (POMTGnT1, 
fukutin, FKRP and LARGE; Takada et al., 1988; Esapa et al., 2002; Brockington 
et al., 2005; Keramaris-Vrantsis et al., 2007; Goder and Melero, 2011; Lynch et 
al., 2012; Figure 1.3).  
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Figure 1.3: Cellular localisation of secondary dystroglycanopathy proteins 
and how they relate to the glycosylation of α-dystroglycan 
As α-dystroglycan moves through the ER and Golgi complex glycans are bound to form 
the classical glycan tetramer of the mucin domain.  The POMT1 and POMT2 complex 
mannosylate α-dystroglycan and glucose is bound by POMGnT1 to the mannose.  It is 
currently unknown which glycosyltransferases are responsible for the final two 
glycosylation events, (Manya et al., 2004; Barresi and Campbell, 2005).  
N-linked glycosylation and the O-mannosylation of α-dystroglycan always 
requires the participation of the lipid dolichol phosphate (Burda and Aebi, 1999).  
Dolichol-phosphate-mannose (DPM) is synthesised by DPM synthase (DPM1) 
catalysing a reaction between guanosine diphosphate mannose (GDP-man) 
and dolichol phosphate on the cytosolic side of the ER lumen (Richards and 
Hemming, 1972; Maeda and Kinoshita, 2008; Figure 1.4).  Putative flippase 
machinery presumably translocates DPM onto the luminal side of the ER (Rush 
and Waechter, 1995).  DPM is subsequently utilized as a donor substrate by the 
POMT1 and POM2 complex for the O-mannosylation of α-dystroglycan (Kim et 
al., 2004; Manya et al., 2004).   
Interestingly, there is a reported case of CMD that results in both N-linked and 
O-linked glycosylation deficiencies of dystroglycan, caused by a missense 
mutation (p.L85S) in the highly conserved coiled-coil domain of the DPM3 gene 
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(Lefeber et al., 2009).  DPM3 is anchored to the ER membrane via this coiled-
coil domain and is important for tethering cytoplasmic DPM1to the DPM 
complex.  The associated hypomannosylation of α-dystroglycan results in 
laminin-211 failing to bind to α-dystroglycan, providing an explanation for the 
CMD phenotype in the patient (Lefeber et al., 2009). 
 
Figure 1.4: Schematic of the O-mannosylation of α-dystroglycan 
For mannose to be incorporated into α-dystroglycan it must be bound cytosolically to 
the lipid dolichol phosphate and the DPM synthase complex first.  Putative flippases 
transport DPM into the ER lumen and the POMT complex binds the mannose to α-
dystroglycan (Manya et al., 2004; Lefeber et al., 2009).  N.B.  It is unclear at present 
whether the α and β dystroglycan subunits are cleaved before or after the initial 
mannosylation of α-dystroglycan.   
1.3.3 α-Dystroglycan Structure 
Under an electron microscope -dystroglycan appears as a 20-30nm long 
dumbbell shaped molecule, the N-terminus being the wider end (Bozic et al., 
2004).  α-Dystroglycan can be divided into four regions, a signal peptide, the N-
terminus, the central mucin domain, and the C-terminus (Hall et al., 2003; 
Figure 1.5).  The first domain is a signal peptide made up from the first 29 
amino acids of the propeptide, is principally hydrophobic and targets the alpha 
peptide to the Golgi complex (Barresi and Campbell, 2005; York and Nunberg, 
2006).  The 30kDa N-terminus of α-dystroglycan has one potential N-
glycosylation site and the C- terminus has two N-glycosylation sites (Holt et al., 
2000).   
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α-Dystroglycan is heavily O-mannosylated with high abundance of the 
uncommon Neu5Ac(α2-3)Gal(β1-4)GlcNAc(β1-2)Man-Ser/Thr tetramer (Chiba 
et al., 1997; Sasaki et al., 1998).  O-glycosylation accounts for the mass 
differences between dystroglycan in skeletal muscle and other tissues 
(Yoshida-Moriguchi et al., 2010; Kuga et al., 2012a).  The final 41kDa and 242 
amino acids of the dystroglycan propeptide is β-dystroglycan containing only 
one N-glycosylation site (Brancaccio et al., 1995; Brancaccio et al., 1997).  
 
Figure 1.5:  Dystroglycan domain organization.  
Circles indicate O-linked sugar chains.  Branches indicate N-linked sugar chains.  SP, 
signal peptide; TM, transmembrane domain; The PPxY motif within the ZZ domain is 
the site where dystrophin binding occurs.  Molecular masses at the bottom refer to the 
protein mass in the absence (core protein) and presence of post-translational 
glycosylation, adapted from Barresi and Campbell, 2005. 
1.3.4 Deglycosylation of Dystroglycan 
Glycosylation of α-dystroglycan is fundamental for binding important 
extracellular matrix proteins.  If the N-linked glycans are removed using N-
glycanases there is no impact on the ligand binding activity of dystroglycan.  
Conversely O-sialoglycopeptidase, which deglycosylates α-dystroglycan’s O-
linked glycans, completely abolishes the ligand binding activity.  This indicates 
that the O-linked glycosylation sites are essential for the role of α-dystroglycan 
as an extracellular matrix receptor (Ervasti and Campbell, 1993).  The accurate 
glycosylation of α-dystroglycan is important for the Ca2+ dependant binding of 
ligands such as laminin, perlecan or agrin in muscle and neurexin in nerves 
(Campanelli et al., 1994; Gee et al., 1994; Sugiyama et al., 1994; Sasaki et al., 
1998; Sugita et al., 2001).  All the ligands that bind the O-mannosylated mucin 
domain of α-dystroglycan, do so through a conserved laminin-G (LG) like 
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domain (Timpl et al., 2000).  The O-glycans on α-dystroglycan are necessary to 
bind LG domains (Hohenester et al., 1999; Tisi et al., 2000). There is a report of 
a small leucine-rich repeat proteoglycan known as biglycan that binds N-linked 
glycosylation site in the carboxy-terminal of α-dystroglycan (Bowe et al., 2000).   
1.3.5 The Functional Diversity of Dystroglycan 
Dystroglycan has diverse roles from cell signalling to supporting the architecture 
of the cell nucleus (Johnson and Kramer, 2012).  This raises the question: 
where does the functional diversity in dystroglycan arise from?  As mentioned 
earlier the two dystroglycan subunits are targeted independently to the 
sarcolemma (Ibraghimov-Beskrovnaya et al., 1992; Holt et al., 2000).  In vitro 
studies found that at the sarcolemma the two dystroglycan subunits are held 
together by relatively weak non-covalent interactions (Bozzi et al., 2006).  
However it remains unclear what advantage lies in separating the two subunits: 
one possibility is that the separation is important for post translational 
modification of each subunit individually (Bozzi et al., 2009).  The ectodomain of 
β-dystroglycan demonstrates plasticity which enables the protein to establish 
low affinity interactions and thus change its conformation (Bozzi et al., 2003; 
Yatsenko et al., 2007).  β-Dystroglycan is known to bind several signalling 
molecules, including mitogen-activated protein kinase, caveolin-3 and growth 
factor receptor bound protein-2 (Spence et al., 2004).  The functional diversity in 
dystroglycan may therefore be possible through a combination of 
conformational plasticity in the ectodomain of β-dystroglycan and differences in 
α-dystroglycan glycosylation patterns afforded by independently processing the 
subunits (Bozzi et al., 2009). 
1.3.6 Dystroglycan as a Bacterial and Viral Receptor 
The O-glycan sugar residues, in particular the O-mannosyl sugars on α-
dystroglycan, act as receptors for bacteria and viruses, such as Lassa fever 
virus and lymphocytic choriomeningitis virus (Cao et al., 1998; Rambukkana et 
al., 1998; Imperiali et al., 2005).  Mycobacterium leprae uses α-dystroglycan 
bound to laminin-211 as a co-factor to infect Schwann cells (Kunz et al., 2005).  
There is also mounting evidence that it is not the O-mannosyl glycans on α-
dystroglycan but the glycosylation by LARGE of α-dystroglycan that is required 
as a recognition site prior to arena-viruses prior to infection (Rojek et al., 2007).  
It is possible that an element of functional redundancy in the post-translational 
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modification of the α-dystroglycan mucin domain that affords a selective 
advantage against viruses and bacteria.  Small changes in α-dystroglycan O-
glycosylation may maintain binding with ECM ligands but prevent parasitic 
invasion (Herson et al., 2012). 
1.3.7 Integrins 
Patients with a congenital myopathy have been identified with either deletions 
resulting in frameshift mutations or a 21-bp insertion caused by a splice site 
mutation in the integrin-α7 (ITAG7) gene (Vachon et al., 1997; Mayer, 2003).  
The homozygous integrin-α7 null mouse shows progressive MD soon after birth.  
The MD associated pathology is variable amongst muscle groups, with the 
soleus and diaphragm affected to the greatest extent.  The key change 
observed on histopathology is impaired myotendinous junction (MTJ; Mayer et 
al., 1997). 
Integrins are a major family of cell surface receptors, which influence the 
development of skeletal muscle by transducing signals through muscle cell 
contact with the ECM and cell-cell interactions (Figure 1.1; Tuckwell et al., 1993; 
Boettiger, 2012).  Integrins occupy a similar position in the sarcolemma to 
dystroglycan and may have overlapping roles (Ribeiro et al., 2011).  Integrins 
are heterodimeric proteins which are comprised of α and β subunits, non-
covalently bound in a divalent cation dependant process (Hynes, 1992).  There 
are approximately 24 combinations of integrin dimers (to date,18α and 8β 
subunits have been identified) which form various combinations of subunit 
associations (van der Flier and Sonnenberg, 2001).  Splice variants however 
account for an even greater diversity in integrin structure (Nishiuchi et al., 2006).  
α-Integrins have shorter intracellular and longer extracellular portions of their 
transmembrane structure, while the β-subunit has the opposite configuration 
(Fu et al., 2012).  The specificity of integrins to ligands is determined 
predominantly by the α-chain (Mayer, 2003).  
Integrins are important for focal contacts at the neuromuscular junction (NMJ), 
MTJ and the sarcolemmal membrane (Schwander et al., 2004; Welser et al., 
2009).  α4, β1 or β7 subunits are expressed to the greatest extent during 
development and in adult skeletal muscle the most important integrin interaction 
is between laminin-211and integrin-α7 (Belkin and Stepp, 2000; Bajanca and 
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Thorsteinsdottir, 2002).  Integrins are dynamically expressed dependant on 
stage of development (Burkin and Kaufman, 1999; Carson and Wei, 2000).  
Intracellular filamin and talin bind integrin, forming a link between the ECM and 
the intracellular cytoskeleton (Calderwood et al., 2001; Moore et al., 2012a).  
The interaction between integrins and the ECM has been shown to be important 
for influencing intracellular signalling (Nieves et al., 2010).  
1.4 Extracellular Matrix 
Muscle ECM forms a small fraction of total muscle mass in comparison to 
contractile material, but has a large influence on muscle function.  For instance 
it is thought that the ECM bears most of the passive load i.e. any force on 
relaxed muscle (Trotter, 1993).  Stiffness and reduced limb motion on clinical 
examination might therefore reflect a disruption to ECM functionality.  With any 
pathological change in muscle there will also be at least a small associated 
degree of excess ECM deposition, a hallmark of fibrosis (Mann et al., 2011).  
There are three main subdivisions of ECM in muscle: endomysium, perimysium 
and epimysium (Purslow, 2010).  The endomysium is a highly ordered network 
surrounding individual muscle fibres (Trotter and Purslow, 1992).  The ability of 
the endomysium to bear weight results from its capacity to elastically deform in 
a nonlinear fashion as the muscle fibre relaxes (Trotter, 1993; Purslow and 
Trotter, 1994) while mechanical strength comes from the geometry of the 
collagen fibres.  The perimysium surrounds bundles of fibres.  The perimysial 
collagen filaments are arranged in dense transverse and longitudinal bands 
connecting muscle fibres at discrete perimysial plates (Rowe, 1981).  The 
epimysial layer surrounds the muscle and is continuous with tendons.  A similar 
“crimp” pattern is seen on scanning electron microscopy (SEM) in muscle and 
tendons (Jarvinen et al., 2002).  This is not surprising considering the 
epimysium fuses with tendon to insert into the bone (Gillies and Lieber, 2011).  
1.4.1 Laminins 
Mutations in the LAMA2 gene result in congenital muscular dystrophy 1A 
(MDC1A; Kuang et al., 1998).  Similar to the patients, the spontaneous Lama2 
dy/dy mouse model presents with peripheral neuropathy and MD (Xu et al., 
1994).  The MD is as a result of a failure of laminin to form the basement 
membrane scaffolds necessary for supporting the DGC (Xu et al., 1994; 
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Miyagoe-Suzuki et al., 2000).  Evans blue dye (EBD) can be used as an in vivo 
tracer and an assay for sarcolemmal stability with a discoloration of skeletal 
muscle indicating a damaged sarcolemma.  In normal muscle EBD is unable to 
cross the sarcolemma following intraperitoneal injection, and is therefore not 
detected in the sarcoplasm on muscle sections (Lin et al., 2011).  EBD has 
been injected into the mdx mouse, a mouse model for DMD, and the dy/dy 
mouse model of MDC1A.  EBD uptake is a frequent finding in the mdx mouse 
but not the dy/dy mouse.  This indicates that dystrophin deficiency is associated 
with sarcolemmal instability while laminin-α2 deficiency is not (Straub et al., 
1997).  In another study disorganisation of the costameric lattice was found in 
the dy2J mouse, a variant of the dy/dy mouse with a splice site mutation, 
whereas longitudinal striations and M-line defects were observed in the mdx 
mouse (Yurchenco and Cheng, 1994).  Together the findings suggest that there 
is a different mechanism for pathology in MD associated with dystrophin 
mutations compared to those associated with deficiencies in LAMA2.   
Laminin is a heterotrimeric protein consisting of a heavy α-chain and two lighter 
chains (β & γ), capable of binding three major receptor types: dystroglycan, 
heparin sulphate based proteoglycans and integrins (Durbeej, 2010).  The 
hetrotrimer is joined by the coiled-coil domains of the three individual 
polypeptide chains.  The α-unit extends beyond the coil-coiled domain to form 
the laminin globular (LG) domain and is composed of five self folding repeats 
(LG domains 1-5).  The calcium containing LG4 and LG5 domains bind the N-
terminus of skeletal muscle α-dystroglycan (Bork et al., 1996; Brancaccio et al., 
1997; Timpl et al., 2000).  Laminin can be subdivided into fifteen types in 
mammals consisting of different combinations of the 5α, 3β and 3γ chains 
(Koch et al., 1999).  Laminin-111 (old nomenclature; laminin-α1, β1, γ1) is the 
isoform expressed during embryogenesis, whereas laminin-211 (merosin or old 
nomenclature; laminin-α2, β1, γ1) is the type found in mature skeletal muscle 
(Aumailley et al., 2005).   
1.4.2 Basement Membranes 
Basement membranes (BM) are specialised ECM, visible on electron 
microscopy as 50-100nm electron dense sheets found basolaterally to 
epithelium, endothelium and muscle fibres.  The main functions of BMs are to 
provide structural support and influence cell behaviour.  The four major 
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components of BM’s are laminin, collagen IV, perlecan and nidogen/enactin 
(Noonan et al., 1991; Olsen, 1999; Nicole et al., 2000; Poschl et al., 2004; 
Kohling et al., 2006).  Laminins and collagens both self assemble into super 
structures held together by perlecan, nidogen and enactin, strengthening and 
stabilising the BM (Yurchenco and Patton, 2009).  Heterogeneity and specificity 
of BMs arise from various combinations of laminin chains, agrin, fibulin, type XV 
collagen, type XVIII collagen as well as many other proteins (Prockop and 
Kivirikko, 1995; Denzer et al., 1997; Xie et al., 2008).  The specific composition 
of BMs in various tissues relates to their unique functions (LeBleu et al., 2007).   
1.5 Dystroglycanopathy 
1.5.1 Primary Dystroglycanopathy 
The first homozygous missense mutation (Thr192/Met) in the DAG1 gene was 
reported in a woman with LGMD and cognitive impairment (Hara et al., 2011).  
In vivo and in vitro studies demonstrated that the missense mutation caused 
loss of post-translational modification of dystroglycan by LARGE, which 
prevented laminin binding and reduced receptor function (Zhang et al., 2011).  
Despite a spectrum of mutations found across numerous other genes that 
cause secondary dystroglycanopathy with various pathogenic mechanisms 
(Hara et al., 2011), this is so far the only mutation to be identified in the highly 
conserved DAG1 gene (Hewitt, 2009; Godfrey et al., 2011; Muntoni et al., 2011).  
1.5.2  Secondary Dystroglycanopathies 
Aberrant glycosylation of dystroglycan is associated with several forms of MD, 
ranging from mild limb girdle MD to severe congenital forms (Figure 1.6; 
Yoshioka and Kuroki, 1994).  The hypoglycosylation of α-dystroglycan can 
result from mutations in one of at least seven genes.  These genes encode 
known O-linked glycosyltransferases, xylosyltransferases, glucuronyltransferase 
or phosphorylation proteins.  These proteins are: Protein O-mannosyl 
transferase (POMT)1, POMT2, protein O-mannose β1,2-N-
acetylglucosaminyltransferase ( POMGnT1), acetylglucosaminyltransferase-
like-protein (LARGE), fukutin, fukutin related protein (FKRP) and the recently 
identified isoprenoid synthase domain (ISPD), see (Table 1.1) for further details.   
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Primary defects in this enzymatic pathway have also provided insights into the 
role of known or putative glycosyltransferases.  The first sugar residue to be 
added to the carbohydrate moiety on α-dystroglycan is an O-mannose-glycan 
catalysed by POMT1.  This mannose residue is bound to the core of α-
dystroglycan by POMT2 which works in a complex with POMT1 (Manya et al., 
2004).  POMTGnT1 then adds the second sugar residue N-acetylglucosamine 
through a β1,2 linkage to the mannose group using uridine 5´-diphosphate N-
acetylglucosamine as a donor substrate (Zhang et al., 2002).  The final two 
sugar residues on the tetrasaccharide are galactose and sialic acid, but the 
nature of the glycosyltransferases responsible for adding them remains 
unknown (Barresi and Campbell, 2005; Figure 1.3).  LARGE has recently been 
shown to be a bifunctional glycosyltransferase with both xylosyltransferase and 
glucuronyltransferase activity responsible for transferring repeating units of [-3-
xylose-α1,3-glucuronic acid-β1-] onto α-dystroglycan (Inamori et al., 2012), and 
plays a role in the phosphorylation of mannose residues on α-dystroglycan 
(Yoshida-Moriguchi et al., 2010; Kuga et al., 2012a).  The exact role LARGE, 
POMTGnT1, FKRP and fukutin play in phosphorylation of mannose remains 
unclear.  Interestingly, overexpression of LARGE reinstates laminin binding 
activity to α-dystroglycan when dystroglycan is in a hypoglycosylated state 
(Barresi et al., 2004; Kuga et al., 2012a).  There is always a loss or reduction of 
immunoreactivity of IIH6 in patient cells with mutations in any of the secondary 
dystroglycanopathy genes and diminished bands on western blots.  Tests that 
utilise IIH6 antibody are therefore invaluable in the diagnosis of 
dystroglycanopathy. 
1.5.3 Fukutin 
Fukuyama congenital muscular dystrophy (FCMD; OMIM: 253800) was first 
reported in Japanese patients in 1960 (Toda and Kobayashi, 1999).  In the 
Japanese population 87% of FCMD can be accounted for by an ancestral 
retrotransposon insertion of a SINE-VNTR-Alu in the 3´ UTR untranslated 
region of exon 10 in the FKTN gene, on chromosome 9q31-33 (Toda et al., 
1993; Kobayashi et al., 1998; Colombo et al., 2000; Taniguchi-Ikeda et al., 
2011).  The result is a reduction in the expression levels of FKTN mRNA.  
FCMD affects cardiac, skeletal muscle, eye and brain (Toda and Kobayashi, 
1999).  FCMD often presents in infancy with hypotonia, weakness and mental 
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retardation (Fukuyama et al., 1981; Toda, 2009).  Homozygous nonsense 
mutations and compound heterozygotes, i.e. patients with the common insertion 
and a missense mutation, are often associated with more severe CMDs such as 
muscle eye brain disease (MEB; OMIM: 253280) and Walker-Warburg 
syndrome (WWS; OMIM: 236670; de Bernabe et al., 2003; Vuillaumier-Barrot et 
al., 2009).  A milder allelic variant was found outside the Japanese population 
which presented with a LGMD-like phenotype and was termed LGMD2M (OMIM: 
607440; Toda and Kobayashi, 1999; Godfrey et al., 2006). 
The human fukutin protein is 461 amino acids long (53.7kDa) and encoded for 
by a 10 exon, 6.8kb transcript located on chromosome 9q31 (Aravind and 
Koonin, 1999; Breton and Imberty, 1999).  In the human adult FKTN mRNA 
expression levels are highest in the brain, liver and kidney with lower 
expression levels in skeletal muscle and heart (Esapa et al., 2002).  Fukutin 
localises to the medial Golgi of normal rat kidney fibroblasts, a finding which is 
consistent with its hypothesised role in the glycosylation of α-dystroglycan.  
Towards the C-terminus there is a DXD domain which is present in a large 
number of glycosyltransferases, supporting the hypothesis that fukutin is 
involved in glycosylation.  Also supporting this hypothesis is the resemblance of 
fukutin to RP688, a member of the Fringe family of proteins, known to function 
as glycosyltransferases in the intracellular parasitic bacterium R.prowazekii and 
T07D3.4, T07A5.1 proteins in C.elegans (Aravind and Koonin, 1999).  
Interestingly, a yeast protein involved in phosphorylation of mannose residues 
also belongs to the fukutin family of proteins (Aravind and Koonin, 1999).  
Recently fukutin has been shown to be important in the post-phosphoryl 
modification of mannose residues on α-dystroglycan (Kuga et al., 2012a).  
1.5.4 Fukutin Related Protein 
The first mutations in the FKRP gene were identified in congenital muscular 
dystrophy type 1C (MDC1C; OMIM: 606612) and LGMD2I patients (OMIM: 
607155; Brockington et al., 2001a; Brockington et al., 2001b; Brockington et al., 
2002).  LGMD2I is a condition on the less severe end of the spectrum which 
predominantly affects the shoulder and hip girdles (Figure 1.6).  LGMD2I is 
frequently caused by a homozygous or compound heterozygous missense 
mutation in the FKRP gene (826 C>A; L276I), prevalent in the Northern 
European population (with an estimated allele frequency of 1:400), as a result of 
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a founder effect (Brockington et al., 2001b; Frosk et al., 2005).  Nonsense 
mutations in the same gene produce conditions at the more severe end of the 
spectrum such as MEB and WWS.  WWS is thought to be the most severe of 
the CMDs and patients with this condition rarely survive longer than a year (Van 
Reeuwijk et al., 2010; Figure 1.6).  WWS is defined clinically by agenesis of the 
corpus callosum, cobble stone lissencephaly, cerebellar hypoplasia and 
structural eye defects (Mercuri et al., 2003; Muntoni and Voit, 2004; Mercuri et 
al., 2006).  
Fukutin Related Protein was first identified by distant homology to fukutin using 
database search tools and shown to be responsible for congenital muscular 
dystrophy (CMD) with hypoglycosylated α-dystroglycan (Aravind and Koonin, 
1999; Breton and Imberty, 1999; Brockington et al., 2001a).  The 12kb FKRP 
gene located on chromosome 19q13.32, has three non-coding exons and a 
single 3.8kb coding exon, with a 1485bp open reading frame.  FKRP encodes a 
495 amino acid protein that contains a catalytic domain, a DXD motif and a type 
II transmembrane domain frequently associated with Golgi proteins (Aravind 
and Koonin, 1999; Esapa et al., 2002; Keramaris-Vrantsis et al., 2007).  A LicD 
domain resides within the catalytic domain and is thought to be important for 
phosphorylcholine metabolism (Zhang et al., 1999).  Early evidence pointed to 
FKRP functioning as a glycosyltransferase, although recent work would suggest 
that FKRP, similar to fukutin, is involved in the post-phosphoryl modification of 
the mannose residue on α-dystroglycan (Kuga et al., 2012a).  Northern blot 
analysis revealed the highest expression levels of the FKRP transcript in adult 
heart and skeletal muscle with lower expression levels observed in brain, lung, 
pancreas, kidney and liver (Brockington et al., 2001a; Brockington et al., 2001b; 
Brockington et al., 2002; Esapa et al., 2002).    
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Figure 1.6: Common mutations in FKRP with associated severity of 
clinical phenotype; a genotype-phenotype correlation 
A, Representation of FKRP protein, position of mutations along the peptide, LicD 
domain (Pfam domain PF04991) important in proteins involved in phosphorylcholine 
metabolism.  Mutations at the signal peptide (SP) prevent FKRP being targeted 
correctly to the Golgi (Esapa et al., 2002).  B, Mutations linked to clinical severity 
ranging from LGMD2I to WWS, including representative patient photographs kindly 
donated by Professor Volker Straub, (Van Reeuwijk et al., 2010).  The patient on the 
left demonstrates that LGMD2I patients can be of considerable age whereas the 
MDC1C patient (middle) is a lot younger and would in most cases have a lower life 
expectancy while the CMD patient on the right is much younger. There is an inverse 
relationship with disease severity, with the lefthand patient being less severely affected 
despite being older, while the right-hand patient is most severely affected despite being 
the youngest.  Note the patient on the left has muscle wasting particularly around the 
hip girdle, the middle patient has signs of pseudo-hypertrophy of the limb girdles and 
finally the patient on the right is clearly very disabled. Out of the three the right hand 
patient is the only one who is non-ambulant, and note that this patient also displays 
visual impairment.     
1.6 DGC Mouse Models 
Over recent years many mouse models that mimic the CMDs associated with 
dystroglycanopathy have been described in the literature (Hewitt, 2009; Godfrey 
et al., 2011).  The DGC mouse literature is too large to cover in great detail here, 
therefore the most important mouse models for our discussion are described 
and discussed below (Durbeej and Campbell, 2002).  A summary of other 
relevant models is provided in Table 1.2, the table highlights some of the key 
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features of the models, for instance the dystroglycanopathy phenotype of 
muscle, eye and brain involvement is limited to the secondary 
dystroglycanopathy mice (Kelly et al., 1994; Grewal et al., 2001; Takeda et al., 
2003; Liu et al., 2006; Ackroyd et al., 2009; Ackroyd et al., 2011).  Because of 
the difficulty in generating viable dystroglycan deficient mice, often only one 
feature of the primary dystroglycanopathy such as muscle weakness or brain 
abnormalities is modelled in any given mouse strain using tissue specific 
promoters, with the exception of the MORE-DG null mouse which has features 
analogous to each aspect of MEB disease (Williamson et al., 1997; Cote et al., 
1999; Cohn et al., 2002; Moore et al., 2002; Satz et al., 2008; Satz et al., 2009).  
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Mouse Gene Protein Phenotype Reference 
Cytoskeletal Proteins 
mdx* Dmd Dystrophin MD (Bulfield et al., 1984) 
mdc3CV Dmd Dystrophin MD (Cox et al., 1993) 
Transmembrane Proteins 
Dag1-/- Dag1 DG  EL (Williamson et al., 
1997) 
Dag1-/- SM 
chimera 
Dag1 DG skeletal 
muscle 
MD (Cote et al., 1999) 
Dag1-/-MCK/cre Dag1 DG skeletal 
muscle 
MD (Cohn et al., 2002) 
Dag1-/- GFAP/cre Dag1 DG brain ND (Moore et al., 2002) 
Dag1-/- MORE  Dag1 DG epiblast MD,ND, RLD (Satz et al., 2008) 
Dag1-/- Nestin/cre Dag1 DG eye RLD (Satz et al., 2009) 
Itag7-/- Itag7 Integrin MD (Mayer et al., 1997) 
Secondary Dystroglycanopathy Proteins 
FkrpKD Fkrp FKRP MD, RLD, ND (Ackroyd et al., 2009; 
Ackroyd et al., 2011) 
Fcmd-/- Fktn Fukutin EL (Kurahashi et al., 
2005) 
Fcmd-/- chimera** Fktn Fukutin MD, ND, RLD (Takeda et al., 2003) 
Fcmd-/hp Fktn Fukutin MD (not 
severe) 
(Kanagawa et al., 
2009a; Taniguchi-
Ikeda et al., 2011) 
myd* Large LARGE MD, ND, RLD (Grewal et al., 2001) 
enr* Large LARGE MD, ND, RLD (Kelly et al., 1994) 
Pomt-/- Pomt1 POMT1 EL (Willer et al., 2004) 
Pomgnt1-/- Pomgnt1 POMTGnT1 MD, ND , RLD (Liu et al., 2006) 
ECM Proteins 
dy/dy* Lama2 Laminin-α2 MD, PN (Sunada et al., 1994) 
Dy2J* Lama2 Laminin-α2 MD (Straub and Campbell, 
1997) 
Table 1.2: Overview of DGC Mouse models  
Mouse models of DGC components including cytoskeletal, transmembrane, secondary 
dystroglycanopathy, ECM proteins.  MD: muscular dystrophy, EL: embryonic lethal, 
RLD: retinal layering defect, ND: neuronal migration defect, PN: peripheral neuropathy, 
DG: dystroglycan, * spontaneously occurring mouse model, ** high percentage chimera.    
1.6.1 Reichert’s Membrane and the Dystroglycan Null Mouse 
Divergent morphology is first observed from embryonic day E6.5 in the 
dystroglycan null Dag1neo2 mouse (Williamson et al., 1997).  By E7.5 the Dag1-
null mice begin to show signs of developmental failure, with indistinct features 
and smaller size in comparison to their normal litter mates.  By E10.5 the 
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embryos are largely resorbed with only a small embryonic mass still visible.  At 
E5.5, the cylinder stage, the gross morphology was similar between Dag1-null 
and wild type embryos with one noticeable exception, the presence of red blood 
cells in the yolk sac cavity in approximately a quarter of the Dag1-null mice.  
Therefore red blood cells were able to cross a perturbed Reichert’s membrane, 
which normally functions as a barrier between the maternal blood and the yolk 
sac in the Dag1-null mice (Inoue et al., 1983).  ECM proteins laminin and 
collagen IV were found to be abnormally distributed at the membrane in Dag1-
null mice (Hogan et al., 1980; Smith and Strickland, 1981; Salamat et al., 1993).  
Parietal endoderm cells were able to differentiate normally, indicating that the 
disruption of Reichert’s membrane is the primary pathological event in these 
mice during the early stages of development (Salamat et al., 1995).  A toxic 
effect is hypothesised to cause the early embryonic lethality, since loss of 
Reichert’s membrane structure and function exposes the uterine environment to 
maternal blood (Hogan et al., 1984; Williamson et al., 1997).   
1.6.2 DG Skeletal Muscle Chimera  
The embryonic lethality observed in the Dag1-null mice limited the utility of null 
alleles at this locus and therefore tissue specific strategies for interrupting this 
gene have been adopted (Williamson et al., 1997).  Targeting vectors were 
used to disrupt the Dag1 gene in embryonic stem cells (Cote et al., 1999; 
Kornegay et al., 2012).  On ultrastructural analysis the mice were found to have 
normal sarcolemma, however on histological analysis all the hall marks of MD 
including central nucleation and phagocytosis were found (Gumerson and 
Michele, 2011; Kornegay et al., 2012).  Immunohistological analysis found 
reduced expression of the sarcoglycan complex, while laminin-α2 had a normal 
expression pattern.  The myoneural synapses did not form correctly in the DG 
skeletal muscle chimera mouse, a finding not recapitulated in dystrophin or 
utrophin deficient mice, and a similar finding was observed in dystroglycan 
deficient Drosophila (Deconinck et al., 1997; Grady et al., 1997; Cote et al., 
1999; Bogdanik et al., 2008).  
 Another muscle specific dystroglycan model the MCK-DG-null mouse has a 
similar phenotype to the DG skeletal muscle chimera mouse (Cohn et al., 2002).  
Interestingly, dystroglycan expression was found to be almost completely 
absent from about 4 weeks, however after ten weeks dystroglycan was re-
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expressed.  The targeting strategy did not remove dystroglycan from the stem 
cell niche and therefore by a process of regeneration the mouse muscle was 
able to acquire dystroglycan positive cells.  If the animals were exposed to18 
and 25 Gy of irradiation inactivating the satellite cells the mice had complete 
absence of dystroglycan at the sarcolemma which persisted for 10 weeks and 
also developed a severe dystrophic phenotype (Cohn et al., 2002).  
1.6.3 MORE DG Null Mouse 
The MORE-DG null mouse was designed to delete dystroglycan from the 
epiblast only, thereby bypassing the pathology associated with loss of 
dystroglycan from Reichert’s membrane (Williamson et al., 1997).  To create the 
MORE-DG null mouse, a mouse carrying a floxed Dag1 allele was crossed with 
the Mox2-Cre mouse expressing Cre recombinase specifically in the epiblast 
(Tallquist and Soriano, 2000; Cohn et al., 2002).  The principal aim was to 
recapitulate the WWS phenotype found in patients (Kanoff et al., 1998) since 
previous models had been proven to be unsuitable for this purpose (Williamson 
et al., 1997; Cote et al., 1999; Cohn et al., 2002; Moore et al., 2002).  The 
MORE-DG null mice were all found to have muscle, brain and eye pathology 
with disrupted basement membranes (Cohn et al., 2002; Satz et al., 2008).  
Microphthalmia is most commonly bilateral in WWS patients, with unilateral 
phenotypes reported in less than 10% of the total cohort and a similar ratio is 
found in the MORE-DG null mouse (Kanoff et al., 1998; Satz et al., 2008).  In 
WWS patients the eye problems are associated with lens and iris tissue 
herniation through the cornea.  The mice were frequently missing lenses and, 
Descemet’s membrane a BM lying between the stroma and the epithelial layer 
of the cornea, was also found to be disrupted with a periodic acid Schiff stain.  
Hematoxylin and eosin (H&E) stained sections highlighted abnormal 
neuroepithelium and ectopic cells internal to the inner limiting membrane (ILM).  
When laminin expression at the ILM was investigated a discontinuous pattern 
was found, indicating discontinuity of the ILM itself maybe providing a 
mechanism by which ectopic cells appear in the anterior chamber (Satz et al., 
2008).  These abnormalities are consistent with findings in WWS and therefore 
the MORE-DG null mouse is a good model for investigating early eye pathology 
analogous to that found in WWS (Yoshioka and Kuroki, 1994; Kanoff et al., 
1998; Beltran-Valero de Bernabe et al., 2002; Balci et al., 2005).  
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1.6.4 Nestin-Cre/DG Null Mouse 
The majority of MORE-DG null mice die two days after birth before the eye can 
fully develop (Satz et al., 2008).  An alternative dystroglycan deficient mouse 
model, for the purpose of investigating eye function is therefore required.  
Floxed dystroglycan mice were crossed with mice containing rat nestin 
enhancer that controls the expression of Cre recombinase to produce the 
Nestin-Cre/DG null mouse (Satz et al., 2009).  The Nestin-Cre transgene is 
useful for deleting particular genes from the retina as early as E9.5.  
Dystroglycan was found to be absent in corneal endothelium, lens, iris, ciliary 
epithelia and the retina in the Nestin-Cre/DG null mice.  ILM disruption in the 
Nestin-Cre/DG null mice was shown to lead to a reduction in the number of 
retinal ganglion cells.  Interestingly, staining of core DGC components at the 
ILM lead to the conclusion that dystroglycan is required early on in development 
but possibly not for later maintenance of the ILM.  The Nestin-Cre/DG null 
mouse had impaired performance when attempting visual tasks such as water-
maze and visual cliff tests.  Interestingly, removing the last 15 amino acids of 
the β-dystroglycan tail affects the physiology of the retina similarly.  The 
implication is the last 15 amino acids of β-dystroglycan may have a role to play 
in targeting dystroglycan to specific locations within the retina (Satz et al., 2009).  
1.6.5  FKRP Mutant Mice 
The FKRPTyr307Asn mouse had no discernible phenotype (Ackroyd et al., 2009),  
which highlights differences between humans and mice, since in the same 
substitution at the homologous amino acid in the human FKRP gene is known 
to cause MEB disease (Beltran-Valero de Bernabe et al., 2004; Mercuri et al., 
2006; Sveen et al., 2006).  Maintenance of the neomycin cassette in intron 2 of 
the mouse (FKRP-NeoTyr307Asn) reduced Fkrp transcript levels to 80% of wild 
type.  The nomenclature for the FKRP-NeoTyr307Asn has subsequently been 
simplified to FKRPKD mouse (Ackroyd et al., 2011), a mouse that dies shortly 
after birth with a classic MEB phenotype.  Muscle fibre density was reduced in 
the gastrocnemius and soleus muscles with oedematous infiltration.  The mice 
had virtually absent IIH6 and laminin-α2 expression in muscles.  The 
abnormalities in the eye included microphthalmia and perturbations in both 
retinal layering and inner limiting membrane (ILM), as indicated by ectopic 
nuclei in the vitreous humor.  Reductions in laminin-γ1 and perlecan staining at 
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the ILM in Fkrp deficient mice confirmed BM pathology.  Dystroglycan 
expression as determined by GT20 antibody was present in both wild type and 
Fkrp deficient mice.  In the brain reduced IIH6 and laminin-α2 staining was 
associated with aberrant pial layering and disorganised radial glia with glial end 
feet not correctly attaching to the pial BM (Ackroyd et al., 2009; Ackroyd et al., 
2011).   
Subsequent studies showed abnormal laminin-α1 deposition under the pial BM.  
This is significant because it is the end feet of the radial glia which attach to the 
laminin-α1 and aberrantly positioned glia don’t project correctly across the 
cortex, therefore providing a possible mechanism for the disruption to radial glia 
scaffolds and loss of cortex partitioning (Ackroyd et al., 2011).  A similar 
process occurs in the eye with abnormal deposition of the laminin-α1 and 
γ1chains in the eye at the ILM.  The result is aberrant binding of the Müller glia 
with the inner limiting membrane (Halfter et al., 2005).  These findings suggest 
alternative modes of action of Fkrp in the brain and eye when compared to 
muscle.  It is clear that Fkrp is important for maintenance of an α-dystroglycan 
laminin-α2 interaction in muscle whereas in eye and brain laminin-111 seems to 
interact with an unknown ligand as the key interaction for stabilizing cells to 
basement membranes (Ackroyd et al., 2009; Satz et al., 2009).  A critical finding 
was the developmental stage dependant regulation of Fkrp transcripts.  Higher 
expression in brain when compared to muscle in the newborn mouse was an 
interesting finding since muscle is often considered to be the major pathological 
change in FKRP deficiency (Ackroyd et al., 2009; Ackroyd et al., 2011).  
1.6.6 Fukutin Chimera Mouse 
Since the Fukutin null mouse was found to be embryonically lethal (Kurahashi 
et al., 2005), a chimera was sought to overcome the problems associated with 
perturbations to Reichert’s membrane.  Vectors were used that targeted both 
alleles of the Fktn gene in ES cells and replaced exon 2 with a neomycin or 
puromycin resistance gene (Horie et al., 2002).  The extent of the chimerism 
was tested by glucose phosphate isomerase isozyme and related well to the 
coat colour in the fukutin chimeras (Takeda et al., 2003).  Premature death in 
the mice corresponded with the extent of chimerism: only 48% of highly 
chimeric but 94% of low chimeric mice survived to 21 months.  Non-progressive 
muscle abnormalities, as determined by behaviour were first observed at one 
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month of age.  Chimeric mice clasped when suspended by the tail and had an 
abnormal gait.  Muscle fibres of the chimeras were necrotic, with mononuclear 
cell infiltration, increased interstitial connective tissue and basophilic 
regenerating fibres at 1 month after birth.  Glycosylated α-dystroglycan was 
greatly reduced at the sarcolemma while β-dystroglycan and laminin-α2 were 
normally localised.  Immunoblotting confirmed the findings and laminin overlay 
showed a reduced binding affinity between α-dystroglycan and laminin-α2 
(Takeda et al., 2003). 
Disorganization of the laminar structures in the cerebral and cerebellar cortices 
as well as the hippocampus was observed in the brain of the fukutin deficient 
chimeric mouse (Takeda et al., 2003).  Over migration in the monolayer (layer I) 
and of the cortical neurons resulted in the normal six layer structure appearing 
unordered in the chimeric mice.  Laminin immunostaining revealed meningeal 
basement membrane abnormalities in the chimeric mice including perturbations 
and granular deposits.  However, not all basement membranes were disturbed, 
including that of the parenchyma that surrounds blood vessels in the brain.  
Loss of b-wave on electroretinography demonstrated eye anomalies in the 
fukutin deficient mice.  The corneas were opaque as result of granular tissue, 
inflammation and degeneration with vascular infiltration.  Lens abnormalities, 
eyeball formation anomalies including detached retina and loss of the laminar 
structure were also observed in these mice (Takeda et al., 2003).   
1.6.7 Fukutin Retrotransposon Mouse 
There was an attempt to generate a mouse that better represented patients with 
FCMD.  First Fktn exon 10 in mouse ES cells was replaced with exon 10 
containing the retrotransposon insertion analogous to that found in FCMD 
patients (Colombo et al., 2000; Taniguchi-Ikeda et al., 2011), and targeted ES 
cells were injected into mouse blastocysts.  The fukutin hp/hp had FKTN 
transcript levels 5-10% of normal levels.  These animals were then mated with 
the fukutin-null mouse to create a compound heterozygote fukutinhp/- that better 
represents the compound heterozygote patients, who generally show the most 
severe pathology (Vuillaumier-Barrot et al., 2009).  Despite hypoglycosylation of 
α-dystroglycan in these mouse models the MD pathology is mild.  Leading to 
the conclusion that a small amount of residual fukutin prevents MD in these 
fukutin deficient mice (Kanagawa et al., 2009a; Taniguchi-Ikeda et al., 2011).  
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1.6.8 Mouse Model Summary 
The dystroglycanopathy mouse models are often embryonically lethal and 
infertile whereas knockout mice models of other DGC components, often with 
secondary defects to other proteins within the DGC, are frequently viable and 
fertile (Durbeej and Campbell, 2002).  The mouse models highlight the critical 
importance of correctly glycosylated dystroglycan in mouse development.  As a 
consequence of the hypoglycosylation of α-dystroglcan and subsequent loss of 
ligand binding much of the early embryonic lethality is attributable to 
perturbations in the basement membranes particularly Reichert’s membrane 
(Williamson et al., 1997; Willer et al., 2004; Kurahashi et al., 2005).  Despite 
strategies that attempt to either bypass the early embryonic development (Cote 
et al., 1999; Cohn et al., 2002; Moore et al., 2002; Satz et al., 2008; Satz et al., 
2009), or models that directly relate to human mutations (Ackroyd et al., 2009; 
Kanagawa et al., 2009a), no individual mouse model is comprehensive in 
modelling every aspect of human dystroglycanopathy, leading the field to look 
towards other model systems (Hewitt, 2009; Godfrey et al., 2011).   
1.7 The zebrafish as a Model for MD 
1.7.1 Danio rerio 
The zebrafish (Danio rerio) is a small freshwater tropical fish becoming an 
increasingly popular model in the field of biological research (Parichy, 2006).  
There are several reasons for the increasing popularity of zebrafish in research 
such as their quick generation time, relatively low maintenance costs, optically 
transparent embryos, ease of gene manipulation and their regenerative 
potential.  The optical transparency and ex-utero development are particularly 
advantageous features for developmental biologists due to ease of access for 
imaging studies (Kimmel et al., 1995).  These properties are also increasingly 
being adopted in high throughput pipelines for drug discovery (Lessman, 2011).  
Importantly there is good coverage of the zebrafish genome.  One major 
drawback of the zebrafish is that many of the genes are duplicated as a result of 
an ancestral genomic duplication event (Westerfield, 2000).  
Importantly, zebrafish do not require Reichert’s membrane for normal 
development.  Zebrafish therefore bypass the embryonic lethality seen in mice 
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associated with deficiencies in dystroglycan, making a case for zebrafish as a 
model in secondary dystroglycanopathy research (Parsons et al., 2002a).  
1.7.2 Zebrafish in Muscle Research 
Recently FKRP and fukutin have been knocked down in zebrafish to study their 
importance in early embryonic development (Thornhill et al., 2008; Kawahara et 
al., 2010; Lin et al., 2011; Wood et al., 2011b).  Zebrafish show precocious 
locomotor development, i.e. there is force generated by the muscles even 
before 1 day post fertilisation (dpf), since the embryos can be seen moving 
within the chorions (Bassett and Currie, 2003; Dowling et al., 2009).  The 
somites are axial muscles that develop from segmented axial mesoderm and 
eventually give rise to the myotome i.e. zebrafish skeletal muscle.  The muscle 
fibres differentiate along the anterior–posterior axis to span an entire somite.  
The distinctive somite chevron seen by 1 dpf is separated dorsally and ventrally 
by a myoseptum which is essentially extracellular matrix (Bassett and Currie, 
2004; Moore et al., 2008). 
The sapje fish illustrates some of the key benefits and limitations of working with 
zebrafish.  The sapje fish is a model for DMD and has a nonsense mutation in 
exon 3 of the zebrafish dmd gene (Parsons et al., 2002a).  There is muscle 
degeneration in the sapje fish because the myofibres fail to adhere to the MTJ 
i.e. in adult fish where muscle is joined to tendon and during development 
where muscle joins myoseptum (Law and Tidball, 1993; Ridge et al., 1994; Law 
et al., 1995; Snobl et al., 1998; Bassett et al., 2003).  Zebrafish are excellent 
model systems for investigating both congenital disorders and more importantly 
for DMD research studies looking at early pathological changes in disease.  
Using zebrafish for initial drug screens with findings validated in mammalian 
systems may prove to be a useful complementary strategy to develop therapies 
for DMD (Tanabe et al., 1986; Lessman, 2011).  There is an argument therefore 
for being selective in choice of animal model, based on their purpose and being 
prepared to alternate between model systems when appropriate. 
Several systems have proved to have great utility for modelling a single aspect 
of dystroglycanopathy.  Drosophila are one example, with mutations in the rt 
and tw genes which are homologues of POMT1 and POMT2 respectively 
having effects on embryonic muscle development and alignment of the adult 
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cuticle (Martin-Blanco and Garcia-Bellido, 1996).  Drosophila, despite being 
used extensively to study the eye during development, lacks the basement 
membranes within the eye and is therefore less suitable as a model than 
zebrafish, which have analogous eye basement membranes to humans 
(Thornhill et al., 2008; Paulk et al., 2012).  Simarly Caenorhabditis elegans have 
been useful in MD for pathway discovery, particularly muscle specific pathways, 
however the system lacks the brain and eye basement membranes present in 
zebrafish (Chamberlain and Benian, 2000; Gupta et al., 2011).  Cellular 
systems such as patient cell lines or the mouse C2C12 line, have long since 
been useful models in MD research for: localisation studies, first principle 
development such as testing novel therapies and to test new antibodies  
(Favreau et al., 2008; Negroni et al., 2011; Lynch et al., 2012).  None of these 
systems have the complexities of the muscle, eye and brain including the 
basement membranes required to study dystroglycanopathy from a holistic 
perspective.  Zebrafish have all the facets important for studying 
dystroglycanopathy, combined with all the advantages of zebrafish over murine 
models.  Zebrafish are therefore an ideal model system to undertake research 
into FKRP and fukutin deficiency.        
1.7.3 Somatogenesis 
Somatogenesis is a complex process, starting as early as the onset of 
gastrulation.  However before any muscle progenitors are seen, the embryo 
undergoes a reorganisation of cells in the blastodisc, occurring during the 
blastula stage of development.  In the process of epiboly at 4 hpf cells 
intercalate by radial rearrangement, thinning the blastoderm by spreading over 
the egg (Solnica-Krezel, 2005).  The blastoderm coverage of the yolk sack 
relates to a percentage that can be used to stage the embryo (i.e. % epiboly).  
The first signs of muscle progenitors are seen as early as 51/4 hpf at the onset of 
gastrulation (synonymous with 50% epiboly; Table 1.3 & Figure 1.7A).  At this 
stage the different territories for specific organs are not clearly demarcated and 
progenitors are intermingled (Figure 1.7B; Kimmel et al., 1990).  At 5 hpf the 
cells at the margins begin to internalize forming the hypoblast, the precursor of 
endoderm and mesoderm.  During the gastrulation process blastocyst self 
reorganization transforms the endoderm and mesoderm layers into a tri-laminar 
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structure: mesoderm, ectoderm and endoderm, (Figure 1.7B-C; Kimmel et al., 
1995; Shih and Fraser, 1996; Saude et al., 2000; Schier and Talbot, 2005).  
Shield cells are the equivalent in zebrafish of organizer cells in amphibians or 
Hensen’s node cells in chick (Stickney et al., 2000).  The shield (thickening of 
epiblast and hypoblast at the animal pole) establishes at approximately 6 hpf on 
the dorsal side of the embryo and gives rise to the notochord and prechondral 
plate.  The paraxial mesoderm, formed from the cells around the margins of the 
early gastrula, is important for notochord development.  The axial mesoderm is 
derived from the shield and the paraxial mesoderm.  However it is the 
convergence of the paraxial mesoderm cells in the midline that forms the 
notochord, contributing to the anterior posterior extension of the embryo.  The 
notochord precursor cells during this stage of development begin to express 
signalling molecules such as sonic hedgehog (Holley and Nusslein-Volhard, 
2000), influencing the patterning of the paraxial mesoderm (Kimmel et al., 1990; 
Kimmel et al., 1995; Schier and Talbot, 2005).  
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Stage hpf Description 
Blastula    
Sphere 
Dome 
30% epiboly 
4 
41/3 
42/3 
Straight border between yolk and blastodisc. 
Beginning of epiboly yolk bulges towards animal pole. 
The blastoderm even thickness situated 30% between the 
animal and the vegetal pole.  
Gastrulation   
50% epiboly 
 
 
Germ- Ring 
 
Shield 
 
75%-epiboly 
 
 
90%-epiboly 
 
 
Bud 
51/4 
 
 
52/3 
 
6 
 
8 
 
 
9 
 
 
10 
The blastoderm even thickness situated 50% between the 
animal and the vegetal pole. 
 
50% epiboly; Germ ring visible at animal pole. 
 
50% epiboly; Shield becomes visible at animal pole. 
 
Thickening of dorsal side, hypoblast, epiblast and 
evacuation zone all become visible. 
 
Segmental plate distinguishable from brain and notochord 
rudiments. 
 
100% epiboly; Tail bud becomes prominent, neural keel 
separates from notochord rudiment. Midsagital groove in 
anterior neural keel.   
Segmentation  
1-somite 
 
5-somite 
 
 
14-somite 
 
 
20-somite 
 
 
 
26-somite 
 
101/3 
 
112/3 
 
 
16 
 
 
19 
 
 
 
22 
 
First somite furrow becomes visible. 
 
In the polster prominent phase, optic vesicle and Küpffer’s 
vesicle first appear. 
 
Somites appear v shaped, brain neuromeres and otic 
placode form. 
 
Muscle twitches, eye lens, rhombic flexure become visible 
for the first time, otic vesicle and hindbrain neuromeres 
become increasingly prominent, tail extension. 
All somites present, sideways tail flexures; Prim 3. 
Table 1.3: Important stages for early somite development in zebrafish  
Zebrafish developmental stages defining the terminology used throughout thesis to 
describe development of the embryo from the blastula stage to the end of the 
segmentation period. Adapted from Kimmel et al., 1995. 
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Figure 1.7: Schematics of early somite development in zebrafish  
(A) Key stages in embryogenesis, important in the segmentation and patterning of the 
paraxial mesoderm, adapted from Stickney et al., 2000.  (B) Fate map of a 50% epiboly 
stage embryo, adapted from Kimmel et al., 1995.  Fates are not completely defined at 
this stage despite the germ layers being organized along animal-vegetal axis.  (C) Cell 
movements during gastrulation, adapted from Stickney et al., 2000.  Cells intercalate 
radially during the dome stage.  Marginal cells internalise and migrate towards the 
animal pole, lateral mesoderm cells converge dorsally during the shield stage.  The 90% 
epiboly stage is concerned with internalization, convergence and extension of the 
embryo (Schier and Talbot, 2005).   
The process of segmentation begins with the first segment at around 10.5 hpf.  
By 24hpf 30 somite pairs bracket the notochord (Figure 1.7A & Figure 1.8).  
Importantly for making inferences about human disease, the development of 
somites in zebrafish is very similar to that of mammals (Kimmel et al., 1995).  
Somites develop in a bilateral symmetrical process beginning with 
mesenchymal cells from the rostral region of the presomitic mesoderm.  A 
proportion of the mesenchymal cells alter their adhesion properties to become 
epithelial cells.  A specialised epithelial layer forms around a proportion of the 
remaining loosely organised presomitic mesenchymal cells i.e. muscle 
precursors, every 30 minutes, in an anterior posterior progression, and once 
bound they are referred to as a single somite.  This formation of uniformly sized 
blocks of presomitic mesodermal cells occurs at regular intervals in a process 
termed segmentation (Stickney et al., 2000).  
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Precise regulation of the timing of segmentation is required to maintain 
uniformity of the somites which has lead to the hypothesis that a molecular 
clock might exist (Palmeirim et al., 1997; Forsberg et al., 1998; McGrew et al., 
1998).  The expression pattern of her1 which controls size and position of the 
presomitic mesoderm supports the molecular clock model in zebrafish (Holley et 
al., 2000).  Also thought to support the molecular clock hypothesis is the 
expression of the Notch family of transmembrane proteins.  Notch activates 
transcription machinery thought to be specifically involved in control of the 
segmentation process (Agathon et al., 2003).  The Notch1a mutant zebrafish 
has no somite boundaries and myoD expression that is not restricted to 
posterior domain of the somites, as seen in wild type embryos at a similar stage 
of development (Takke and Campos-Ortega, 1999).   
 
Figure 1.8: Detail of the myotome of zebrafish embryos  
At (A) 13hpf and (B) 24hpf.  The cells marked in blue are the precursors of the 
sclerotome i.e. the somitic structure that eventually becomes the vertebrae. The 
adaxial cells at 13hpf (shown in red) become non-pioneer slow muscle by 24hpf.  The 
notochord in the centre of the embryo provides developmental cues and structural 
support during development.  Neural keel: NK, notochord: N and spinal cord: SC,  
adapted from Stickney et al., 2000. 
1.7.4 Muscle Organisation 
The transverse tubule system (T-tubules) are an extension of the sarcolemma 
penetrating deep into the myofibre allowing the rapid depolarization of the 
membrane to be synchronously transmitted to the entire contractile unit.  A triad 
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is formed by two terminal cristernae which are enlargements of sarcoplasmic 
reticulum flanking a specialised area of the T-tubules.  At the periphery of the 
fibre adjacent to the sarcolemma lie the myonuclei.  Myonuclei are centrally 
located with higher frequency in MD when compared to the peripheral location 
in healthy individuals (Anderson, 1991).  Centrally located myonuclei act as a 
useful assay for regeneration in damaged muscle (Cohn and Campbell, 2000).  
1.7.5 Notochord Development 
The notochord is an embryonic mid line structure that arises from the dorsal 
organiser in Chordates (Harland and Gerhart, 1997).  The notochord has both a 
signalling and a structural role.  The notochord is positioned centrally in two of 
three embryonic axes (dorso-ventral and lateral), important for secreting factors 
which control development of the central nervous system, angiogenesis and 
somatogenesis.  Initially the notochord has a structure closely resembling 
cartilage and therefore serves as the axial skeleton.  Later the notochord 
ossifies to become the vertebral column in adult fish.  In zebrafish embryonic 
and larval development the structure is also important for locomotion (Figure 1.7 
& Figure 1.8; Stemple, 2005).   
1.7.6  Embryonic Origin of Zebrafish Eye 
The earliest signs of eye development can be traced to the onset of gastrulation 
at 51/4 hpf.  The first sign of brain development in zebrafish is the dorsal 
ectoderm becoming the neural ectoderm (Kimmel et al., 1995), a process 
controlled by signals from the underlying axial mesoderm.  Molecular cues from 
the notochord induce the adjacent ectoderm to form the neural plate.  The 
neural plate is visible at 10hpf as a thickening on the dorsal side of the embryo 
(Chow and Lang, 2001) which results from a change in shape of the cells (the 
cells become columnar forming pseudostratified epithelium) and not from 
proliferation.  The anterior neural plate is comparable to the proencephalon i.e. 
an anterior part of the brain that develops from the anterior part of the neural-
tube and is regionalised early in gastrulation.  Several homeobox containing 
gene families (Sox3, Rx, Pax6 & Otx2) are expressed in the neural ectoderm at 
this stage of development, all are essential for eye development (Grindley et al., 
1995; Boncinelli and Morgan, 2001; Purcell et al., 2005).  These regulatory 
genes are important for controlling the fate of neural progenitors which 
eventually become the optic primordium (Chuang and Raymond, 2002).  
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Subsequent patterning is controlled by developmental pathways including 
canonical regulators such as BMP, Hedgehog, Wnt and Fgf family members.  
(Rubenstein and Beachy, 1998; Wilson and Rubenstein, 2000; Schier, 2001). 
 
Figure 1.9: Early eye development in vertebrates 
A, Arrows show factors from extra-ocular mesenchyme, optic stalk and surface 
ectoderm regulating the patterning of retinal layering.  B, Lens vesicle and optic cup 
formation.  The lens placode (lens ectoderm) invaginates the distal optic vesicle (neural 
retina).  RPE: retinal pigmented epithelium.  Adapted from Fuhrmann., 2008. 
The zebrafish eye forms from the neuroepithelium, surface ectoderm and the 
extra ocular mesenchyme.  The interaction between these three layers co-
ordinates the single eye field formation in the midline of the anterior neural 
plate.  Signalling from ventral midline structures underlying the neural plate 
splits the eye field bilaterally.  The inner layer of the optic cup forms the neural 
retina and the retinal pigmented epithelium forms the outer layer (Figure 1.9).  
Peripheral structures such as the iris and ciliary body develop from the margins 
of the two layers.  The optic fissure is a ventral fissure in the developing optic 
cup, through which blood vessels pass to the enclosed mesenchyme, derived 
from a narrowing of the optic stalk (Figure 1.9).  The optic stalk is an 
evagination of the neural tube, from which the optic cup develops.  At its 
extremity the optic stalk persists as the optic nerve.  The lens ectoderm forms 
an enclosed cellular mass that eventually separates and becomes the adult lens 
(Rembold et al., 2006; Fuhrmann, 2010).   
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1.7.7 Adult Zebrafish Eye 
The adult zebrafish eye is a complex organ, which shares a great deal of 
structural homology with the mammalian eye.  The adult eye is formed of many 
different cell types arranged into distinct retinal layers.  Precise developmental 
control is required to form this complex structure in adult zebrafish (Mohideen et 
al., 2003), which includes the three basement membranes of the eye, important 
for influencing the fate of the cells that surround them.  These membranes are: 
the internal limiting membrane (ILM), external limiting membrane (ELM) and 
Bruch’s membrane.  Disruption of any of these membranes will alter retinal 
layering, as seen in the MORE DG and FKRPKD mouse models (Avanesov and 
Malicki, 2004; Young et al., 2006; Figure 1.10).   
 
Figure 1.10: Schematic of retinal layering and basic neuronal circuitry  
The eye is a highly complex structure made from neuronal layers, pigmented 
epithelium, the lens and three basement membranes: inner limiting membrane, 
external limiting membrane and Bruch’s membrane.  RPE: retinal pigmented epithelium, 
ELM: external limiting membrane, ONL: outer nuclear layer, OPL: outer plexiform layer, 
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INL: inner nuclear layer, IPL: inner plexiform layer, GCL: ganglion cell layer, ILM: inner 
limiting membrane.  Adapted from Young et al., 2006.  
1.7.8 Vasculogenesis 
The “vascular hypothesis” of MD predicts that muscle necrosis associated with 
MD is caused by chronic muscle ischemia and so a causative vascular 
pathology has long been sought after in MD (Cazzato, 1968; Demany and 
Zimmerman, 1969; Mendell et al., 1972; Jerusalem et al., 1974).  Nitric oxide 
synthase (nNOS) is closely associated with the DGC and also involved in the 
regulation of vasodilation, and is therefore a candidate for the central mediator 
of the “vascular hypothesis” (Crosbie, 2001; Sharma et al., 2010; Verma et al., 
2010; Lombard, 2011; Dabire et al., 2012).   
Angioblasts are the precursors of endothelial cells not yet incorporated into 
blood vessels, originating from the ventrolateral mesoderm (Ellertsdottir et al., 
2010).  In situ aggregation of angioblasts into blood vessels is referred to as 
vasculogenesis.  The sprouting of vessels from existing vessels is termed 
angiogenesis (Moiseeva, 2001).  These processes are integral to all organs 
making them useful for comparing structural changes within specific organs.   
The zebrafish TG(fli-1:EGFP) or fli-1 was designed to investigate early vascular 
development in zebrafish replacing former models that required the injection of 
fluorescent carboxylated latex beads into wild type fish (Lawson and Weinstein, 
2002; Figure 1.11).  The transgenic model expresses enhanced green 
fluorescent protein (EGFP) driven by the fli-1 promoter in the vascular 
endothelium, cranial neural crest derivatives, a presumptive hemangioblast 
lineage, and a small subset of myeloid derivatives (Isogai et al., 2001).  
 
Figure 1.11: Vascular anatomy of 2dpf zebrafish 
Embryo injected with fluorescent carboxylated latex beads, produced from confocal 
projections.  Se: intersegmental vessel, DA: dorsal aorta, DLAV: dorsal longitudinal 
anastomotic vessel, PCV: posterior cardinal vein, CA: caudal artery, CV: caudal vein, 
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IOC: inner optic circle, Image is an unaltered copy from Isogai et al., 2001; Lawson and 
Weinstein, 2002. 
The first signs of zebrafish eye vasculogenesis are seen at 24-29 hpf.  The optic 
artery branches from the primitive internal carotid artery, entering the eye 
ventrally through the optic fissure.  The optic artery later becomes the hyaloid 
artery running from the back of the eye through the hyaloid canal to the ILM.  By 
60 hpf the hyaloid artery has formed a loop around the lens, exiting through the 
hyaloid canal and eventually the optic fissure as the optic vein.  These internal 
vessels are referred to as the hyaloid vessels, the external vessels that supply 
the retina are known as the optic vessels (Isogai et al., 2001; Alvarez et al., 
2007; Fadool and Dowling, 2008; Gore et al., 2012; Figure 1.11).   
1.8 Current Approaches for Generating Stable 
Zebrafish Mutant Lines 
To date there are no stable mutant zebrafish lines modelling any of the 
dystroglycanopathies.  All studies investigating dystroglycanopathies have been 
carried out using morpholino antisense-oligonucleotides (MOs).  Morpholino 
oligonucleotides (MO) are small chains of typically around 25 nucleotides 
complementary to specific target sites in transcribed sequences (Summerton 
and Weller, 1997).  The MO structure is different from DNA and RNA in two 
distinct ways.  Firstly the ribose or deoxyribose sugar is replaced with artificial 
morpholine rings preventing the morpholino from being recognised by 
endogenous enzymes and degraded.  Secondly, non-ionic phosphorodiamidiate 
replaces the anionic phosphates, also preventing recognition by endogenous 
enzymes that degrade DNA and RNA.  Efficient knockdown can be achieved 
with MOs since they bind to native nucleic acids at high affinity, but are resistant 
to degradation and therefore persistent in vivo (Nasevicius and Ekker, 2000; 
Summerton, 2007).  
MOs have two modes of action either spliceosomal or translational.  MOs that 
block an intron-exon boundary generating dysfunctional splice products are 
referred to as splicesomal MOs.  The translational MOs sterically block the 
translation initiation complex, thereby preventing the translation of the target 
mRNA.  Spliceosomal MOs are desirable in many instances because the 
efficiency of target knock down can be tested by RT-PCR.  Translational MO 
knockdown efficiency is normally tested by Western blot but is dependent on a 
57 
 
well characterised antibody (Summerton, 1999).  Despite fukutin antibodies 
being commercially available an antibody that is capable of detecting 
endogenous fukutin in fish is yet to be reported in the literature, hence a 
spliceosomal MO is more desirable (Draper et al., 2001; Lynch et al., 2012).  
The problem of testing MO efficacy previously occurred with the FKRP 
morphant fish, another dystroglycanopathy model (Thornhill et al., 2008) in this 
case tested with a laminin overlay assay.  Zebrafish injected with MO can be 
investigated up to 5 dpf for two main reasons.  Firstly, in the UK the Home 
Office will not allow fish injected with MO to be kept past 5dpf.  Secondly, over 
time the MO becomes diluted through passive diffusion and distribution 
amongst the increasing number of cells as the larvae develops.  Concentrations 
after 5 dpf of MO might therefore be considered less reliable for experiments 
than zebrafish earlier on in the development.  
A stable mutant line would circumvent the problems of transient knockdown 
systems. Traditional site-directed DNA recombination methodology used to 
create knock-out mice models unfortunatly has had limited success in zebrafish.  
The technology uses the flexibility of Cre-recombinase to target palindromic 
DNA, catalysing strand exchanges at the locus of crossover (Iox sites; Dong 
and Stuart, 2004).  In murine research where embryonic stem (ES) cell culture 
is well established there have been many models created successfully and the 
technology has been widely adopted, whereas culture of zebrafish ES cells has 
proven to be difficult.  This approach therefore has not been widely adopted in 
zebrafish (Fan and Collodi, 2006).  The zebrafish field is therefore looking 
towards an approach receiving increasing attention: customised zinc fingers 
nucleases (ZFNs), enabling the introduction of frame shift mutations at targeted 
genetic loci in zebrafish (Porteus and Carroll, 2005; Foley et al., 2009).   
1.8.1 Zinc Finger Nucleases 
Zinc fingers were discovered in 1985 by Miller, McLachlan & Klug based on an 
observation by Roeder & Brown that 5S RNA requires RNA polymerase III and 
a 40kDa protein transcription factor III (TFIIIA) to initiate transcription in 
Xenopus laevis (Picard and Wegnez, 1979; Pelham and Brown, 1980; Brown, 
1984).  TFIIIA was found to have large repeating protein motifs and atomic 
absorption spectroscopy showed these to contain zinc ions.  Later the zinc ion 
was noted to play a key role in co-ordinating the DNA binding motifs.  These 
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binding motifs were found to be capable of binding specific DNA sequences 
(Klug, 2010b).  
 Zinc fingers can be classified into different “fold groups” based upon the 
conformational structure of their back bone.  The most common example is the 
Cys2His2-like zinc finger otherwise known as the classical zinc finger (zinc 
ribbon and treble clef are other examples).  The classical zinc finger structure 
consists of an α-helix and an antiparallel β-sheet co-ordinating the zinc ion via 
two conserved cysteines and two conserved histidine residues.  Cys2His2 zinc 
fingers bind nucleic acid in the major groove of DNA through the N-terminus of 
the α-helix (Razin et al., 2012).  Specificity is achieved by interaction of the DNA 
with side chains on the α-helix of the zinc finger.  Regulation of transcription is 
thought to be the most important task of Cys2His2 zinc fingers with roles in 
mediating protein-protein interaction hypothesised.  The first artificial application 
of zinc fingers was developed shortly after their discovery with an unsuccessful 
attempt to silence oncogenes in mice in 1994 (Choo et al., 1994; Corbi et al., 
2004; Klug, 2010a). 
 ZFNs are artificial enzymes composed of a zinc finger DNA binding domain 
and a Fok-I nuclease domain (Kim et al., 1996; Figure 1.12).  Fok-I are 
restriction endonucleases consisting of an N-terminal DNA-binding domain and 
a non-specific DNA cleavage domain at the C-terminal, found naturally 
occurring in Flavobacterium okeanokoites.  The Fok-1 nuclease domain induces 
double stranded breaks in DNA at the site of zinc finger binding.  ZFNs act as 
obligate heterodimers that normally require non-palindromic nine base pair (bp) 
target sites either side of a 5-7bp spacer region to induce double stranded DNA 
breaks within a gene of interest.  The DNA is repaired by the endogenous 
process of non-homologous end-joining (Porteus and Carroll, 2005; Foley et al., 
2009; Maeder et al., 2009; Figure 1.12 & Figure 3.1B).  
The two main strategies currently being adopted to derive ZFNs are: 
Oligomerized Pool Engineering (OPEN) and Context Dependant Assembly 
(CoDA; Maeder et al., 2009; Sander et al., 2010).  In an earlier system known 
as “modular assembly” each individual finger is treated as an independent unit.  
Zinc finger domains are now known to be dependent on their context within an 
array which may account for the low success rate of modular assembly.  Low 
target binding efficacy of ZFNs produced using modular assembly meant the 
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approach became superseded by OPEN and CoDA (Ramirez et al., 2008).  
ZFNs are also commercially available through Sigma-Aldrich’s CompoZr service 
(Hansen et al., 2012).  These ZFNs are constructed based on a propriety 
method developed by Sangamo Biosciences (Richmond CA, USA) and their 
success rates are comparable to the OPEN protocols (Maeder et al., 2009; 
Remy et al., 2010).   
 
Figure 1.12: Schematics of ZFN mode of action 
ZFNs are obligate heterodimers that introduce double stranded breaks between the 
two target half sites.  The DNA is repaired by non-homologous end joining, a process 
likely to result in indel mutations (Porteus and Carroll, 2005). 
Each pair of zinc fingers requires two sets of three fingers.  Each set binds a 9-
bp half-site, and the pairs of ZFN binding sites are usually separated by a small 
5-7bp section of DNA.  With the OPEN protocol zinc finger pools are selected 
from a catalogue of pools each consisting of approximately 95 fingers therefore 
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potentially producing a library with a complexity of 953 (8.5x106).  Bacterial two-
hybrid screening of the library using the target sequence cloned into a reporter 
vector selects for the multi-finger arrays with the highest binding affinities, 
maximising the probability that they function efficiently as ZFNs.  The OPEN 
protocol therefore produces ZFNs which work well together and takes into 
account the context-dependent DNA binding of each finger, which is not 
considered in the modular assembly approach (Maeder et al., 2009). 
In the CoDA approach one of 319 N-terminal fingers (F1 units) and one of the 
344 C-terminal fingers (F3 units) of the array are positioned either side of one of 
only 18 fixed (F2 units).  The F1 & F3 units have been shown to function well 
with a particular F2 unit and therefore the CoDA protocol takes into account the 
context of adjacent fingers based on prior knowledge.  CoDA increases the 
probability that a ZFN array will function with a high efficiency (Sander et al., 
2010).  The protocol is relatively simple in comparison to OPEN, in that complex 
bacterial two-hybrid systems are not required (Maeder et al., 2009; Figure 1.13).     
 
Figure 1.13: Schematic overview of CoDA ZFNs 
Zinc fingers (units F1-F3) and their respective 3-bp DNA ‘subsites’ are shown.  Two 
different three finger arrays, each engineered to bind different 9-bp target sites that 
have in common a middle F2 unit, can be used to create a three-finger array with a 
new specificity by joining together the F1 unit from the first array, and the F3 unit from 
the second array (Sander et al., 2010). 
The DNA sequences encoding zinc fingers from these approaches are then 
cloned into a vector expressing a Fok-I nuclease domain, with paired nuclease 
domains on each strand being required for cleavage of the DNA target.  RNA 
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transcribed in vitro from the T7 RNA polymerase promoter in these vectors is 
injected into the embryo at the single cell stage.  Mutant embryos can be 
screened by direct sequencing for mutations (Foley et al., 2009).  
1.8.2 TALENs      
Transcription activator-like effector hybrid nucleases (TALENs), are similar to 
ZFNs in the respect they are also capable of binding to specific regions of DNA 
and inducing double-stranded breaks (Huang et al., 2011).  The transcription 
activator-like proteins (TALEs) are virulence factors of phytopathogenic bacteria 
(Xanthomas genus).  Once inside the cell, TALEs translocate to the nucleus, 
and their central repeat domain binds specific regions within the host DNA.  
TALEs are capable of mimicking transcription factors and re-program the host’s 
gene expression to their advantage.  The Hax3 binding domain can be 
manipulated to bind different DNA regions.  The hybrid Hax3 can be then fused 
to a FokI cleavage domain, important for inducing double stranded breaks, to 
produce a TALEN (Wood et al., 2011a).  Recently the modified Goldy TALEN 
scaffold was combined with the addition of a single stranded nucleic acid 
template to refine TALEN efficacy (Bedell et al., 2012).  The introduction of a 
complementary single stranded DNA scaffold provides a template for homology 
directed repair (HDR).  HDR uses the exogenous sequence as a template to 
precisely insert a desired sequence into the cut site.  The template strand also 
reduces error arising as a result of NHEJ (Radecke et al., 2010; Moore et al., 
2012b).   
1.8.3 Chemical Mutagenesis and the Zebrafish Mutation Project  
The chemical mutagen N-ethyl-N-nitrosourea (ENU) has been extensively used 
for mutagenesis screens in various organisms, including zebrafish.  ENU can 
produce a mutation in approximately 1:700 gametes making it an attractive way 
to create mutations (Justice et al., 1997).  ENU is an alkylating agent, acting by 
transferring an ethyl group to the bases of nucleotides in DNA.  However the 
method is random and this lack of specificity means that a large number of 
animals must be screened, making this approach difficult to justify for small labs 
(Knapik, 2000).  
The Zebrafish mutation project is run by the Stemple Laboratory as part of the 
Wellcome Trust Sanger Institute (Hinxton, Cambridge, UK) and takes 
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advantage of ENU technology to create mutant zebrafish lines (Stemple, 2011).  
The process remains random but by creating a genotyping pipeline the project 
hopes to achieve a nonsense mutation in every protein coding gene in the 
zebrafish genome.  To date >1200 nonsense and splice mutations have been 
identified.  The exomic DNA of F1 generation fish with phenotypes are 
sequenced following enrichment with the Agilent Sure Select system on an 
Illumina Hi-seq platform.  Specific alleles are then sequenced in the generated 
F2 by KASpar (allele specific amplification, developed by KBiosciences) to 
confirm any mutations (Clark et al., 2011; Kettleborough et al., 2011). 
1.8.4  Retrovirus Strategy  
An alternative strategy is the use of retroviruses as insertional mutagens.  This 
approach uses exogenous DNA as a mutagen which also serves as a molecular 
tag for identifying the particular gene which when mutated has produced the 
phenotype.  The pseudotype retrovirus is based on Moloney murine leukaemia 
virus and the envelope glycoprotein of the vesicular Somatitis virus.  Injection 
into the developing embryo results in random integrations in the zebrafish 
genome producing chimeric fish.  The insertions can be passed through the 
germline by inbreeding and approximately 1 in 80 embryos will have insertional 
mutations.  The method is applicable for large scale screens as it does not rely 
on expensive exomic sequencing (Amsterdam et al., 2011).  To date only 
approximately 500 mutations at 350 loci have been identified which is less than 
by ENU based protocols.  
1.8.5 Tetracycline Systems 
The tetracycline Tet-on or Tet-off system is another model system gaining 
increasing attention to produce a conditional knock-down in zebrafish (Gossen 
and Bujard, 1992).  Tetracycline controlled activation systems can turn on or off 
expression of a particular gene in a reversible manner, depending upon the 
concentration of tetracycline added to the aquarium water.  Gene expression via 
a specific promoter is regulated by the tetracycline response elements (TRE’s) 
that are bound by the tet-repressor protein, resulting in inhibition of gene 
expression.  Tetracycline binds to the tet-repressor, resulting in de-repression of 
the engineered locus (Knopf et al., 2010).  Target gene repression is achieved 
by controlling the expression of a synthetic shRNA which is capable of directing 
the cognate mRNA from the locus of interest for degradation.  Tetracycline 
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systems are flexible in that genes can be over or underexpressed and can be 
localised to a specific tissue.  The system also enables control of the specific 
level of gene expression by means of titration of the tetracycline in the system.  
The major drawback in zebrafish is the low efficiency with which transgenic 
animals can be developed and the requirement of a closed water system in the 
zebrafish facility (Munoz et al., 2005). 
1.8.6 Binary Systems 
Binary systems have been used in Drosophila research to regulate gene 
expression and are becoming available in zebrafish (Potter and Luo, 2011).  
The Q-transcriptional regulatory system of Neurospora crassa is used to 
produce 4 tandem, non-repetitive upstream activating sequences.  These act as 
targets for Gal4 transcription factor, known to be less prone to transcriptional 
silencing over generations via methylation than other approaches such as 
models produced with retroviruses (Svoboda et al., 2000; Munoz et al., 2005).   
1.9 Direction of Study 
The overall aim of the project is to investigate the role of FKRP and fukutin in 
early zebrafish development.  The aims can be split into two broad categories 
either resource building or hypothesis based. 
Resource Building Aims: 
 The project initially aims to establish the best approach to modelling fkrp 
and fukutin deficiency in zebrafish. 
 Attempt to create an alleilic series of fkrp mutant lines with ZFNs.   
 In parallel the project aims to investigate dystroglycanopathy using an 
antisense oligonucleotide morpholino (MO) strategy by knocking down 
fkrp, fukutin and dystroglycan.   
 Characterise the phenotypes of fkrp, fukutin and dystroglycan knock 
downs compensating for differential efficacy of the morpholinos by 
controlling for the severity of the phenotype. 
Thesis Hypothesis:  
 The pathological features of muscle, eye and brain associated with 
secondary dystroglycanopathies may be attributable to pathological 
disturbance of basement membrane.  
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Chapter 2 Materials and Methods 
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2.1 Animal Models 
2.1.1 Fish strains and maintenance 
The two fish strains used in this study were the wild-type AB* strain [Zebrafish 
International Resource Centre (ZIRC), Oregon USA] and the transgenic line TG 
(fli 1: EGFP) expressing EGFP in the blood vessel endothelium under control of 
the Fli-1 promoter (Lawson and Weinstein, 2002).  Males and females were 
paired and separated by gauze the night before embryos were required.  The 
following morning the gauze was removed.  Zebrafish embryos were collected 
and raised at 28.5°C in E3 medium (5mM NaCl,0.17mM KCl, 0.33mM CaCl2, 
0.33mM MgS04, 0.1PPM
 methylene blue) using established procedures and 
staged in hours or days post fertilisation (hpf or dpf) according to Kimmel criteria 
(Kimmel et al., 1995).  1-2dpf embryos were dechorionated manually or bathed 
in 0.5 - 2 mg/ml pronase (Roche) for 5 minutes and washed several times in E3 
medium.  All fish, including 3-5dpf larvae, were euthanized in 4mg/ml tricaine 
methanesulfonate, E3 medium mix (50:50; Westerfield, 2000).  
2.1.2 Criteria for the Classification of Morphant Phenotype  
This section outlines the criteria for the classification of fukutin, fkrp and 
dystroglycan morphant zebrafish between 1-5 dpf into phenotype severity 
groups (Table 2.1 & Figure 2.1; Kimmel et al., 1995).  The zebrafish being 
translucent at 1dpf is a particularly attractive attribute of the system for studying 
dystroglycanopathy; key features have been outlined in the schematics in 
Figure 2.1 (Kimmel et al., 1995). 
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Stage of 
Development 
Time Main Features of Period 
Zygote 0 hrs Single cell stage to first zygotic cell division.  Cytoplasm 
moves toward animal pole forming the blastodisc (a thin 
layer of cells on the inside of the blastula) N.B. MO 
injection period. 
Cleavage ¾ hrs 2-128 cell stage formation of three regular tiers of 
blastomeres. 
Blastula 2 ¼ 
hrs 
Formation of the epiblast (tissue derived from blastodisc), 
hypoblast (embryonic precursor of the endoderm) and 
embryonic axis through morphogenetic movements of 
involution, convergence and extension. 
Gastrula 5 ¼ 
hrs 
Germ ring and embryonic shield are at 50% epiboly 
(controlled movement of cells into germ layers and axis 
formation), visible from animal pole.  Brain and notochord 
rudiments thicken becoming distinct structures, tail bud 
becoming prominent by the end of the phase. 
Segmentation 101/3 
hrs 
First somite furrow to 26 somites, optic vesicle and 
Küpffer’s vesicle (epithelial ciliated sac involved in left-
right signalling) start to develop at 112/3 hpf.  By 16hpf otic 
placode (thickening of ectoderm forming sensory tissue), 
brain neuromeres, all begin to form and v shaped 
somites.  Towards the end of the period muscular 
twitches, optic vesicle and hind brain are all visible.   
Pharyngula 1 dpf At the beginning of the phase the embryo is 1.6mm in 
length and 3.1mm by the end.  Early touch reflex and 
pigmentation begin to develop.  Caudal artery is almost at 
the end of the tail by the end of the period.  Pericardium 
becoming prominent towards the end of the period.   
Hatching 2 dpf By the end of the period the fish are 3.5mm in length.  
Pigmentation and pericardium become prominent.  Small 
mouth visible. 
Early Larva  3 dpf Phase also known as protruding mouth.  Rapid growth of 
embryo - all systems develop further. 
Mid Larva 14 dpf 6.2 mm in length, first hypural cartilage in tail fin, 
ossification of pharyngeal skeleton, neural maturity i.e. 
Rohon –Beard neurones replaced by dorsal root ganglia. 
Juvenile 30 dpf 10 mm in length, adult fin and pigmentation patterns, 
lateral line shifts ventrally.   
Adult 90+ 
dpf 
18mm-500mm, earliest time to breed. 
Table 2.1: Stages of zebrafish development  
Table outlines prominent stages in the development of zebrafish from the single cell 
stage through to the fully grown adult fish.  Zebrafish have an approximate life span of 
four years and produce high quality eggs from about six months to two years.  Since 
temperature affects the rate of development fish are always staged according to 
Kimmel criteria and grown in incubators at 28oC (Kimmel et al., 1995; Westerfield, 
2000). 
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Figure 2.1: Camera lucida schematics of 1, 2 & 3dpf zebrafish 
Figure shows orientation diagram of major regions i.e. the head, tail and myotome 
trunk.  Trunk and tail can be used interchangeably, however it should be noted the 
myotome trunk is more precisely concerned with the somites and notochord whereas 
the tail also includes the gastrointestinal tract (Westerfield, 2000).  Red arrows: somites, 
red triangles: notochord, MB: mid brain, HC: hyaloid canal, YS: yolk sack & OV: otic 
vesicle.  Adapted from Kimmel et al., 1995. 
 Anatomical structures important for investigating dystroglycanopathy have 
analogues in zebrafish, such as somites, mid brain and eye, and can be 
assessed on morphological grounds.  By the beginning of the pharyngeal stage 
of development 1dpf, the embryonic body axis is straight and therefore even a 
slight effect of MO injection on tail curvature can be detected.  Tail curvature is 
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therefore a sensitive indicator of phenotypic severity.  Pigmentation begins at 
approximately 2dpf obscuring some of the key anatomical features from this 
point onwards.  The tail curvature remains past 1dpf as the most suitable way to 
sort the embryos into phenotype categories (Table 2.2).   
Phenotype Somitic 
Region 
Eye Brain Other Features 
Normal No angled 
curvature of 
somitic region 
Two small 
round eyes  
with pupil 
present 
Clear midbrain 
structure 
present at 
higher 
magnification 
Embryo swims 
with/without 
stimulation 
(after early 
dechorionation) 
Mild  0-15o Angle of 
trunk region  
Small 
decrease in 
diameter but 
no notable 
shape 
changes 
Small, no 
notable brain 
changes at 
higher 
magnification 
May have 
cardiac oedema 
and swim in 
circles  
Moderate 15-30o Angle 
of trunk region 
- may be 
curling to a 
greater degree 
at posterior of 
fish (tail). 
Eye notably 
smaller and 
may have 
disrupted 
shape 
Mid brain not 
always visible  
Fasciculations 
regularly a 
feature  
Severe Tail curvature 
> 30o - tail 
often shorter in 
length and 
dorsal 
curvature 
should also be 
considered 
Eyes often 
missing or 
very irregular 
in size and 
shape 
Brain not visible Very irregular  
overall in 
appearance on 
dechorionation, 
very unlikely to 
move 
Table 2.2: Phenotypic classification of 1-5dpf embryos as judged under 
the dissecting microscope  
The classification allows comparison of the phenotypes for each MO.  It should be 
noted that for MO injected embryos the very severe embryos and no phenotype were 
not included in further assessment of pathology.  
2.1.3 Antisense oligonucleotide morpholino preparation 
Antisense morpholino oligonucleotide (MO, Gene Tools LLC) were designed to 
target to the putative start of translation of the zebrafish fkrp transcript (5´-
ACTGATACGCATTATGGCTCTTGTG-3´; Thornhill et al., 2008).  The 30-
12Apr05B fktn splice MO 5´-GCCCAGAAACCTCTTCAGCAGATGC-3´ is 
directed against the splice donor site of exon 4 in the zebrafish fktn gene, 
predicted to lead to the skipping of the exon and consequently to a frame shift 
that results in premature translation termination.  The dag1 translation blocking 
MO 5´-CATGCCTGCTTTTATTTTCCCTCGC-3´ has previously been described 
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(Parsons et al., 2002a).  The gfat1 (glucosamine-fructose-6-phosphate 
aminotransferase 1) splice MO was used as described (Senderek et al., 2010).  
The Gene Tools standard control morpholino: 5´-
CCTCTTACCTCAGTTACAATTTATA-3´ was used for control MO injections.  
The MOs were re-suspended in 1x Danieau solution (0.4mM MgSO4, 58 mM 
NaCl,0.7mM KCl, 5mM HEPES, 0.6 mM Ca(NO3)2; pH 7.6; Westerfield, 2000). 
2.1.4 Glass Needle Preparation 
Glass Capillaries were pulled using a P97 Flaming Brown Micropipette Puller 
with a heat of 695, a pull of 70 and velocity of 60.  Needles were filled with 
injection solution using Microloader Tips (Eppendorf) and broken sequentially 
up the needle towards the injector using forceps under a dissecting microscope 
until an optimal volume was achieved on injection.  Volume was judged by 
measuring the initial diameter of a drop of injection solution in mineral oil on a 
graduated microscope slide under a dissecting microscope. 
2.1.5 Micro-manipulation  
Individual MO MWs were calculated from sequences.  MOs were diluted to 
1µmol and an injection volume was calculated from a desired amount of MO 
e.g. 10ng fkrp MO, using the following equation: 
Volume = Mass / Concentration 
The volume could then be used in the following equation to derive the radius of 
the drop size. Diameter was obtained by doubling the result: 
Radius =    
 
   
  
 
 
10ng of fkrp or control MO, 2ng of 30-12Apr05B fktn MO and 7ng of dag1 MO 
were injected into the embryos yolk sac at the one to two-cell stage, using 
phenol red as an injection indicator. 
2.2 Molecular Biology for ZFN CoDA Protocol 
2.2.1 DNA Extraction 
Embryos were collected, washed several times in PBS, lysed in SDS lysis 
buffer (10mM Tris, pH8.0, 200mM NaCl, 10mM EDTA, 0.5% SDS and 100µg/ml 
Proteinase K) and incubated at 50oC overnight.  Phenol-Chloroform-Isoamyl 
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alcohol (25:24:1 Invitrogen) was mixed with the lysates to form an emulsion and 
centrifuged at 14,000rpm for 5 minutes at room temperature (RT).  The 
supernatant was mixed with 100% ethanol and centrifuged at 14,000rpm for 20 
minutes at 4oC.  The supernatant was completely removed and 70% ethanol 
was used to wash the pellet with a further spin at 14000 rpm for 10 minutes at 
4oC.  Samples were left to air dry at RT then left to dissolve in 20µl of EB buffer 
(Qiagen) for 2 hours at RT.    
2.2.2 RNA Isolation   
RNA was collected from approximately 30 zebrafish embryos for RT-PCR 
analysis.  The embryos were homogenised in 200µl lysis buffer see 2.2.1 for 
further detail, 1ml of Trizol (Invitrogen) was added to lysates and incubated at 
RT for 1 minute then spun at 14,000rpm for 10 minutes at 4oC.  0.2ml of 
chloroform was added and tubes shaken vigorously by hand for 15 seconds.  
Samples were then incubated for 3 minutes at RT and centrifuged at 14,000rpm 
for 15 minutes at 4oC.  The aqueous phase was transferred to an Eppendorf 
containing 0.5ml isopropyl alcohol, shaken by hand and incubated at RT for 10 
minutes.  The samples were spun at 14,000rpm for 15 minutes at 4oC and the 
supernatant removed.  The pellet was washed in 0.5ml of 70% ethanol and 
centrifuged at 14,000rpm for 5 minutes at 4oC.  The supernatant was removed 
and the pellet dried at 60oC for 10 minutes.  The pellet was dissolved in 30µl of 
ddH2O and stored at -20
oC or -80°C for extended periods of time.  The 
absorbance at 260 and 280nm was measured on a nanodrop (ND-8000, 8-
Sample Spectrophotometer) to give the RNA purity and concentration.   
2.2.3 First-Strand cDNA Synthesis 
The isolated RNA was mixed with RNase free water, random primers (100ng/µl, 
Promega) and 10mM dNTPs (Fermentas).  The tube was briefly centrifuged and 
heated to 65oC for 5 minutes, and incubated on ice for one minute.  First-Strand 
Buffer, 0.1mM DTT, RNaseOUT Recombinant RNase inhibitor (40units/µl, 
Invitrogen) and Superscript III RT (200units/µl, Invitrogen) were added.  The 
cDNA was generated by incubation at 25oC for 5 minutes then 50oC for 1 hour.  
The reaction was inactivated by heating to 70oC for 15 minutes.  The cDNA was 
stored at -20oC, or used directly as a template for PCR.  
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2.2.4 RT-PCR 
The following was made up to 50μl with dH2O to perform PCR:  
 4μl PCR enhancer 
 Template DNA 10-100ng 
 10 mM dNTPs 
 10x PCR reaction buffer 
 1μl Moltaq DNA polymerase (Moltaq) 
 PCR primers to a final concentration of 50pmol/μl (Table 2.5) 
After mixing and brief centrifugation, reactions were incubated in a thermal 
cycler (Senso Quest, Labcycler) with the parameters in Table 2.3 & Table 2.4.   
Step No. Step Name Temperature (oC) Time 
1 Initialisation 95 2 minutes 
2 Denaturation 95 15 seconds 
3 Annealing 55-65  1 minute 
4 Elongation 72 2 minutes 
5 Final Elongation 72 7 minutes 
6 Hold 4 ∞ 
Table 2.3: Standard PCR programme  
Steps 2-4 were repeated 35 times. 
Step No. Step Name Tm (oC) Time 
1 Initialisation 94 2 minutes 
2 Denaturation 94 10 seconds 
3 Annealing 55 30 seconds  
4 Elongation 68 2 minutes 
5 Denaturation 94 10 seconds 
6 Annealing 55 30 seconds  
7 Elongation 78 20 seconds 
8 Final Elongation 78 7 minutes 
9 Hold 4 ∞ 
Table 2.4: Long PCR programme 
 Steps 2-4 and 5-7 were repeated 9 and 19 times respectively. 
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Name Gene Sequence (5´-3´) Tm (oC) 
Fukutin exon 2 FWD 
Fukutin exon 5 REV 
fktn(Danio 
rerio) 
TGTGTCGGATCGCTCTAATG 
CGTTAAAGCGGAACAGGAAG 
57 
FKRP FWD 
FKRP REV 
fkrp(Danio 
rerio) 
GCATCACTTTTGGCCAGACT 
TTCTCCATCATTTGCTGCTG 
56 
FKRP 5-1 ZFN FWD 
FKRP 5-1 ZFN REV 
fkrp 
(Danio 
rerio) 
TCGCGGGCTCAGCAGCAAAT 
ATCAGGGGGCGCCCTAAGGG 
63 
FKRP 5-2 ZFN FWD 
FKRP 5-2 ZFN REV 
fkrp 
(Danio 
rerio) 
CATCTTGTATTATGTCTCGCGGGCT 
AGGCCGCAGGGCTGTAAGTG 
58 
Table 2.5: PCR primer pairs  
2.2.5 Gel Electrophoresis 
1µl/ml of safe view nucleic acid stain (NBS biological) was mixed into the molten 
1-2 % agarose gel in 1xTAE buffer pH8.0 (Tris base, acetic acid and 
Ethylenediaminetetraacetic acid – EDTA).  5µl of PCR product was mixed with 
1µl of loading dye (dH2O, 15% glycerol, 0.25% bromophenol blue, 0.25% xylene 
cyanol) and subjected to electrophoresis for a minimum of 30minutes at 100V 
before being visualised under UV light.  Gel images were captured on a 
GelDoc-It 310 Imaging system (UVP). 
2.2.6 Purification of Plasmids and DNA Extraction  
A single colony was selected from 100µg/ml Ampicllin LB agar (10g Bacto-
tryptone, 5g yeast extract, 10g NaCl, 15g agar in 1litre dH2O, sterilised by 
autoclaving), incubated in 10ml LB media (10g Bacto-tryptone, 5g yeast extract, 
10g NaCl, in 1litre dH2O) containing 100µg/ml Ampicillin overnight at 37
oC in a 
shaking incubator.  1ml of the media was spun down and pellet resuspended as 
per the directions of Quiagen plasmid purification kit manual (QIAprep Spin 
Miniprep Kit; 27106).  The final product was eluted in 20µl of EB buffer supplied 
in the kit and concentration was estimated on a NanoDrop (ND-8000, 8-Sample 
Spectrophotometer) and whole plasmids were sent for sequencing at Eurofins 
MWG with a forward primer for each region of interest. 
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2.2.7 ZFN CoDA Specific Methods 
The zebrafish fkrp transcript (NC_007126.5) was entered into ZiFit Version 3.3.  
The returned sequences from in the in silico tools for the FKRP 5-1 & 5-2 were 
sent for synthesis by Eurofins MWG Operon and returned in pCR2.1 vectors.  
The vectors were digested using XbaI and BamHI restriction enzymes and each 
zinc finger array was subsequently recloned into the Fok-1 nuclease containing 
vectors pMLM290/292.  Plasmids were digested at the BamHI and XbaI 
restriction sites, to test whether the inserts were correctly cloned into 
pMLM290/292, the products were visualised on an agarose gel, and 
plasmidswere then sent to Eurofins MWG for sequencing, see section 2.2.6 and 
Table 2.5.  To generate the mRNA the pMLM290/292 plasmids containing the 
correct inserts were linearised with PmeI.  A small volume was tested by 
visualisation on an agarose gel. 
2.2.8 Generating mRNA 
All reagents in the protocols below are part of T7 Ultra mMessage mMachine kit 
(Ambion). 
Capped Transcription Reaction Assembly 
Reagents were thawed on ice, mixed by vortexing and briefly centrifuged.  The 
transcription reaction is assembled at RT as below: 
 10µl T7 2x NTP/ARCA  
 2µl 10x T7 reaction Buffer 
 0.1-1µg linear template DNA 
 dH2O to a final volume of 20µl 
The reaction was mixed by gentle pipetting and incubated at 37oC for 2 hours.  
To remove template DNA 1µl of TURBO DNase was added and incubated at 
37oC for 15 minutes. 
Poly (A) Tailing Procedure 
The following reagents are used for the addition of poly-A tails to the mMessage 
mMachine T7 Ultra reaction: 
 21 µl mMessage mMachine T7 Ultra reaction 
 35 µl nuclease free water 
 20 µl 5x E-PAP Buffer 
 10 µl 25mM MnCl2 
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 10 µl ATP  
As a control 2.5 µl was set aside and 4 µl of E-PAP was added then incubated 
at 37oC for 45 minutes before being returned to ice.  Another 2.5 µl aliquot was 
kept for running on a 1% agarose gel alongside the samples without poly-A tails.  
The kit includes a formaldehyde based loading dye essential for accurately 
resolving RNA size.      
Lithium Chloride Precipitation for RNA Recovery  
Lithium chloride precipitation removes unincorporated nucleotides and most 
proteins.  50 µl of lithium chloride precipitation solution was mixed with the 
mMessage mMachine T7 Ultra reaction and chilled for 30 minutes at -20oC 
before being centrifuged at 4oC for 15 minutes at 14,000 rpm to pellet the RNA.  
The supernatant was removed and the pellet washed in 70% ethanol and 
centrifuged for 10 minutes at 4oC, 14,000rpm.  The ethanol was removed and 
the pellet air dried until it became transparent.  The pellet was resuspended in 
20µl of RNAse free water (Ambion).  
Micro-Injection of mRNA  
2nl (300pg) of the following mixture was injected behind the cell into the yolk of 
a single cell staged egg.  
 RNA encoding left half-site ZFN      750ng 
 RNA encoding right half-site ZFN      750ng 
 1% phenol red        0.5μl 
 1x Danieau Solution      to 6μl 
2.2.9 Screening Samples for Mutations  
Two sets of 10 2dpf embryos were collected from the ZFN injected clutches with 
no discernible phenotype, N.B. high levels of mRNA in about a third of injected 
embryos creates a disrupted developmental phenotype which is undesirable for 
further analysis.  The ten embryos were pooled and lysed for DNA extraction, 
as described above in section 2.2.1.  The pooled DNA was amplified in a 
standard PCR reaction with either FKRP ZFN 5-1 or 5-2 primers (Table 2.5) and 
purified PCR products were cloned using the pGEM-T easy vector system, as 
described in the manufacturer’s guidelines.  The pGEM-T easy vector 
containing inserts was transformed into XL-1 blue E.coli cells and plated on LB 
Xgal-amp plates.  95 colonies were selected and mixed directly into PCR 
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mastermix on a 96 well plate.  Long PCR as described above in Table 2.4, was 
performed to amplify the inserts, 5µl was ran on a gel to check for successful 
PCR reactions and sent for sequencing using MWG Eurofins plate sequencing 
service.    
2.3 Whole-mount Antibody Immunofluorescence 
Staining 
Embryos were fixed in 4% paraformaldehyde (PFA) in phosphate-buffered 
saline (PBS) overnight at 4°C and then further fixed and permeabilised in pre-
cooled acetone at -20°C.  Non-specific antibody binding sites were blocked in 
PBS containing 5% horse serum and 0.1% Tween-20 (PBST, blocking solution).  
Embryos were incubated overnight at 4°C in blocking solution containing either 
of the following primary antibodies: IIH6 (anti α-dystroglycan mouse IgM 1:50; a 
kind gift from Professor Kevin Campbell, University of Iowa), 43DAG (anti β-
dystroglycan mouse IgG 1:50; Novocastra) and pan-laminin (anti rabbit IgG 
polyclonal 1:250; Sigma).  The embryos were washed several times with PBST 
and incubated with the following secondary antibodies: Goat anti-mouse IgM 
Alexa Fluor 594 (Invitrogen), Goat anti-mouse IgG Alexa Fluor 594 (Invitrogen), 
donkey anti-rabbit IgG Fluor 594 (Invitrogen) all at a dilution of 1:500.  Texas 
Red conjugated phalloidin 1:100 (Invitrogen) was used to label F-actin.  A 
minimum of twenty embryos from three independent injections were stained and 
imaged for each individual experiment. 
2.4 Cryosectioning and Immunohistochemistry  
Euthanized 3dpf embryos were incubated in 4% PFA at 4oC overnight followed 
by three 5 minute washes in PBS.  The fish were incubated in increasing 
concentrations of sucrose in PBS (5%, 15% & 30%) waiting each time until the 
fish sank to the bottom of the tube to ensure full permeation of the sucrose to 
the specimen.  Excess sucrose was removed and fish were aligned in OCT 
embedding medium (RA Lamb), three on a single piece of filter paper, pre-cut 
into thin strips.  Samples were snap frozen in pre-chilled isopentane and stored 
at -80oC.  Embedded fish were allowed to thaw for 1 hour in the cryostat prior to 
sectioning (specimen -23oC and blade -21oC).  The paper was removed and the 
specimen mounted on cork disks with OCT embedding medium.  Fish were 
trimmed to the level of the lens by cutting in a transverse plain.  Sections 8µm 
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thick were mounted on gelatine coated slides (0.3% gelatine, 0.1% Chromium 
Potassium Sulphate), slides were left overnight in a fume cupboard to dry. 
 A wax pen was used to draw around samples before a 1 hour incubation in 
either 5% horse serum in PBST or 4% bovine serum albumin (BSA) in tris-
buffered saline solution containing 0.1% tween-20 (TBST).  Samples were 
washed three times with either PBST or TBST and incubated in primary 
antibody: 43DAG (anti β-dystroglycan mouse IgG 1:50; Novocastra), IIH6 (anti 
α-dystroglycan mouse IgM 1:50) in 5% Horse serum PBST and pan-laminin 
(anti rabbit IgG polyclonal 1:100; Sigma) in 4% BSA PBST overnight at 4oC.  
Primary antibody was removed and slides washed three times in either PBST or 
TBST for a minimum of 5 minutes.  Sections were incubated in secondary 
antibody: (Goat anti-mouse IgM Alexa Fluor 594, Invitrogen; 1:500, Goat anti-
mouse IgG Alexa Fluor 594, Invitrogen; 1:500), in 5% Horse serum PBST 
(Donkey anti-rabbit IgG Fluor 594, Invitrogen; 1:250) as described above in 4% 
BSA PBST for 2 hours at room temperature.  Samples were washed a further 
three times in PBST or TBST and mounted in Vectorshield without DAPI.  
Slides were sealed with a cover slip and clear nail varnish.  
2.5 Microscopy   
2.5.1 Light Microscopy 
An epifluorescence stereo microscope (Leica MZ16F) was used to image live 
embryos.  A minimum of five pictures were taken of each individual fish for each 
experimental group.  Toluidine blue stained sections were imaged using an 
Axioplan-2 microscope with an Axiocam HRc camera and the Zeis Plan 
Neofluar 20x/0.5.  The Leica DM2000 Axioplan-2 microscope with a 
PlanNeofluar 20x/0.5 objective and AxioCam HRM was used to capture images 
of immunofluorescence experiments on cryosections.  Wild type fish were used 
to set exposure times and unstained controls were used to confirm minimal 
background levels in fluorescence studies.  
2.5.2 Confocal Microscopy 
Whole mount embryos were analysed on a Zeiss LSM 510 Meta laser scanning 
confocal microscope, using the Argon laser line at 488nm and the HeNe 543nm 
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Plan Neofluar 20x/0.5 Ph2 or Plan Neofluar 40x/1.3 Ph3 (oil) and analysed with 
LSM software-V4.2.0.121.  
2.5.3 Electron Microscopy  
Fish were washed in dH2O and fixed immediately in 2% glutaraldehyde in 0.1M 
sodium cacodylate buffer (Sigma-Aldrich) overnight.  The fish were subjected to 
three 15min washes in cacodylate buffer then stained in 1% osmium tetroxide 
(Agar Scientific) in dH2O for 1 hour.  The fish were washed twice in dH2O for 
15min each before being dehydrated sequentially through acetone solutions of 
increasing concentration (25%, 50%, 75% & twice in 100%).  The samples were 
incubated through increasing concentrations of resin in acetone (25%, 50%, 75% 
& 100%; epoxy resin kit, TAAB Lab. Equip.) and left overnight on a rotator in 
100% resin at RT.  The samples went through a further 4 changes of resin the 
next day over a minimum of 5 hrs.  Resin was polymerised in a 60oC oven 
overnight. 
Blocks were orientated and trimmed on a Reichert-Jung Ultracut-E microtome 
before cutting sections at 1μm thickness.  Sections were collected on glass 
slides in water, dried on a heat block and stained with toluidine blue (0.5% di-
sodium tetraborate, 1% toluidine blue in dH2O and filter sterilised) for 1min on 
the heat block at ~50oC.  Sections were mounted in DPX for imaging.  
Ultrathin sections were cut to 80-110nm as judged by the colour which should 
be a pale gold and collected on washer grids (3mm diameter).  Sections were 
stretched by exposing them to chloroform vapour to eliminate compression 
(undesirable folds) and mounted on pioloform (Agar Scientific) copper washer 
grids.  The washer grids were prepared by dipping a slide in 0.5% pioloform in 
chloroform to create a film on the slide and dried in chloroform vapour.  A 
square piece was cut in the pioloform film coating on the slide and removed by 
floating the square pioloform film piece onto dH2O, the slide was discarded.  
Grids were placed on the pioloform film floating on the dH2O and collected by 
placing parafilm on top (films and grid stick to the parafilm and can be stored in 
a sealed container).  Grids were washed and stained on an EM AC20 (Leica UK 
Ltd.) in 2% aqueous uranyl acetate lead citrate (Agar Scientific).  
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Samples were imaged on a Phillips CM100 Compustage (FEI) Transmission 
Electron Microscope.  Digital images were collected using an AMT CCD camera 
(Deben).    
N.B.  Most of the cutting and preparation of ultrathin sections in the project was 
carried out by Newcastle University Electron Microscopy Unit staff.  The rest of 
the TEM work was carried out independently including normal microtomy and 
imaging.  
2.6 Analysis 
2.6.1 Image Analysis Software and Data Storage 
Image J software was used to calculate the area of the eyes of 3 dpf larvae, 
derived from confocal image projection stacks of the eye vasculature (complete 
cross sections of the eyes; z stacks of 35 slices projected together into one 
image).  The intersegmental vessel heights from the dorsal aorta were 
expressed as a proportion of total somite height as measured using Image J 
software.  Image J was also used to measure eye size from light microscopy 
images and used to calculate the area of each eye of 3dpf larvae.  The vertical 
myosepta angles were calculated using light microscopy images of 3dpf larvae 
of the myotome trunk region.  Data was stored on a secure university server 
which is backed up regularly, files contained reference to magnification, date, 
MO and were organised accordingly in files dependent on experiment and at a 
higher level by technique.    
2.6.2 Statistics 
All basic statistical analysis including un-paired student T-tests were carried out 
in Excel 2007 Microsoft Office.  Chi squared tests and ANOVA analysis was 
carried out in Minitab 16 statistical software package.  To analyse variability 
using a one way ANOVA test, data was first checked for approximate normal 
distribution using a normal probability plot. Comparisons were made using 
Tukey’s analysis.   
N.B. I would like to thank Dr Peter Avery for providing his expert opinion and 
advice on the statistics within the thesis.  
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Chapter 3 Fukutin Deficient Zebrafish have a 
Muscle Eye Brain Phenotype 
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3.1. Introduction 
By using zebrafish as a model for investigating FKRP and fukutin deficiency, a 
greater insight into the mechanism of the associated MD in humans can be 
gained (Fukuyama et al., 1981; Takada et al., 1988; Yoshioka and Kuroki, 1994; 
Bassett and Currie, 2003).  This chapter will focus particularly on the criteria for 
judging the fukutin morphant phenotype and the recapitulation of the 
dystroglycanopathy phenotype in the zebrafish (Yoshioka and Kuroki, 1994; 
Hino et al., 2001; Thornhill et al., 2008).  There is currently no single model that 
recapitulates human fukutin deficiency.  The major drawback of the 
homozygous null mouse model is its inability to survive foetal development past 
E9.5 (Chiyonobu et al., 2005; Kurahashi et al., 2005).  The retrotransposon 
knock-in fukutin mouse model, described in the introduction, survives the 
embryonic stage but have little in the way of pathology despite 
hypoglycosylation of α-dystroglycan.  The fukutin chimeric mouse remains the 
most suitable model to investigate fukutin deficiency (Takeda et al., 2003; 
Kanagawa et al., 2009a; Taniguchi-Ikeda et al., 2011).  As a pilot for the use of 
ZFNs this chapter also describes an attempt to create a stable fkrp mutant line 
in zebrafish using the CoDA protocol. 
 Here the aim is to investigate whether the dystroglycanopathy phenotype is 
present in fukutin knock down zebrafish, comparing the results with those 
published in Lin et al. study (Lin et al., 2011).  Criteria will be applied to the 
knock downs to attempt to align the fukutin morphants with FKRP and 
dystroglycan morphants.  Ultimately, any similarities with other primary and 
secondary dystroglycanopathy models will be assessed (Heasman, 2002; 
Rosen et al., 2009).  
3.1.1 Aims  
 Design ZFNs targeted at the fkrp locus in zebrafish. 
 Assess the efficacy of ZFNs in producing mutations at the fkrp locus in 
zebrafish.  
 Produce an allelic series of fkrp mutant zebrafish. 
 To test MO that inhibit fktn expression and to study any associated 
pathology. 
 To design criteria for the classification of morphant severity that is 
applicable for dystroglycanopathy knock down models.  
 To assess the 30-12Apr05B fktn MO phenotype in the context of the 
phenotype range described in FKRP and dystroglycan knock down 
zebrafish.  
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 To assess the 30-12Apr05B fktn MO phenotype in the context of the 
muscle, eye and brain pathology observed in patients with mutations in 
the FKTN gene.  
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3.2 Results  
3.2.1 CoDA Based ZFN Technology 
An attempt to create an allelic series of fkrp mutant zebrafish was made using 
the CoDA protocol.  Overall the protocol involved designing ZFN pairs in silico 
that targeted regions within the fkrp gene to be synthesized commercially.  
These sequences were then cloned into expression vectors that contained both 
the Fok-1 nuclease coding sequence and a T7 RNA polymerase initiation site.  
These vectors could then be linearised and used to generate mRNA, combining 
the pair of in vitro trasnscribed ZFNs for injection into zebrafish eggs.  A 
selection of injected zebrafish were then screened for somatic mutations that 
could potentially be passed through the germline into the next generation of fish.  
At this stage genotype and phenotype could be defined for any mutants 
successfully generated (Sander et al., 2010). 
The zebrafish fkrp transcript (NC_007126.5) was entered into ZiFit Version 3.3.  
The programme identified two potential zinc finger pairs with five base pair 
spacer regions (5-1 & 5-2) and one with a seven base pair (7-1) spacer region.  
The first 5-1 FKRP ZFN was targeted close to the N-terminus and the 5-2 was 
targeted with proximity to the LiCD domain of the fkrp transcript.  Both regions 
have previously been associated with mutations in the FKRP gene in patients 
(Figure 1.6; Van Reeuwijk et al., 2010).  The sequences for the FKRP 5-1 & 5-2 
were sent for synthesis by Eurofins MWG Operon.  Each zinc finger array was 
subsequently cloned into the Fok-1 nuclease containing pMLM290/292.  
Vectors were digested at the BamHI and XbaI restriction sites, to test whether 
the inserts were correctly cloned into pMLM290/292, the products were 
visualised on an agarose gel, and excised bands were then sent to Eurofins 
MWG for sequencing.  Bands were observed at just under 300bp and 
sequencing confirmed the inserts were the correct sequence (Figure 3.1).  
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Figure 3.1: Digestion of pMLM290/292 vectors containing zinc finger 
arrays 
 A: Plasmids containing 5-1 (L1,R1) and 5-2 (L2,R2) ZFNs were digested with BamHI 
and XbaI and resolved on an agarose gel relative to a 1kb ladder.  pMLM290/292 
vectors are as expected above the 1kbp and inserts just below 300bps.  BPs: base 
pairs.  Vector maps for Fok-1 nuclease containing vectors pMLM290 and pMLM292.  
pMLM290 used for left hand ZFNs and pMLM292 for right hand ZFNs, with a 5 bp 
spacer region.  Figures copied directly from the addgene website: 
[http://www.addgene.org/zfc/, accessed 4 January 2013]. 
Injected mRNA in zebrafish is translated by the embryonic translation 
machinery into the ZFN proteins.  The poly-adenylation of the mRNA is an 
important step for several reasons including nuclear export, translation and 
stability.  The addition of a cap to the first 5' guanine residue of the mRNA is 
essential for maturation of the mRNA and therefore translation.  To generate the 
mRNA the pMLM290/292 plasmids containing the correct inserts were 
linearised with PmeI.  A small volume was tested by visualisation on an agarose 
gel and found to be correctly linearised.  Capped mRNA with poly-adenylated 
(poly-A) tailing was generated from the linearised pMLM290/292 vectors (Figure 
3.2).  The positive (+) bands represent successful mRNA creation with poly-A 
tails and 5' cap, the negative bands have no poly-A tailing and therefore were 
observed as lower molecular weight bands on the gel.  A denaturing gel would 
give better resolution, which is not required in this instance as the step only acts 
as check that mRNA is created and has been fully poly-adenylated.  
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Figure 3.2: In vitro transcription reaction 
Capping andadding a poly adenylated tail to mRNA greatly imporves the efficiency of 
mRNA translation into ZFNs. pMLM 290/292 containing ZFN inserts were linearised 
and mRNA is generated in vitro.  mRNA before poly-A tailing (-) and after (+), 5-1 
(L1,R1) and 5-2 (L2,R2) ZFNs .  The generated mRNA of the two fingers was 
combined and injected into the zebrafish embryos.   
The FKRP 5-1 and 5-2 mRNA was injected into the yolk sack close to the cell 
nucleus of zebrafish embryos at the single cell stage of development.  The 
embryos were allowed to develop for 4 hours before an initial check on their 
viability was carried out and none of non-injected embryos were found dead at 
this stage.  Dead embryos were found in both sets of injected embryos with 5-1 
and 5-2 ZFN mRNA.  At 1dpf both injected groups had higher proportions of 
dead embryos than the non-injected controls.  The embryos that survived in the 
injected FKRP 5-1 and 5-2 groups could in 17% and 21% of cases respectively 
be seen to have an abnormal morphological phenotype in comparison to 
controls where no embryos had abnormal phenotypes (Table 3.1).  Embryos 
injected with mRNA are expected to have an “RNA phenotype” (Persengiev et 
al., 2004; Figure 3.3).  The RNA phenotype can be defined as all the non-
specific effects that arise from injection of concentrated mRNA.  Note the 
straight tails of the 3dpf non-injected larvae in comparison to occasionally dorsal 
curvature in the tail of the injected embryos.  Recent reports predict CoDA ZFNs 
to produce a much lower somatic mutation rate (~1.1-3.3%) in the injected 
embryos than previously thought (~10%; Sander et al., 2010; Moore et al., 
2012b).  The dorsal tail curvature therefore is likely to be a non-specific side 
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effect of mRNA injection and not as a result of inducing an indel mutation in the 
fkrp gene.  
 
Dead 4hpf 
(%) 
1dpf 
Total (n) 
Dead (%) Alive (%) 
Phenotype 
(%) 
FKRP 5-1 51 (11) 204 (46) 116 (26) 76 (17) 448 
FKRP 5-2 63 (20) 116 (37) 71 (23) 62 (20) 312 
Non-
Injected 
0 (0) 126 (21) 464 (79) 0 (0) 590 
Table 3.1: Viability of fish injected with ZFNs 
Viability data from injection of 300pg of FKRP 5-2 ZFN in AB* wild type or non-injected 
zebrafish embryos at 1dpf.  Dead embryos were removed at 4hpf and 1dpf the 
remaining embryos were sequenced for mutations. 
 
Figure 3.3: Light microscope images of wild type larvae at 3dpf 
 Fish were either uninjected (A) or injected with 300pg of FKRP 5-2 ZFN (B). Note the 
straight tails in the larvae in (A) and the curvature of the tail in about a third of the 
mRNA injected fish (B).  Tail curvature is a common finding in fish injected with mRNA 
and is unlikely to be as a result of a mutation created by the ZFNs.   
Two small clutches of 10, 2dpf embryos DNA were pooled for each ZFN pair to 
investigate the somatic mutation rate.  Neither the 5-1 nor 5-2 ZFN pair 
produced an insertion or deletion within the zebrafish fkrp gene when the 190 
samples were screened for each ZFN pair.  The 50% predicted success rate 
discussed in the initial CoDA literature has been revised by more recent data to 
a much more conservative 17% (Sander et al., 2010; Moore et al., 2012b).  
Since not even a low somatic mutation rate was achieved with either pair of 
ZFN’s, no further work was continued using ZFN technology.   
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3.2.3 The Zebrafish Fukutin Protein  
It has previously been proposed that since fukutin and FKRP have very similar 
structures based on homology in the hydrophobic transmembrane spanning 
region and the putative catalytic domains.  Here the similarities in amino acid 
structure are compared between species: zebrafish, human and mouse (Figure 
3.4).  A  Database (ZDB-GENE-070410-96) search identified a single gene for 
fukutin in the zebrafish genome, encoding a 457-amino-acid polypeptide located 
on chromosome 5.  There was 57% identity and 72% similarity of amino acid 
sequence between zebrafish and humans (Figure 3.5; Moore et al., 2008; 
Drummond AJ, 2011 ).   
 
Figure 3.4: Unrooted phylogenetic tree to show the inferred genetic 
relationship of the fukutin and FKRP proteins in humans, mouse and 
zebrafish 
Each node represents FKRP or fukutin in zebrafish, mice or humans.  Distances are 
based on the amino acid sequences of each of the nodes.  The distance between the 
fukutin nodes is smaller than that between fukutin and any FKRP node (Drummond AJ, 
2011 ).    
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Figure 3.5: Comparative homology plot of Fukutin protein sequence from 
zebrafish and human.  
Identical amino acids are on a green background, similar amino acids are on a red 
background.  Overall, there is 57% identity and 72% similarity of amino acid sequence 
between zebrafish and humans. 
3.2.4 Morpholino 30-12Apr05B Induces Splicing Abnormalities Leading to 
Truncation of Fukutin Transcript 
The wild type AB line (Cha and Weinstein, 2007) was chosen to study the 
effects of knocking down fukutin in zebrafish.  Importantly the AB line is the best 
characterised and most used wild type strain.  A novel antisense spliceosomal 
MO (30-12Apr05B) targeting fktn at the boundary between intron 3 and exon 4 
(Figure 3.6A) was designed to induce a frameshift mutation.  Analysis by 
reverse transcriptase-polymerase chain reaction (RT-PCR) using primers in the 
flanking exons confirmed the ability of 30-12Apr05B to alter fktn mRNA splicing 
(Figure 3.6B).  Wild type fukutin PCR products were observed in all embryos at 
the expected size of approximately 500bps.  In the injected embryos a mis-
spliced band was observed at 400bp which was not completely separated from 
wild type fktn PCR product (Figure 3.6B) and might represents a truncated form 
of fktn. Mis-spliced products were observed at 200 bp and 150 bp which were 
identified as representing loss of exon 4 following isolation and sequencing 
(Figure 3.6C-D).  Previously published translation blocking MO were used to 
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knock down expression of FKRP and dystroglycan as previously described 
(Parsons et al., 2002a; Thornhill et al., 2008; Kawahara et al., 2010; Lin et al., 
2011). 
 
 A 
 
 B 
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Figure 3.6: 30-12Apr05B-fukutin MO induces splicing aberrations in vivo 
 A: Diagram of the zebrafish fktn gene, the MO target site and the position of the 
primers used to verify the splicing defects induced by the MO. Boxes represent exons, 
the lines between the boxes represent the introns.  Boxes below shows number of 
base pairs in exons and introns, numbers represent number of bps and correspond to 
box and line fktn gene diagram directly above them.  B: RT-PCR of fktn transcripts 
using primers in exons on either side of the target site.  The band at 500bp 
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corresponds to normally spliced fukutin, while the shorter fragments correspond to mis-
spliced products.  2ng of 30-12Apr05B-fukutin MO was injected into the embryos and 
only embryos that were judged to have a phenotype at 1dpf by the criteria in Table 2.2 
were used.  C: Sequencing results of excised bands top wild type (2-3-4-5), middle (2-
3-5A) and bottom (2-3-5B) refer to bands excised from gel sequence aligned with wild 
type fktn mRNA, accession number: NM_001042694.  D: Chromatograms of splice 
products aligned against mRNA.   
3.2.5 Optimising 30-12Apr05B-fukutin MO to Produce the Most 
Comprehensive Range of Morphant Phenotypes  
MOs are known to produce a spectrum of phenotypes, a valuable attribute for 
investigating diseases that have a range of clinical severity.  The severity of 
human dystroglycanopathies varies as a result of different mutations or 
combinations of mutations and heterogeneity in genetic background, see 
introduction Figure1.3, (Yoshioka and Kuroki, 1994; Van Reeuwijk et al., 2010).  
The spectrum of phenotypes produced by MO occurs due to differences in site 
of injection within the yolk sack, concentrations of MO and factors such as 
individual zebrafish epigenetic heterogeneity or simply the stochastic nature of 
living organisms (Nechiporuk et al., 1999).  Criteria were designed that would 
aid in the classification of FKRP, fukutin and dystroglycan morphant phenotypes 
(Table 2.2).  The mildest end of the phenotypic spectrum included fish with no 
visible morphological differences compared to wild type AB strain at a particular 
stage of development based on Kimmel criteria (Kimmel et al., 1995), whilst the 
most severely affected fish did not survive (Thornhill et al., 2008).  Fish with 
intermediate phenotypes were grouped into mild, moderate and severe based 
on the criteria as outlined in Table 2.2.  In most experiments the normal and 
lethal groups were removed from further analysis 
In order to determine the optimal concentration of 30-12Apr05B fukutin MO to 
produce a balanced spectrum of phenotypes, a range of injection 
concentrations were tested.  A balanced range of phenotypes is the optimal 
titration of phenotype to MO concentration.  Fertilised eggs were collected and 
injected between the zygote and first cleavage phases (up to approximately 45 
minutes post fertilisation).  The embryos were collected at 24hpf in the 
pharyngeal phase and manually dechorionated.  A minimum of 3 clutches were 
investigated for each injection concentration.  A range of injection 
concentrations were investigated from 0.5ng-7.5ng of 30-12Apr05B fukutin MO.  
At the lowest concentration no abnormal phenotypes were observed, as judged 
by light microscopy.  However, there was an increase in the number of embryos 
92 
 
which died (24% vs. 8% in the control; Table 3.2).  At the highest MO 
concentration no embryos had survived by 24hpf.  1 & 3ng injection 
concentrations both produced a range of phenotypes, skewed to high 
percentages of mild phenotypes or a greater proportion of morphants at the 
severe end of the spectrum respectively.  The 2ng injection concentration 
produced the most balanced range of phenotypes and was chosen for all 
subsequent 30-12Apr05B-fukutin MO injections (Figure 3.7).  FKRP and 
dystroglycan MO concentrations were chosen based on previously published 
concentrations known to produce suitable ranges of phenotypes (Parsons et al., 
2002a; Thornhill et al., 2008).  
  Normal 
(%) 
Mild 
(%) 
Moderate 
(%) 
Severe 
(%) 
Dead 
4hpf 
(%) 
Dead 
24hpf 
(%) 
Total 
(n) 
0.5ng 64 0 0 0 12 24 208 
1ng 12 24 3 3 8 50 177 
2ng 10 11 9 14 9 47 325 
3ng 6 0 4 5 13 72 153 
7.5ng 0 0 0 0 15 85 278 
Uninjected 88 0 0 0 4 8 892 
Table 3.2: Proportion of each phenotypic class following injection of a 
range of 30-12Apr05B-fukutin MO amounts 
The amount of MO injected was calculated as outlined in the methods, see 2.1.3.  For 
each MO amount phenotype severity was assessed at 24 hours post fertilisation (hpf).  
Morphants were assessed as in Table 2.2 and final counts are expressed as a 
proportion of the total.  Number of dead was also recorded at 4 hpf as an indicator of 
survival after the injection process. 
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Figure 3.7: Proportion of each phenotypic class following injection of a 
range of 30-12Apr05B-fukutin MO amounts 
The amount of MO injected was calculated as outlined in the methods, see 2.1.3.  As 
the amount of MO increases the number of embryos with a more severe phenotype 
increases (Table 2.2) and the phenotype spectrum is skewed towards the severe 
phenotypic categories.  Based on the most balanced and highest number of phenotype 
to no phenotype ratio, 2ng is the optimal amount for the 30-12Apr05B fukutin MO and 
was chosen for all subsequent experiments.  
  Normal 
(%) 
Mild 
(%) 
Moderate 
(%) 
Severe 
(%) 
Dead 
(%) 
Total (n) 
Fukutin Mo 
2ng 
10 9 7 12 62 252 
FKRP Mo 
10ng 
12 17 14 11 46 286 
Dystroglycan 
Mo 5ng 
40 9 2 3 46 384 
CoMo 10ng 84 0 0 0 16 346 
Uninjected 85 0 0 0 15 427 
Table 3.3: The range of phenotypes induced by injection of 10ng control, 
10ng FKRP, 2ng 30-12Apr05B-fukutin and 5ng dystroglycan MO 
For each MO phenotype severity was assessed at 1 day post fertilisation (dpf).  
Morphants were assessed as in Table 2.2 and final counts are expressed as proportion 
of the total.  The amount of MO injected was calculated as outlined in the methods, see 
2.1.3. 
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Figure 3.8: The range of phenotypes induced by injection of 10ng control, 
10ng FKRP, 2ng 30-12Apr05B-fukutin and 5ng dystroglycan MO 
Phenotypes were judged on morphological grounds based on Table 2.2.  The range of 
phenotypes observed spanned embryos with a normal appearance to the most severe 
which were found dead at 1dpf.  The amount of MO injected was calculated as outlined 
in the methods, see 2.1.3. 
The proportion of embryos found dead in the control MO injected group was not 
significantly different from that of the uninjected controls.  The FKRP and 
dystroglycan MO injections produced the greatest and narrowest phenotype 
ranges respectively.  FKRP, fukutin and dystroglycan MO injected embryos all 
had a higher proportion of dead embryos at 1 dpf when compared to controls, 
indicating that mortality was due to specific effects of the MO sequence (Table 
3.3 & Figure 3.8).  
Phenotype ranges had previously been reported for FKRP and dystroglycan 
MO injections.  However no criteria had been established to define each 
phenotype category (Thornhill et al., 2008; Kawahara et al., 2010).  The criteria 
in Table 2.2 were established on the basis that difference in MO sequences will 
have different effects on gene expression.  Redundancy and turnover of the 
gene will also have differential outcomes that affect the efficacy of the individual 
MO.  A criterion allows MO concentration to be titrated against severity of 
phenotype.  In order to compare the function of FKRP and fukutin and 
dystroglycan in the same molecular axis, it is desirable to knock each of them 
down to a similar extent.  The assumption can be made that genetic pathways 
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are being knocked down to a similar extent, once similar phenotype ranges are 
achieved, by testing a range of MO concentrations.  Therefore effects observed 
on structure are thought to be genuine and not based on individual variation 
amongst the MOs.   
As expected, the wild type embryos showed no deviation from the normal group, 
but occasional mild pathological features were identified in fish in the control 
MO group (Table 2.2).  These features are defined as non-specific effects of 
MO injections and have been discussed in a wide range of zebrafish MO 
literature (Bill et al., 2009).  Each of the fukutin, FKRP, and dystroglycan MO 
produced phenotypes that fell into each major category of the criteria at both 1 
and 3 dpf ranging from normal to lethal.  The mild to severe phenotypes can be 
seen in Figure 3.9 and Figure 3.10.  A comparable range of phenotypes as 
observed at 1dpf is present at 3dpf for all FKRP, fukutin and dystroglycan 
morphants.  Fukutin, FKRP and dystroglycan morphants have clear overlapping 
morphology, (Figure 3.9 & Figure 3.10) that can be sorted based on the criteria 
described in Table 2.2.  The feature with the greatest utility for assessing 
phenotype is tail curvature.  1dpf tail curvature (Figure 3.9) correlates well with 
that of the 3dpf in equivalent phenotype categories across the spectrum of the 
FKRP, fukutin and dystroglycan morphants.  Therefore the combination of tail 
curvature, eye, brain and other variable features was considered in the 
classification of the phenotype up to 1dpf.  Thereafter, the tail curvature was 
used as the most appropriate indicator for sorting morphant fish within the 
phenotype spectrum.   
96 
 
 
Figure 3.9: Light microscope images of embryos at 1 dpf  
Embryos were either untreated or injected with MO at 10ng control & FKRP, 2ng 
fukutin, or 5ng dystroglycan.  Embryos were staged according to Kimmel et al. 1995, 
(Table 2.1 & Figure 2.1).  Embryos were sorted according to phenotypes as described 
in Table 2.2.  The amount of MO injected was calculated as outlined in the methods, 
see 2.1.3, 
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Figure 3.10: Light microscope images of larvae at 3dpf 
Fish were either untreated or injected with MO at 10ng control & FKRP, 2ng 30-
12Apr05B fktn MO, or 5ng dystroglycan.  Embryos were staged according to Kimmel et 
al. 1995, (Figure 2.1 & Table 2.1).  Embryos were sorted according to phenotypes as 
described in Table 2.2.  The amount of MO injected was calculated as outlined in the 
methods, see 2.1.3, 
3.2.6 30-12Apr05B- Fukutin MO Produces a Dystroglycanopathy 
Phenotype at 1 dpf  
Morphant morphology was assessed at 1dpf to establish efficacy of the 30-
12Apr05B fktn MO in generating a muscle, eye and brain pathology in the 
morphant embryos.  Light microscopy was used to capture a minimum of five 
images of embryos within each phenotype group.  Embryos were staged 
according to Kimmel’s criteria and placed into phenotype groups according to 
criteria outlined in Table 2.2. 
Overall, there was a clear overlap of abnormalities detected in the fukutin fish 
with those that had been previously described in FKRP and dystroglycan 
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morphants (Parsons et al., 2002a; Thornhill et al., 2008; Kawahara et al., 2010).  
The morphological data suggest a slight delay in muscle, eye and brain 
development of morphant fukutin embryos in comparison to control injected 
embryos at 1dpf (Figure 3.11A-D).  The muscle morphology was investigated at 
1dpf, a time point prior to the development of pigmentation.  The segmentation 
period is the key period in early muscle development occurring between the first 
somite furrow appearing at 101/3 hpf and the start of the hatching period at 2dpf 
(Kimmel et al., 1995).  By 1dpf all 26 of the somites are present and are visible 
in the non-injected embryos (Figure 3.11A).  In control embryos the somites 
have a “chevron” shape delineated by the vertical myosepta which is more 
rounded in all morphant embryos (Figure 3.11 A-D).  At the severe end of all 
phenotypic spectra somite boundaries were no longer visible.  More severely 
affected fish as judged by overall criteria outlined in Table 2.2, had less clearly 
delineated myosepta.  Aberrant muscle morphology can demonstrate potential 
sarcolemmal instability in fukutin deficient embryos (Figure 3.11; Takeda et al., 
2003; Kurahashi et al., 2005). 
Numerical analysis of the angles inside the chevron of the vertical myosepta 
were measured (Figure 3.12).  The angle inside the chevron was measured in 
controls to have a mean of (94o) in non-injected and in control MO injected (95o).  
The difference was found to not be significant with a student unpaired T-test 
between control MO and non-injected embryos.  The vertical myosepta chevron 
angle was found to be significantly more obtuse in the FKRP (132o), fukutin 
(144o) and dystroglycan (131o).  The FKRP, fukutin and dystroglycan morphants 
all were significantly more obtuse in myosepta angle than control injected 
embryos (p<1x10-4 in all cases; Figure 3.11 & Figure 3.12). 
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Figure 3.11: Light microscope images of embryos at 1day post fertilisation 
(dpf)  
Morphology was investigated using light microscopy in 1dpf dechorinated embryos.  
Embryos were either untreated AB or injected with 10ng of control MO (A), 2ng of 30-
12Apr05B-fukutin MO (B), 10ng of fkrp MO (C), 5ng of dystroglycan MO (D).  Embryos 
were staged according to Kimmel et al. and phenotypes were sorted according to the 
criteria outlined in Table 2.2.  Enlarged views of myotome (orange border), eyes (green 
border) and brain (blue border), it should be noted in some instances the boxes are not 
exactly placed due to limitations in software.  Fukutin morphants have abnormal somite 
shape, due rounding of the vertical myosepta, outlined by red dashes and denoted by 
red arrows.  Fukutin morphants have micropthalmia and mid brain (MB) definition loss 
in the most severe fukutin morphants, black triangle- NC= notochord & YS= yolk sack.  
The tail curvature is indicative of the loss of sarcolemmal stability and 
perturbation of myosepta structure, therefore it is a good indicator of muscle 
pathology (Steffen et al., 2007).  The chorion might be accentuating the 
curvature of the tail in the embryos that are moving less, and further analysis of 
this point is required.  The tail in control embryos is straight with a small ventral 
curvature at the most distal end of the tail at 1dpf (Figure 3.11A & Figure 3.13).  
The fukutin morphants in the mild phenotype category had a slight ventral 
curvature of their entire distal portions (Figure 3.11B & Figure 3.13).  The tail 
curvature in the mild and moderate phenotype categories was in general more 
pronounced in the fukutin morphants compared to FKRP and dystroglycan 
morphants.  The severe fukutin and dystroglycan morphants were found to have 
clearly abnormal body shape and much shorter tails (Figure 3.11B-D & Figure 
3.13).  An increasing proportion of the fukutin morphants from the mild to severe 
morphant phenotype had dorsal tail curvature.  Embryos at the more severe 
end of the FKRP and dystroglycan morphant spectrum were observed to have a 
dorsal tail curvature (Table 3.4 & Figure 3.13).  Chi-squared tests comparing 
number of morphant fish with a curved tail against controls found there to be 
significantly P-value<1x10-4, more curved tails in the combined morphant 
embryo group than in the combined control group. 
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Figure 3.12: Angle of the vertical myosepta in 1dpf morphant embryos 
Image-J analysis software was used to measure vertical myosepta angles of light 
microscopy images of 1 dpf trunks.  Angle measured from where the horizontal 
myosepta bisects the vertical myosepta to each of the ends of the vertical myosepta at 
the periphery of the embryo.  A minimum of five somites in threeembryos were 
assessed in for each morphant phenotype and grouped.  Fukutin morphants were 
shown to have the most obtuse angled vertical myosepta when compared to 
dystroglycan and fkrp morphants.  Morphant vertical myosepta angles were compared 
to control MO vertical myosepta angles using the unpaired students t-test:  *** p <1x10-
4.  
Studies have shown that FKRP and fukutin are important for the correct 
development of the glia limitans, an important basement membrane in the brain 
(Chiyonobu et al., 2005; Kurahashi et al., 2005).  Loss of glia limitans integrity 
results in glia projecting beyond the membrane, resulting in cobblestone 
lissencephaly in dystroglycanopathy patients (Yoshioka and Kuroki, 1994; Satz 
et al., 2008).  Mid-brain abnormalities have been demonstrated in 1dpf 
zebrafish embryos (Thornhill et al., 2008) and so the hypothesis is that a similar 
abnormality might be present in fukutin morphant embryos.  The mid-brain is a 
defined structure visible by light microscopy as a small vertical groove posterior 
to the eye at 1dpf in controls (Figure 3.11A).  From a morphological perspective, 
the fukutin knockdown embryos showed structural mid-brain abnormalities, 
most prominent in fish embryos with a more severe phenotype (Figure 3.11B).  
FKRP and dystroglycan morphants also show increasing loss of definition of the 
mid-brain groove with increasing severity of phenotype (Figure 3.11C-D).  
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 Straight (%) Dorsal (%) Ventral (%) Total (n) 
Wild type 100 0 0 478 
Control MO 98 0 2 345 
Fukutin mild 0 5 95 81 
Fukutin moderate 0 36 64 76 
Fukutin severe 0 53 47 50 
FKRP mild 12 0 88 63 
FKRP moderate 0 5 95 56 
FKRP severe 0 14 86 60 
Dystroglycan mild 4 0 96 46 
Dystroglycan moderate 0 2 98 49 
Dystroglycan severe 0 11 89 41 
Table 3.4: Assessment of tail curvature in 1dpf embryos 
Tail curvature was assessed to be either straight, curved dorsally or ventrally in 
dechorionated dystroglycanopathy morphant embryos at 1dpf. 
 
Figure 3.13: Assessment of tail curvature in 1dpf embryos  
Tail curvature was assessed using light microscopy and judged to be either straight or 
have a ventral curvature or dorsal curvature in 1dpf dechorinated embryos.  All 
morphants had an increased proportion of curvature in tails as would be expected 
when criteria in Table 2.2, are applied.  Fukutin morphants had the highest proportion 
of dorsal tail curvature compared to dystroglycan and FKRP morphants. Dorsal and 
ventral tail curvature was combined and classified as abnormal tail curvature, this 
group was then compared against staright tails.  Chi-squared analysis for each group 
was subsequently carried out against the control MO group and in each case was 
found to be p<1x10-4.  
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Both the fish and mouse models for FKRP deficiency have micropthalmia and 
morphological eye structural problems (Satz et al., 2008; Thornhill et al., 2008) 
and  these abnormalities are visible at 1dpf in fukutin deficient morphants.  The 
vertical groove in the eye known as the hyaloid canal is only found in control 
fish (Figure 3.11A), whilst deformed outer eye structure is found in the more 
severe fukutin, fkrp and dystroglycan morphants, (Figure 3.11B-D). 
The notochord is an important structure during the early stages of development, 
providing developmental cues for zebrafish trunk morphogenesis (Stemple, 
2005).  A previous study identified notochord abnormalities in fkrp morphants 
(Thornhill et al., 2008).  The notochord is visible in non-injected and control MO 
injected embryos as a cylinder running from the mid line through the full length 
of the myotome (Figure 3.11A).  The notochord is visible in all morphants and 
no noticeable structural defects were observed at this level of resolution (Figure 
3.11B-D).  Histological analysis is therefore required to draw firm conclusions 
on notochord structure.  
3.2.7 2 dpf Fukutin Morphant Embryos 
The main features of the 2dpf embryo period are: hatching, increase in 
pigmentation and the development of a visible pericardium.  Based on previous 
studies where fkrp and dag1 expression were knocked down in zebrafish, the 
prediction is that the above features would also be affected by knockdown of 
fktn expression (Parsons et al., 2002a; Thornhill et al., 2008; Kawahara et al., 
2010).  
Evaluating the pigmentation patterns of the zebrafish can help to distinguish a 
systemic developmental defect from a defect in a specific system.  Pigmentation 
in the natural environment is important for camouflaging the zebrafish.  At the 
hatching stage of development (long-pec period, 2dpf), the melanophores 
(equivalent to human melanocytes and expressing black pigment) are visible 
along the lateral stripe (Figure 3.14A-D).  Melanocytes run along the dorsum of 
the posterior portion of wild type and control MO injected embryos.  
Pigmentation irregularities and delays in hatching suggest that the fukutin MO 
might have induced a developmental delay.  The changes in melanocyte pattern 
might suggest the fukutin MO has affected Wnt signalling, a factor known to be 
important for melanocyte migration (Jin et al., 2001).  The somitic structure is 
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not visible in non-injected controls since at this stage of development 
pigmentation obscures these structures.  Therefore it is not possible to conclude 
whether there is tissue specific developmental delay.  It would be difficult to 
conclude that a change in pigmentation pattern is anything other than 
secondary to the overall changes to body shape of the zebrafish.  Drawing firm 
conclusions from examining pigmentation patterns lies outside the scope of this 
study (Kelsh et al., 1996).  Using a fish line such as Golden which has 
significantly reduced pigmentation, would be a way to view structures 
unhindered by pigmentation.  
The otic vesicle which is visible from 42hpf during the high-pec phase, between 
pharyngeal and hatching phases, can be used as a marker for normal 
development.  At 48hpf the otic vesicle had a similar appearance (i.e. round 
structure directly posterior to the eye dorsal to the pericardium) in fukutin, FKRP 
and dystroglycan morphants when compared to controls.  This suggests, that 
fukutin morphant embryos are not substantially developmentally delayed and 
therefore muscle, eye and brain abnormalities observed in the fukutin 
morphants are due to tissue specific effects of fukutin knock down (Figure 
3.14A-D). 
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Figure 3.14: Light microscope images of embryos at 2dpf. 
Morphology was investigated using light microscopy in 2dpf dechorinated embryos. 
Embryos were either (A) untreated AB or injected with 10ng of control MO (B) injected 
with 2ng of 30-12Apr05B-fukutin MO (C) injected with 10ng of fkrp MO or (D) injected 
with 5ng of dystroglycan MO. Embryos were staged according to Kimmel et al. and 
phenotypes were sorted according to the criteria outlined in (Table 2.2).  Enlarged 
views of head (orange border), trunk (green border).  Red triangle= pericardium, red 
arrows= melanocytes, blue arrows= lateral line, OV= otic vesicle, YS= yolk sack.  
Hatching in embryos maintained at 28oC occurs by 2dpf and a delay in hatching 
is considered to represent a developmental delay.  The majority (96%) of wild 
type and control MO injected embryos (93%) had hatched by 2dpf.  45% of the 
fukutin, 42% of FKRP and 49% of the dystroglycan morphants had to be 
manually dechorionated at 2dpf (Table 3.5 & Figure 3.15). Controls and 
morphants were grouped and tested against one another using a chi-squared 
test p< 1x10-3.  Providing evidence to suggest there is a significant difference in 
hatching at 2dpf in controls when compared to morphants.  Whilst the delay in 
hatching suggests an overall developmental delay, it is also possible that the 
delay in hatching is a consequence of reduced muscle contractures.  Motility is 
required to break out of the chorion thus the defect might be a secondary 
consequence to primary muscle pathology.  Tail coiling is the first identifiable 
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muscle motor function present between 17-26hpf (Saint-Amant et al., 2008).  
Spontaneous embryo coiling within a chorion is absent in other studies where 
motility is impaired (Dowling et al., 2009).  Inducing a developmental delay and 
comparing with immobilised fish, might resolve the difference between 
developmental delay and motility in regards to hatching.  
 Wild Type Control MO Fukutin FKRP Dystroglycan 
Hatched (%) 96 93 55 58 51 
Unhatched (%) 4 7 45 42 49 
Total (n) 240 138 101 95 135 
Table 3.5: Delay in embryo hatching at 2 dpf 
Light microscopy was used to investigate the hatched/unhatched status of embryos at 
2dpf it would be expected that most embryos would hatch by 2dpf.  Wild type, control 
MO, 30-12Apr05B-fukutin MO, fkrp MO and dystroglycan MO were observed to be in 
(unhatched) or out of their chorions (hatched) at 2dpf. 
 
Figure 3.15: Delay in morphant embryo hatching at 2dpf  
Light microscopy was used to investigate the hatched/unhatched status of 
embryos at 2dpf it would be expected that most embryos would hatch by 2dpf.  
Wild type, control MO, 30-12Apr05B-fukutin MO, fkrp MO and dystroglycan MO 
were observed to be in (unhatched) or out of their chorions (hatched) at 2dpf.   
3.2.8 The Fukutin Morphant Larvae at 3dpf 
To investigate the range of fukutin, fkrp and dystroglycan morphant phenotypes 
at 3dpf, light microscopy was used to image the larvae.  The pathology at 3dpf 
may be as a result of developmental delay since at the severe end of the 
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morphant phenotype spectrum there were fewer somites observed in the trunk.  
A developmental delay would imply fkrp, fukutin and dystroglycan are important 
developmentally, whereas tissue specific pathology suggests an alternative 
mechanism.  Melanophores in lateral stripe and iridiphores in the eye are 
present in early larval phase control embryos but are not visible in moderate or 
severe fukutin morphants, suggesting a possible developmental delay in the 
morphants (Figure 3.16A-D).  The melanophores were similar to controls in all 
dystroglycan and most fkrp morphants.  The pattern of the melanophores in the 
fkrp and dystroglycan morphants is likely to be as a consequence of the tail 
curvature and distortion rather than a primary abnormality. 
The tails of the wild type and control MO injected fish are straight through their 
full length from the primula-16 (16mm length) stage of development at 31hpf to 
the protruding mouth phase at 3dpf.  The mild fukutin morphants had a slight 
ventral tail curvature which was at a greater angle ventrally in the moderate 
phenotype group.  The tail curvature could also be observed in fkrp and 
dystroglycan mild and moderate morphants.  An abnormal body shape and 
shorter tail as consequence of fewer somites were observed at the severe end 
of the spectrum of all morphants.  A dorsal curvature in the tail was found more 
often than ventral curvature in dystroglycan and fukutin morphants (Figure 
3.16A-D).  
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Figure 3.16: Light microscope images of larvae at 3dpf 
Morphology was investigated using light microscopy in 3dpf Larvae. Larvae were either 
(A) untreated AB or injected with 10ng of control MO (B) injected with 2ng of 30-
12Apr05B fktn MO (C) injected with 10ng of FKRP MO or (D) injected with 5ng of 
Dystroglycan MO.  Embryos were staged according to Kimmel et al. and phenotypes 
were sorted according to the criteria outlined in (Table 2.2).  Enlarged views of head 
(orange border), trunk (green border).  Red triangle: notochord, blue triangle: 
pericardium, red dashes vertical myosepta, green arrows: melanocytes, blue arrows: 
lateral line, OV: otic vesicle, YS: yolk sack.  
Wild type and control MO injected larvae had eyes which were round and 
pigmented preventing clear observations of the lens.  Fukutin, fkrp and 
dystroglycan MO injected embryos had eyes where notable distortion to eye 
shape at the severe end of the phenotypic spectrum was evident.  Eye area 
was smaller in the fukutin morphants and at the severe end of the fkrp morphant 
spectrum, (Figure 3.16A-D) when compared to control fish eyes.  Eye area of 
the fukutin morphant was significantly smaller than control MO injected embryos, 
fkrp and dystroglycan morphants (Table 3.6 & Figure 3.17).  
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Figure 3.17: Mean eye size for 3dpf fish 
Eye size was assessed on Image-J analysis software using light microscopy images of 
3dpf larvae eyes and expressed in arbitrary units.  A minimum of four fishfish from each 
of the three phenotype groups for each morphant group were assessed for eye size, 
phenotypes groups defined by criteria outlined in Table 2.2.  Fukutin eye size was 
significantly smaller than control MO injected embryos, FKRP and dystroglycan 
morphants.  Morphant eye areas were compared to the control MO eye areas using the 
unpaired student t-test: * p= <0.05 ** p= <1x10-3, *** p= <1x10-4. 
Since progressive cardiac involvement is a characteristic of FCMD patients 
signs of cardiac failure were investigated in the morphant zebrafish (Nakanishi 
et al., 2006).  A swollen pericardium is a sign of cardiac hypertrophy and can be 
observed in a higher proportion of control MO injected larvae (9%) when 
compared to wild type larvae (0%).  Therefore cardiac oedema in a small 
proportion of morphant fish can be considered to be a nonspecific effect of MO 
injection (Bill et al., 2009).  However, a swollen pericardium was observed in a 
higher proportion of the severe morphants (fukutin 42%, fkrp 37%, dystroglycan 
46%).  All morphants were observed to have cardiac oedema with higher 
frequency than observed in control injected morphants (Table 3.6, Figure 
3.16A-D & Figure 3.18).  Cardiac muscle is therefore also affected in 
dystroglycan-deficient zebrafish.  
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 No oedema (%) Pericardial oedema (%) Total (n) 
Wild type 100 0 267 
Control MO 91 9 124 
Fukutin mild 83 17 39 
Fukutin moderate 82 18 43 
Fukutin severe 58 42 66 
FKRP mild 85 15 45 
FKRP moderate 79 21 46 
FKRP severe 63 37 35 
Dystroglycan mild 77 23 48 
Dystroglycan moderate 78 22 27 
Dystroglycan severe 54 46 31 
Table 3.6: Pericardial oedema in 3dpf larvae 
Pericardial oedema was judged on morphology in 3 dpf larvae in the morphant fish.  
 
Figure 3.18: Pericardial oedema in 3dpf larvae 
Pericardial oedema was judged on morphology in 3 dpf larvae in the morphant fish 
using images taken on light microscopy.  Pericardial oedema was found in a small 
proportion of Control MO injected fish.  The morphant fish all had a higher incidence of 
pericardial oedema than control MO injected larvae.  The most notable pericardial 
oedema was observed in the morphants in the most severe phenotypic groups. 
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Active avoidance is a feature observed in the early larval phase of development 
in the majority of wild type larvae.  With stimulation (a light touch of a pipette tip 
to the body at 3dpf) the wild type larvae swim away.  A very small proportion of 
wild type and control MO injected larvae did not move at all in each case (n=25).  
Rarely, control MO were observed fasciculating (involuntary muscle contraction 
or relaxation) suggesting another non-specific MO effect.  Swimming in circles 
and fasciculations are not considered normal features of development at this 
stage.  An increasing proportion of fkrp, fukutin and dystroglycan morphants 
with these features were observed as the phenotypic severity increased.  
Fukutin morphants were observed fasciculating or swimming around in a tight 
circle, indicating that they have an intact peripheral nervous system, as also 
observed in fkrp and dystroglycan morphants (Thornhill et al., 2008).  The no 
movement phenotype also increased with increasing phenotype severity in the 
morphants.  Consequently with increasing morphant severity the proportion of 
fish with a normal swim response decreased (Figure 3.19).   
 No 
Movement 
Fasciculation Swims in 
Circles 
Swims 
Away 
Wild type 1 0 0 24 
Control MO 1 1 0 23 
Fukutin mild 3 6 14 2 
Fukutin moderate 7 6 11 1 
Fukutin severe 18 5 2 0 
FKRP mild 4 4 7 10 
FKRP moderate 7 8 8 2 
FKRP severe 15 5 5 0 
Dystroglycan mild 4 8 7 6 
Dystroglycan 
moderate 
9 7 8 1 
Dystroglycan 
severe 
15 4 6 0 
Table 3.7: Response to touch of 3dpf larvae 
Larvae were categorised as “swims away” (as expected for wild type fish as an escape 
mechanism), “swims around a point”, fasciculates, or no movement.  Morphant larvae 
display increasing touch response severity with severity of phenotype. 
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Figure 3.19: Response to touch of 3dpf larvae 
3dpf larvae’s movement was tested by stimulating with the point of a 10µl pipette tip.  
Larvae were categorised as “swims away” (as expected for wild type fish as an escape 
mechanism), “swims around a point”, fasciculates, or no movement.  Morphant larvae 
display increasing touch response severity with severity of phenotype.  
3.2.9 The Fukutin Morphant Fish at 5dpf 
The phenotype of the fukutin morphant embryos was investigated up to 5dpf 
and for regulatory reasons the fish were not able to be maintained past 5dpf.  
The morphology of 5dpf larvae was observed under light microscopy (Figure 
3.20A).  The 5dpf wild type larvae had a straight tail and the vertical myosepta 
forming the boundaries of the somites had a chevron appearance.  In 5dpf 
fukutin morphants the tail was found to have a ventral curvature and was 
shortened with visible rounding of the somitic myosepta which was similar to 
fkrp and dystroglycan morphants (Figure 3.20B-D).  The microphthalmia and 
cardiac oedema phenotype was also clearly present in 5dpf fukutin, fkrp and 
dystroglycan morphants when compared to controls (Figure 3.20A-D).  The 5dpf 
wild type zebrafish had melanocyte pigmentation regularly spaced along the 
dorsum.  The melanocytes of the fukutin and the more severe fkrp morphants 
were less regularly spaced and fewer in number than in the controls.    
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Figure 3.20: Light microscope images of phenotypes at 5dpf larvae. 
Morphology was investigated using light microscopy in 5dpf larvae.  Larvae were either  
untreated AB or injected with 10ng of control MO (A), injected with 2ng of 30-
12Apr05B-fukutin MO (B), 10ng of fkrp MO (C), 5ng of dystroglycan MO (D).  Larvae 
were staged according to Kimmel et al. 1995, and phenotypes were categorised 
according to the criteria outlined in (Table 2.2).  Enlarged views of head (orange 
border), trunk (green border).  Red triangle: notochord, blue triangle: pericardium, red 
dashes vertical myosepta, green arrows: melanocytes, blue arrows: lateral line, OV: 
otic vesicle, YS: yolk sack, SB: swim bladder.  
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3.3 Summary  
This chapter investigated whether inhibition of fukutin function using antisense 
MO is associated with the dystroglycanopathy features of a muscle-eye-brain 
phenotype, as might be inferred from the human phenotype (Takada et al., 
1988; Yoshioka and Kuroki, 1994; Hino et al., 2001; Toda, 2009).  By testing the 
effect of these MO knockdowns within the confines of defined criteria, fukutin 
knockdown zebrafish could be compared alongside other fkrp and dystroglycan 
morphants without confounding effects of MO efficacy.  Overall, the fukutin 
morphant could be validated as an appropriate model for dystroglycan 
glycosylation defects (Parsons et al., 2002a; Bassett and Currie, 2003; Thornhill 
et al., 2008; Kawahara et al., 2010).     
3.3.1 Dystroglycanopathy Specific Pathology Associated with Fukutin 
knockdown by MO  
Overall the dystroglycanopathy phenotype cannot be distinguished between the 
FKRP, fukutin and dystroglycan morphants.  Morphants had ventral and 
occasional dorsal curvature of the tail and in the most severe morphants smaller 
tails.  Rounding of the chevron appearance of the vertical myosepta suggests 
sarcolemmal abnormalities, a characteristic also seen in muscle specific filamin-
c mutant zebrafish (Ruparelia et al., 2012).  The micropthalmia and 
abnormalities in eye appearance were also observed in fkrp, fukutin and 
dystroglycan morphants, which correlates well with human fukutin associated 
MD (Yoshioka and Kuroki, 1994).  Brain abnormalities in FCMD patients range 
from polymicrogyria to cobblestone lissencephaly.  Similarly, the chimeric mice 
have been shown to have abnormal neuronal migration in the cerebral cortex, 
cerebellum and hippocampus (Takeda et al., 2003; Kanagawa et al., 2009b).  In 
the fukutin, fkrp and dystroglycan knock down zebrafish the mid-brain is 
diminished or completely absent on morphological examination.  Therefore the 
fukutin morphant zebrafish between 1-5dpf recapitulate fukutin deficiency in the 
human condition.  The fukutin morphants are very similar on morphological 
grounds to FKRP and dystroglycan morphants suggesting that the fukutin 
morphant potentially has a similar pathological mechanism (Parsons et al., 
2002b; Takeda et al., 2003; Thornhill et al., 2008; Kawahara et al., 2010). 
While in the process of characterising this model, another study was published 
where fukutin and fkrp were knocked down in, and compared to, a dystroglycan 
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mutant line (dag1hu3072).  The fukutin spliceosomal MO targeted the intron/exon 
boundary of exon 2 producing a similar phenotype to that of the 30-12Apr05B 
fktn MO, described here (Lin et al., 2011).  Although the morphant phenotype 
described in Lin et al. show strong similarities to ours, their work mainly 
characterises the skeletal muscle phenotype and it is therefore complementary 
to our study in the full characterisation of fukutin morphant zebrafish.  Lin et al. 
show that the fkrp and fukutin morphants don't accumulate Evans blue dye 
(EBD) in the muscle fibres suggesting an intact sarcolemma.  Interestingly, this 
result is in contrast to the dag1hu3072 mutant fibres, suggestive of alternative 
mechanisms of pathology in primary to secondary dystroglycanopathy.  The 
evidence presented indicates there might be an alternative mechanism to 
sarcolemmal damage in these morphants, such as the unfolded protein 
response (UPR).  The study also found the elevated endoplasmic reticulum (ER) 
stress was as a direct consequence of proteins that were not folded correctly.  
BiP/GRP78 a chaperone of unfolded proteins was used as a marker of the UPR, 
was found to be increased in fkrp and fukutin knock down models.  It is clear the 
UPR may form part of the mechanism for secondary dystroglycanopathy, 
however the delay in development of the notochord in the models could indicate 
simply a developmental delay in fukutin and fkrp fish muscle (Lin et al., 2011).  
3.3.2 Conclusion 
The clear MEB phenotype in zebrafish where fukutin has been knocked down 
between 1-5dpf indicates that the MO approach is an appropriate strategy to 
investigate the pathology associated with fukutin deficiency (Yoshioka and 
Kuroki, 1994).  The morphological abnormalities found in the fukutin morphants 
are comparable with those found in fkrp and dystroglycan morphant zebrafish 
(Parsons et al., 2002a; Thornhill et al., 2008; Kawahara et al., 2010), an 
unsurprising result considering they have been implicated in the same 
biochemical pathway i.e. modification of mannose residues on dystroglycan 
(Barresi and Campbell, 2005; Kuga et al., 2012a).  Since the dystroglycan 
morphants had a very similar phenotype to both FKRP and fukutin knock down 
fish a more in depth histological and immunological analysis is required to 
distinguish the effects of each gene.  It is however entirely possible that fkrp and 
fukutin have similar function based on the conservation of protein structure and 
morphology of knock downs.  Both may have been conserved as different 
121 
 
pathways that lead to similar modification of dystroglycan, perhaps in a tissue 
and developmental specific fashion.  Under this hypothesis subtleties in 
modification may act as protective mechanisms from old world adeno-viruses 
known to bind to dystroglycan (Manya et al., 2004).  In conclusion, studies 
based on morphological examination alone are unlikely to identify specific 
mechanisms for the pathology associated with 30-12Apr05B-fukutin MO 
knockdown and therefore inferences need to be confirmed with further detailed 
investigation.  
122 
 
Chapter 4 Abnormal Muscle and Notochord in 
Morphant Zebrafish  
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4.1 Introduction 
A clear muscle pathology associated with the knock down of fukutin, fkrp and 
dystroglycan by MO in zebrafish between 1-5dpf, has been shown in the 
previous chapter.  However, no perturbation in the morphant morphology was 
observed that would indicate any notochord pathology, contrary to expectations.  
Further investigation of the notochord is therefore important and is examined in 
more detail in this chapter.  Immunohistochemical and histological analysis 
have been used to investigate the muscle and notochord phenotypes further.  
These two structures are discussed together because of their close association 
during development.  The notochord provides developmental cues for zebrafish 
tail development and generation of myotome (Stemple, 2005).  Specifically, loss 
of basement membrane stability is hypothesised to underpin tail pathology in 
the dystroglycanopathy morphants (Bassett et al., 2003; Bassett and Currie, 
2003; Thornhill et al., 2008; Kawahara et al., 2010). 
In this chapter angiogenesis in dystroglycaonopathy will be investigated.  Here 
the hypothesis is that correct glycosylation of α-dystroglycan is central to 
vascular development.  This is an alternative hypothesis to the “classic vascular 
hypothesis in MD” which is centred on nNOS and chronic hypoxia, discussed in 
the introduction.  For vascular endothelial cells (VEC) to succeed in migrating 
through the myotome they must digest the extracellular matrix (ECM).  The 
behaviour of the VEC’s is known to be influenced by various components of the 
ECM including integrins and laminins.  Other studies have proposed 
dystroglycan to be present at the tip of the growing intersegmental vessels and 
therefore guiding angiogenesis by interacting with laminin in the surrounding 
ECM (Hosokawa et al., 2002; Jacoby et al., 2009).  It would therefore seem 
logical to presume dystroglycan on the angiogenic growth cone, would need to 
be correctly glycosylated by FKRP and fukutin for the growth cone to migrate 
successfully across a somite. 
4.1.1 Aims  
 Histological assessment of muscle and notochord pathology associated 
with fukutin, FKRP and dystroglycan deficiency at 3dpf. 
 Qualitative examination of the ultrastructure of muscle, myosepta and 
notochord in the FKRP, fukutin and dystroglycan morphant larvae. 
 Immunohistochemical studies to examine potential molecular 
mechanisms of muscle pathology. 
124 
 
 Characterisation of the vascular phenotype of the FKRP, fukutin and 
dystroglycan morphant fish. 
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4.2 Results 
4.2.1 Investigation of the Morphant Myotome from a Histological 
Perspective 
Sections through the myotome trunk were stained with toluidine blue to 
investigate the phenotype of fukutin, FKRP and dystroglycan morphants from a 
histological perspective (Figure 4.1 & Figure 4.2).  Longitudinal sections through 
the myotome of the trunk were cut to view muscle fibres running between the 
vertical myosepta.  Another set of transverse sections were cut through the 
trunk at the level of the fifth somite to examine the muscle, horizontal myosepta, 
the notochord and the neural tube.  The sections were cut from 3dpf larvae with 
a moderate phenotype.  In the case of the morphants, a minimum of four 
embryos from two separate experiments were sectioned and the most 
representative image is shown. 
The myosepta in zebrafish are the origin and insertion points of muscle fibres, 
forming boundaries between myotome segments.  The vertical myosepta run 
from the ventral to the dorsal side of the zebrafish, the shape closely resembles 
a chevron when viewed on a longitudinal section of wild type and fish injected 
with control MO.  The normal chevron appearance of the vertical myoseptum is 
disrupted in all morphants appearing flattened and rounded.  The horizontal 
myoseptum runs continually from the anterior to posterior of the trunk either 
side of the notochord in the wild type and control injected fish.  In the 
dystroglycan morphants disruption to the horizontal myoseptum was also visible.  
The fukutin and fkrp morphants appeared to have an enlarged notochord 
preventing clear visualisation of the horizontal myoseptum.  The fkrp , fukutin 
and dystroglycan morphant muscle fibres all run a non-linear course or 
appeared in some instances to be torn.  Whilst there does not seem to be an 
increase in fatty infiltration in the morphants, clear areas between fibres may 
indicate oedematous infiltration.  Overall, the fukutin morphant had the more 
severe muscle fibre phenotype when compared to fkrp or dystroglycan 
morphants (Figure 4.1).   
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Figure 4.1: Longitudinal sections of 3dpf larvae stained with toluidine blue 
showing the myotome trunk 
Morphants were all judged to be moderate phenotype group based on (Table 2.2). 
Muscle fibres in the wild type embryos run between vertical myosepta whereas in the 
dystroglycanopathy fish fibres were found to be disrupted.  Vertical myosepta: green 
dashed line, muscle fibre: red dashed line, horizontal myosepta: black arrows, 
disrupted muscle fibre: red arrows and fat globules: blue arrow, scale bar; left = 50μm, 
right = 20μm. 
The myotome is divided in its entirety by the horizontal myosepta in wild type 
and control MO injected larvae.  In fukutin and dystroglycan morphants the 
horizontal myosepta are completely absent and only partially visible in the fkrp 
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morphants.  There are two alternatives to explain this observation: it is possible 
that the section was cut veryclose to the centre thereforethe horizontal 
myosepta may be being masked by the notochord.  The alternative is that the 
horizontal myosepta is missing, due to reduced myotome volume.  In the fkrp 
morphants, the horizontal myosepta are visible but disrupted, suggesting that 
loss of the horizontal myoseptum is due to the MO knockdown, and not an 
artefact.  The morphants all have a reduced muscle fibre density i.e. lower 
numbers of fibres per unit of area within the myotome, when compared to 
controls with apparent oedematous infiltration observed as clear space (Figure 
4.2).   
In the previous chapter the morphant notochord was indistinguishable from that 
of the wild type on morphological grounds despite a hypothesised disruption.  In 
wild type and control MO injected larvae the notochord has a round appearance 
on sections, visible in the middle of the myotome trunk.  In fkrp, fukutin and 
dystroglycan morphants the notochord is distorted, losing its characteristic 
round shape.  In the dystroglycan morphants the notochord is ectopic, 
positioned ventrally towards the yolk sack, whereas in the fukutin and fkrp 
morphants the notochord has remained central (Figure 4.2).  Therefore there is 
clear abnormal notochord pathology; however at this level of magnification it 
would be difficult to distinguish a primary change in notochord structure from a 
secondary change due to ECM disruption.  
The neural tube is the larval precursor to the central nervous system.  In the 
myotome trunk the neural tube becomes the spinal cord of the adult fish.  
Dystroglycan glycosylation has been implicated in synaptic plasticity and 
therefore an effect on the neural tube might be expected in models for 
dystroglycanopathy.  However a more macroscopic view may argue that neural 
tube defects are a secondary consequence of ECM changes.  The oval shaped 
neural tube in wild type and control larvae is located in the midline towards the 
dorsum, situated directly above the notochord.  In the fukutin morphants the 
neural tube is more rounded than in controls, whereas the neural tube in fkrp 
morphants is irregular in shape.  The dystroglycan morphant neural tube is the 
most severely affected with a highly abnormal shape (Figure 4.2).  
 
128 
 
 
 
129 
 
Figure 4.2: Transverse sections of 3dpf larvae stained with toluidine blue 
showing the myotome region.  
Morphants were all judged to be in the moderate phenotype group based on Table 2.2.  
Notochord: NC, neural tube: NT and horizontal myosepta: red arrows, scale bar: 50μm.  
Bottom part of the figure shows a schematic red dotted line of where the section has 
been cut in the 3dpf larvae, figure adapted from kimmel et al. 1995.  
4.2.2 Immunohistochemical Analysis of Protein Expression in Morphant 
Somites 
The presence of glycosylated -dystroglycan in fish embryos at 1 dpf was 
investigated by immunostaining with the antibody IIH6, which specifically binds 
to correctly glycosylated -dystroglycan (Kuga et al., 2012b).  In control fish 
IIH6 stained the somite boundaries and horizontal myosepta with the greatest 
intensity.  The muscle fibres that run longitudinally attaching to the vertical 
myosepta, were observed to have only weak IIH6 signal along the length of the 
fibres.  In fukutin knockdown fish a similar reduction was found to that which 
had previously been described in the fkrp morphants (Thornhill et al., 2008).  
Unsurprisingly, no staining was observed in the dystroglycan morphants 
(Parsons et al., 2002a).  
To examine the consequences of a reduction in glycosylation on the whole 
expression of the dystroglycan complex, 1 dpf embryos and morphants judged 
to have a phenotype of moderate severity, were immunostained with the 
43DAG antibody recognising -dystroglycan.  In control embryos 43DAG 
stained the vertical myosepta, which have a classical chevron appearance.  The 
horizontal myosepta running through the midline was also detected in controls.  
In the fukutin morphants the intensity of the staining in the myosepta was 
reduced, but interestingly 43DAG staining seemed reduced to a lesser extent 
than in the fkrp and dystroglycan morphants, where the staining was almost 
completely abolished (Figure 4.3).  
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Figure 4.3: Projections from confocal microscopy through the myotome 
trunk of 1dpf embryos after IIH6 and 43DAG staining.  
1dpf embryos were manually dechorionated and fixed before staining with IIH6 (for 
glycosylated dystroglycan) or 43DAG (β-dystroglycan) antibodies.  White scale bar 
represents 80µm.  Upper panel: IIH6 staining, lower panel: 43DAG.  From left to right: 
uninjected fli-1 control, embryo injected with control MO, fukutin MO, fkrp MO and 
dystroglycan MO. 
To investigate the consequences of knocking down fukutin and fkrp on laminin, 
one of the known ECM binding partners of α-dystroglycan, 1dpf embryos were 
immunostained with a pan-laminin antibody.  The pan-laminin antibody is raised 
against an ECM homogenate, and therefore recognises most laminin isoforms.  
The classic chevron appearance of the myosepta is present when stained with 
the pan- laminin antibody in control fish (Figure 4.4).  The myosepta of the fkrp 
morphants are increasingly rounded with increased severity of the phenotype.  
In the most severe fkrp morphants the myosepta appear to have greater width 
which is similar to that observed by bright field microscopy (Figure 4.1).  The 
fukutin morphant myosepta are almost straight in all phenotype groups with very 
little laminin staining visible in the most severe embryos.  No signal from the 
immunolabelling was detected in the dystroglycan morphants, suggesting 
laminin ligand binding to dystroglycan had been abolished, as a result of loss of 
dystroglycan at the vertical myosepta.  Despite repeats and controls both 
positive and negative, the possibility that the staining did not work should be 
considered since laminin binding integrin-α7 should be detectable (Belkin and 
Stepp, 2000; Postel et al., 2008; Sztal et al., 2012).  The specificity of the 
antibody should also be considered, without an antibody specifically detects 
laminin-α2, little in the way of conclusions can be drawn about this specific 
laminin chains expression at the vertical myosepta.  
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Figure 4.4: Pan-laminin staining of whole mount 1dpf embryos.   
1dpf embryos were manually dechorionated and fixed before staining with a pan-
laminin antibody. (A-C)  Fukutin MO injected embryos, mild to severe phenotype, (D-F) 
fkrp MO injected embryos, (G) wild-type non-injected embryos, (H) Control MO injected 
embryos and (I) dystroglycan MO injected embryos.  Scale bar: 80μm. 
4.2.3 Structural Changes in Morphant Muscle Fibres 
Myofibrils consist of small repeating structures known as sarcomeres contained 
between two zwischenscheibe (Z-lines).  Surrounding each Z-line is the I-band 
or zone of thin filaments.  The anistropic (A-band) spans the length of a full thick 
fibre and is contained within this band, while myosin is cross linked at the 
central Mittelscheibe (M-line).  Transmission electron microscopy (TEM) allows 
the investigation of sarcomere structure at the nanometre scale and all 
components of the sarcomere including, can all be clearly visualised on TEM, 
(Figure 4.5). 
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Trunk muscle in zebrafish develops into dorsoventral subdivisions of 
epaxial/hypaxial somites (Figure 1.8), separated by the horizontal myosepta.  
The somites are also divided into mediolateral subdivisions of slow/fast twitch 
fibre territories.  The process of zebrafish myogenesis is almost complete by 
3dpf, with the slow twitch red fibres segregating to the periphery and the fast 
twitch white fibres positioned more medially.  Here the hypaxial medial fast 
twitch fibres at 3dpf are investigated.  Despite the sub populations of fast and 
slow twitch fibres being distinguishable there are no important physiological 
differences critical for development between the fibres types at this stage of 
development.  Most of the features which distinguish fast from slow twitch fibres 
including ATPase reactivity and accumulation of mitochondria, occur after 3dpf.  
No new motor neurones will be generated after 3dpf, making this time period 
ideal to investigate muscle fibre structure.    
Muscle fibres from wild type and control injected larvae are straight, running 
between vertical myosepta, filling the myotome trunk as seen in the lowest 
magnification part of the panel, (Figure 4.5).  The fibres are surrounded by small 
areas of amorphous material and enclosed globules of fat, more easily seen at 
lower magnifications.  Excessive sarcolemmal fluid and adipose globules are 
suggestive of muscle degeneration, indicating the muscle did develop but 
degenerated on movement.  The morphants were all chosen from the moderate 
phenotype category and a minimum of three fish were imaged for each MO.  
The morphant muscle fibres fill less space in the myotome trunk due to reduced 
fibre density, most run in a non-linear fashion between myosepta.  The classical 
chevron appearance of the vertical myosepta is also rounded in the morphants 
when compared to controls, as seen in the lowest magnification panel.  The 
fatty infiltration and amorphous material is more extensive in all morphants 
when compared to controls.  Similar to previous findings the fukutin morphant 
appeared to have the most severe phenotype (Figure 4.5). 
At higher magnifications the sarcomere is clearly visible.  In the controls the 
sarcomere forms regular repeating units separated by areas of ECM, 
sarcoplasm and mitochondria.  The morphants all have torn sarcomeres around 
the boundaries of the fibres.  Despite the torn appearance of the morphant 
sarcomeres the M-line and Z-lines are straight i.e. a normal appearance.  In 
areas where the sarcomeres are not torn the A-band is intact, similar to controls.  
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The sarcomeres of the fukutin morphant have the most severe phenotype 
amongst the morphants with larger areas of tearing within the A-band.  On 
occasion the morphants were observed to have enlarged mitochondria which is 
a non-specific sign of degenerative muscle, a feature not seen in the controls 
(Figure 4.5).    
A 
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Figure 4.5: TEM of 3dpf larvea somitic muscle  
A: 3dpf wild-type sarcomere structure, scale bar: 10nm.  B: Longitudinal sections of 
3dpf muscle.  Lowest-highest magnification left-right, scale bars: 20μm, 2μm, 1μm & 
500nm.  Red square shows area of magnification.  Note at lowest magnification there 
are some creases visible on the section which is a normal feature of TEM at low 
magnifications.  Panels from top to bottom: larvae injected with fukutin MO, fkrp MO, 
dystroglycan MO, Control MO and non-injected wild type larvae.  
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It became clear that it was not possible to distinguish primary pathology in the 
myotome or vasculature from secondary changes due to structural alterations of 
the entire fish body.  In order to control for this gfat1 protein expression was 
downregulated since this was known to induce a comparable bended body 
phenotype as observed in fukutin/fkrp morphants.  The gfat1 deficient fish were 
shown to have muscle fibre abnormalities (Senderek et al., 2010), a finding 
recapitulated in Figure 4.7.  On closer examination the gfat1 morphants were 
observed to have predominantly ventral curvature of the tail enabling the 
classification of the gfat1 knock down fish based on the criteria in Table 2.2.  
The injection of gfat1 MO produced morphants that were evenly distributed 
between each phenotypic category as described in Table 2.2, overall 47% of 
morphants and 0% of wild type controls had abnormal phenotypes (Figure 4.6).  
gfat1 deficient zebrafish embryos therefore have a similar morphological 
phenotype to the fkrp and fukutin knockdown fish (Figure 4.6).  These fish were 
therefore used to distinguish primary events from pathology secondary to the 
bended body phenotype.  
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Figure 4.6: gfat1 1dpf phenotype 
(A) Morphological phenotypes assessed with the muscle criteria in Table 2.2, staged using Kimmel criteria and raised as described by 
Westerfield.  (B)  Graphical representation of phenotype spectrum of gfat1 morphants compared to wild type control.  (C)  Table of phenotype 
range data of gfat1 morphants.  
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To determine structural changes in muscle at 1 dpf, fish were stained with 
phalloidin used to detect F-actin.  Phalloidin is a toxin derived from Amanita 
phalloides and conjugated with a flurophore.  In control fish the fibres between 
the vertical myosepta were straight and filled most of the myotome trunk.  In 
mild fukutin, FKRP and dystroglycan morphant embryos muscle fibres 
connected with the vertical myosepta but were less linear than controls between 
myosepta.  In the mild morphants the muscle fibres were more spaced out and 
thinner than in controls, while the vertical myosepta maintained their classic 
chevron shape.  With increasing morphant severity the fibres became more 
distorted.  In the most severe phenotypes the myosepta lost their chevron 
appearance and became more rounded similar to the observations reported 
earlier on brightfield and TEM (Figure 4.1 &Figure 3.13).   
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Figure 4.7: Muscle fibre F-actin staining with phalloidin 
Projections from confocal microscopy through the myotome trunk of 1dpf embryos.  
White scale bar represents 100µm. Panels from top to bottom: embryos injected with 
fukutin MO, fkrp MO, dystroglycan MO.  The embryos have been selected as mild, 
moderate or severe phenotype (from left to right).  The bottom panel shows control 
embryos: uninjected fli-1 control, embryo injected with control MO, and embryo injected 
with the gfat1 MO. 
4.2.4 Disrupted Sarcolemma and Myosepta in Morphant Embryos 
The sarcolemma is the thin excitable membrane that encapsulates the 
contractile components of striated muscle.  The ECM of the sarcolemma fuses 
at the ends of fibres to form tendons in humans or myosepta in fish.  Disruption 
139 
 
to either component might be the aetiological cause of the muscle pathology in 
FKRP and fukutin deficient fish. 
At lower magnifications in transverse sections from wild type fish the muscle 
fibres have a dense coverage of the myotome, running a linear course between 
vertical myosepta within the myotome trunk.  The morphant embryos were all 
chosen from the moderate phenotype category and a minimum of three fish 
were imaged for each MO.  In all the morphants there is lower muscle fibre 
density, similar to the longitudinal sections.  In the space in which fibres would 
normally occupy there is amorphous material and additional adipose tissue 
distinguished by its globular appearance in the micrographs.  Overall at lower 
magnifications the fukutin morphants appear to have the most severe 
phenotype.   
Myofibrils run longitudinally in the myotome attaching to the vertical myosepta 
which allows transmission of force to run along the fish body.  Consequently, 
the vertical myosepta will most likely have the greatest transmission of force as 
compared to the horizontal myosepta.  The morphants were all chosen from the 
moderate phenotype category and a minimum of three fish were imaged for 
each MO.  The vertical myosepta seen at low magnifications in control fish are 
straight and dark in appearance with occasional small processes.  At higher 
magnifications the insertion of the myofibrils into the vertical myoseptum can be 
seen.  The vertical myoseptum at lower magnifications in the morphants 
appears deviated from the typical chevron appearance with lower muscle fibre 
density surrounding it on either side.  At higher magnifications the myofibrils 
appear to be detached from the myoseptum.  The myoseptum in all morphants 
remains intact albeit more disorganised i.e. enlarged with irregular borders 
when compared to the control injected and wild type fish myoseptum.  Finally, 
the myosepta in the morphants are not as dark suggesting that they may be 
thinner than in the controls (Figure 4.8). 
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Figure 4.8: TEM of longitudinal sections from 3dpf embryos showing 
muscle fibre attachment to vertical myosepta  
Lowest magnification is on the left, highest on the right, Scale bars: 4μm, 1μm, 500nm 
respectively.  Red square shows area of magnification.  Note at lowest magnification 
there are some creases visible on section a normal feature of TEM at low 
magnifications.  Panels from top to bottom: larvae injected with fukutin MO, fkrp MO, 
dystroglycan MO, Control MO and non-injected larvae.  Vertical myoseptum: red arrow.  
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4.2.5 Notochord Abnormalities in Morphants 
The notochord is an essential structure for producing diffusible factors that act 
as molecular cues for muscle development in zebrafish (Stemple, 2005).  These 
cues control muscle specification and guide angiogenesis in the developing 
embryo.  Here, the notochord in particular the sheath or peri-notochord has 
been studied at TEM level.  The peri-notochord is divided into three membranes 
(Figure 4.9), the outer, medial and inner basement membrane, with the medial 
being the largest of the three layers.  The wild type notochord at low 
magnifications is a regular round structure.  The FKRP and fukutin morphant 
notochords are oval in shape.  The dystroglycan morphant notochord are differs 
from the other morphants because of the several significant irregularities in 
shape.  The shape changes in the dystroglycan morphants are most likely due 
to kinks in the notochord that are observed at higher magnifications.  The 
morphants have noticeably larger vacuoles on the basement membranes when 
compared to controls, perhaps suggesting an up regulation of degradation 
processes.  At higher magnifications the three layers of the peri-notochord are 
all visible in the controls.  All three layers are disrupted in the FKRP, fukutin and 
dystroglycan morphants with the most noticeable change being to the medial 
layer of the notochord.  The medial layer of the controls is made up of tight 
concentric circles whereas in the morphants the medial layer is distorted with 
few intact concentric circles visible.  
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Figure 4.9: TEM of 3dpf notochord 
Lowest-highest magnification left-right (transverse sections), scale Bars: 10μm, 2μm, 
1μm & 500nm.  Red square shows area of magnification.  Panels from top to bottom: 
larvae injected with fukutin MO, fkrp MO, dystroglycan MO, CoMO and non-injected 
larvae.  Peri-notochord basement membrane: red arrow, medial layer peri-notochord: 
blue arrow and outer layer peri-notochord green arrow. 
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4.2.6 Abnormal somitic vasculature in fukutin, FKRP and dystroglycan 
morphants 
Zebrafish such as floating head and no tail have no notochord (Odenthal et al., 
1996) and fail to develop axial vasculature (Sumoy et al., 1997).  These models 
are thought to lack signalling cues such as vascular endothelial growth regulator 
that arise from the notochord (Fouquet et al., 1997).  Thus a potential 
consequence of loss of notochord structure might be abnormalities in vascular 
development.  Fli-1 embryos were imaged using a confocal microscope to 
capture images of the vasculature through the myotome trunk.  During the 
pharyngeal phase the segmental arteries of zebrafish embryos arise from the 
dorsal aorta, following the course of the vertical myosepta (Figure 1.7), 
eventually connecting with the dorsal longitudinal anastomotic vessel at 24-26 
hpf (Childs et al., 2002).  At this developmental stage the segmental vessels of 
control embryos spanned from the dorsal aorta to the dorsal longitudinal 
anastomotic vessel in almost all cases (Figure 4.10). 
In fukutin, fkrp and dystroglycan knockdowns with a mild phenotype, 
intersegmental vessels were unsuccessful in reaching the dorsal longitudinal 
anastomotic vessel pectorally at 24 hpf, (Figure 4.10A).  In some instances the 
intersegmental vessels of the fkrp morphants branched at the tops of the 
segmental arteries from the midline upwards.  With increasing phenotypic 
severity of the fukutin (10%) and FKRP (40%) morphants the intersegmental 
vessels were found to be missing with greater frequency (Figure 4.11).  The 
intersegmental vessels of moderate to severe fukutin morphants were more 
disorganised with increasing severity of the phenotypes (Figure 4.10).  The 
dorsal aorta in most cases was the only distinguishable vessel in the 
vasculature of the severe fukutin, fkrp and dystroglycan morphants within the 
myotome trunk region.  There were several instances, where segmental artery 
branching occurred below the midline in the morphants with severe phenotypes.  
In two fukutin and one dystroglycan knockdown embryos with moderate 
phenotypes the vessels joined together via anastomoses in the embryo mid-line 
(Figure 4.10B).  Despite having a bended body phenotype the vasculature in 
the GFAT1 morphant fish could not be distinguished from control, indicating that 
vascular changes were a primary pathological change. 
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Figure 4.10: Somite vasculature of 1dpf embryos detected as EGFP 
fluorescence in the fli-1 strain using confocal microscopy 
 A: The fkrp, fukutin and dystroglycan injected embryos were staged according to 
phenotype at 1dpf.  Intersegmental vessels project from the dorsal aorta (bottom 
horizontal vessel) towards the dorsal longitudinal vessel at the top.  White scale bar 
represents 100µm, SV: segmental vessel, DA: dorsal Aorta, DLAV: dorsal longitudinal 
anastomotic vessel.  B: Intersegmental vessels joining in the midline of fukutin 
morphants: white arrow, white scale bar represents 50µm. 
The vertical height of the segmental vessels above the dorsal aorta was 
measured and expressed as a proportion of body height and expressed as a 
percentage from a minimum of three independent injections for each MO.  Five 
embryos and four intersegmental vessel heights from each injection were 
measured for each phenotype (Figure 4.11).  All morphants segmental vessel 
heights were significantly smaller (P= <1x10-4) than observed in the 
controls( Tukey analysis of the one-way ANOVA).  In each of the morphants 
phenotypic severity category there was a progressive reduction in size of 
segmental vessel with increasing phenotype severity.  Blood vessels in the fkrp, 
fukutin and dystroglycan morphants were not significantly different in height 
across the mild phenotype category.  While blood vessels in the dystroglycan 
morphants were significantly larger than in fkrp morphants and fukutin when 
moderate and severe phenotype are compared respectively, using one way 
ANOVA Tukey analysis.
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                            N     Mean    Grouping 
Fli-1                     20    92.48      A 
CoMo                  20    81.96       A 
Dyst Mild            20    59.60          B 
Fukutin Mild       20    50.45          B   C 
FKRP Mild          20    50.20          B   C 
Dyst Mod            20    49.78          B   C 
Dyst Severe        20    39.13               C 
Fukutin Mod       20    38.28               C 
Fukutin Severe  18    19.72                     D 
FKRP Mod          20    18.75                     D 
FKRP Severe      12    12.27                    D 
Figure 4.11: Intersegmental blood vessel length 
Measured from the dorsal aorta relative to body height at 1dpf.  Graph bars 
represent 95% confidence interval, y-axis is a percentage of body height.  The 
fkrp, fukutin and dystroglycan injected embryos were staged according to 
criteria specified in Table 2.2.  One-way ANOVA with Tukey analysis is 
displayed in the table below the graphical representation of the data.  Tukey 
analysis was based on the assumption the data was approximately evenly 
distributed and allowed variability to be assessed across morphant phenotype 
groups. Means that do not share a grouping are significantly different.  The 
analysis allowed fli- and control MO to be grouped together and distinguished 
them from fkrp, fukutin and dystroglycan morphants, confirming that the 
morphants were all significantly smaller than control MO injected embryos.  The 
analysis also shows no single morphant MO injection spectrum i.e. mild, 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
Intersegmental height / total myotome height 
147 
 
moderate severe, was significantly different from another, and while the mild 
and moderate categories showed substantial overlap, both were distinct from 
the severe category.   
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4.3 Discussion  
Based on previous studies (Parsons et al., 2002a; Thornhill et al., 2008; 
Ackroyd et al., 2009) loss of muscle integrity was hypothesised to be the key 
pathological cause responsible for the bent body phenotype observed in the 
fkrp and fukutin morphants.  Muscle was therefore investigated at the structural 
level in order to assess this hypothesis as an aetiological cause of the bent 
body phenotype.  As expected, morphant muscle was disrupted with detached 
myofibres in fkrp, fukutin and dystroglycan morphants.  F-actin staining 
confirmed the loss of myofibres, which were sparse and deformed in the 
morphant embryos.  Ultrastructural analysis revealed that fkrp, fukutin and 
dystroglycan morphants all have torn sarcomeres and loss of vertical 
myoseptum structure.  
4.3.1 Muscle  
Knock down of fukutin and fkrp using MOs was successful in reducing the levels 
of glycosylated -dystroglycan in the morphants as shown by IIH6 
immunostaining.  A weak laminin-dystroglycan interaction may be the critical 
deficiency in the destabilisation of the sarcolemma, accounting for the muscle 
pathology of the morphants (Lin et al., 2011).  Work carried out previously 
reported the importance of correctly glycosylated -dystroglycan for maintaining 
sarcolemmal stability (Reed et al., 2004; Thornhill et al., 2008; Lin et al., 2011).  
Surprisingly, there was a detected concurrent reduction of β-dystroglycan 
immunostaining in the fkrp and fukutin morphants.  The observation is in 
contradiction to data formerly published by (Kawahara et al., 2010), but in 
accordance with observations in mouse models of dystroglycanopathy indicate 
that the structural defects caused by deficient glycosylation of -dystroglycan 
may lead to misplacement of -dystroglycan (Michele et al., 2002).   
Laminin was investigated as the binding partner of α-dystroglycan.  However, 
no reduction in pan-laminin staining in the fkrp and fukutin morphants was 
observed.  This finding is in contradiction to a previous study (Lin et al., 2011), 
that observed a small reduction in laminin staining in fkrp and fukutin 
knockdowns, and in a dystroglycan mutant line.  The discrepancies between 
results may be attributable to the sensitivity of the assay or to minor residual 
expression of fkrp and fukutin in the morphants analysed.  The possibility of an 
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integrin-α7 laminin compensatory mechanism should also not be overlooked, 
considering the mechanism has been reported in dystroglycanopathy mice 
models previously (Mayer et al., 1997; Sztal et al., 2012).   
Since no disturbances to the sarcomere could be found in the morphants 
beyond torn fibres, the perturbations in the sarcolemma and vertical myosepta, 
observed on ultrastructural examination were considered to be the basis of 
primary muscle pathology.  The dystroglycanopathy morphant fibre damage can 
be attributed to loss of integrity of both the sarcolemma and vertical myosepta 
(Thornhill et al., 2008).  The laminin-α2 & β2 mutant zebrafish candyfloss & 
softy mutant lines have irregular vertical myosepta borders and a similar torn 
sarcomere phenotype to our morphants (Hall et al., 2007; Jacoby et al., 2009).  
The mutants bashful (laminin-α1), grumpy (laminin-β1) and sleepy (laminin-γ1) 
were not found to have the same muscle basement membrane pathology 
indicating the dystroglycan laminin-211 interaction is specific for muscle 
pathology (Parsons et al., 2002b; Pollard et al., 2006).  Loss of the α-
dystroglycan laminin-211, interaction may therefore be the key change 
responsible for the loss of the sarcolemmal interaction with the vertical 
myosepta in the morphants.  The loss of strength in the interaction between 
sarcolemma and vertical myosepta results in the muscle fibre becoming 
susceptible to shear stress on contraction thus becoming torn.  Hence tears to 
the sarcomere could be considered as secondary to sarcolemmal and vertical 
myoseptal instability.    
4.3.2 Notochord 
The disruption in all three layers of the tri-laminar notochord was found in fkrp, 
fukutin and dystroglycan morphants.  Interestingly the mutants bashful, grumpy 
and sleepy all have been shown to have similar basement membrane 
abnormalities (Parsons et al., 2002b; Pollard et al., 2006).  This leads to the 
hypothesis that it is the loss α-dystroglycan laminin-111 interaction at the 
notochord that is responsible for mis-localisation of the laminin-111 chains with 
a consequential loss of notochord basement membrane stability.  Loss of 
notochord basement structure may prevent correct axial signalling and thereby 
interfere with myotome development or vascular patterning in developing 
zebrafish.  It is also possible that loss of notochord mechanical strength is due 
to the perturbations in the basement membrane in the morphants, potentially 
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providing a mechanism for the bended body and poor locomotive function 
phenotypes discussed in the previous chapter (Odenthal et al., 1996; Stemple 
et al., 1996; Stemple, 2005).   
4.3.3 Conclusions  
Perturbations in the sarcolemma and vertical myosepta due to loss of the 
laminin-211 α-dystroglycan interaction is argued to be the key pathology 
responsible for sarcomeric tearing in the morphants (Thornhill et al., 2008).  The 
angiogenic phenotype is therefore thought to be a secondary consequence of 
ECM disorganisation rather than the primary cause of the muscle pathology 
associated with knock down of fukutin, fkrp or dystroglycan.  The hypothesis is 
supported by previous studies (Pollard et al., 2006) that suggest correct 
localisation of the laminin-α1 chains is essential for blood vessel and notochord 
development.  Interestingly mutant zebrafish that don't develop notochords such 
as floating head and no tail fail to develop a dorsal aorta and therefore 
intersegmental vessel sprouting will not occur (Fouquet et al., 1997).  It can be 
postulated that lack of guidance cues as a result of perturbations in notochord 
may be failing to induce intersegmental vessel sprouting.  When combined with 
rounded disorganised vertical myosepta structure intersegmental vessels fail to 
correctly navigate through the myotome.  Therefore notochord basement 
membrane instability may at least in part be responsible for the bended body 
element of the morphant zebrafish phenotype.  Whether the bended body 
phenotype is due to the muscle fibre tearing as a component of the pathology is 
yet to be confirmed. 
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Chapter 5 Perturbations of the Basement 
Membranes in the Eye of fkrp and fukutin 
Deficient Zebrafish 
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5.1 Introduction 
Micropthalmia with clearly abnormal eye morphology was previously found in fkrp, 
fukutin and dystroglycan deficient zebrafish, see chapter 3.  In this chapter the eye 
pathology is investigated further, to gain a better understanding of the aetiological 
cause of the eye abnormalities associated with fkrp and fukutin deficiency.  
Disruption to retinal layering was previously found in Fkrp deficient mice (Ackroyd et 
al., 2009) and zebrafish (Thornhill et al., 2008).  Based on the presence of analogous 
structures within the human and zebrafish eye, the pathological phenotypes 
associated with dystroglycanopathy in both are predicted to be comparable (Hino et 
al., 2001; Bourteel et al., 2009).  The eye retinal layering abnormalities in fkrp and 
fukutin deficiency in both systems are hypothesised to be a secondary consequence 
that results from disruption to basement membranes within the eye.  This hypothesis 
is based on abnormal basement membranes found in the muscle and notochord of 
morphant zebrafish as discussed in the previous chapter.  Angiogenesis in morphant 
myotome was found to be delayed, also discussed in chapter 4.  Loss of vascular 
structure in the developing zebrafish of eye will therefore also be investigated in the 
fli-1 fish.   
5.1.1 Aims 
 To study retinal layering in 3dpf morphant larvae using histological techniques. 
 Establish the most suitable time point for investigation of basement 
membrane pathology using TEM. 
 Investigate any perturbations in basement membranes of fkrp, fukutin and 
dystroglycan morphant fish and characterise these at the ultrastructural level.  
 Investigate abnormalities in vasculogenesis of the eye as a possible 
consequence of fkrp, fukutin or dystroglycan deficiency.
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5.2 Results 
5.2.1 Retinal Neuronal Layering and Basement Membranes are not 
present at 1dpf 
In order to define a suitable time point for investigation of the basement 
membrane formation in zebrafish eyes, transverse sections of 1 dpf embryo 
eyes through the lens were prepared and viewed using TEM.  Three eyes from 
1dpf AB wild type embryos were sectioned and imaged (Figure 5.1).  Neither 
the ILM nor ELM could be identified in the sections (Figure 5.1).  The 1dpf time 
point was also too early to identify retinal layering, consistent with other studies 
(Soules and Link, 2005).  The lens cells and the retinal cells could also not be 
distinguished from each other (Figure 5.1).  The round lens structure was found 
anterior and ectopic to the retina.  Retinal pigmented epithelium (RPE) granules 
could be found in low numbers at the back of the eye.  No small blood vessels 
or erythrocytes could be identified in the eyes at 1dpf.  The lack of retinal 
layering and ectopic lens at 1dpf, lead to further investigation of the eye being 
carried out at the later time point of 3dpf.     
 
Figure 5.1: TEM micrograph in 1dpf zebrafish embryo eye.  
A: Overview of eye.  Note cell types are poorly differentiated in lens and retina and no 
retinal layering is identifiable, scale bar: 10μm.  B: High magnification image between 
lens and retina, blue triangle indicates a gap between lens and retina.  C: Posterior eye 
red triangle points to choroid.  B-C: scale bar: 2μm, green arrows in A&C RPE. 
5.2.2 Histological Assessment of the Morphant Eye Phenotype 
To assess overall structure of the developing zebrafish eye transverse sections 
were cut through the centre of the eye in 3dpf larvae and stained with toluidine 
blue (Figure 5.2).  Wild type and control MO injected larvae eyes were spherical 
in shape, with a round lens approximately one quarter of the size of total eye, 
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positioned anterior to the retina.  The eyes were abnormal in shape in all the 
fkrp, fukutin and dystroglycan morphants in the moderate severity group.  
Dystroglycanopathy morphants and control fish lenses were comparable in 
shape and size.  The fkrp and fukutin morphants were judged to have 
microphthalmia consistent with findings in chapter 3 (Figure 3.17).  The fukutin 
and dystroglycan morphants had lenses which were ectopic i.e. detached from 
the ganglion cell layer.  The finding was not recapitulated in any of the six 
morphant fish with a moderate fkrp phenotype, indicating that the lens 
attachment may be a point of divergence in the phenotypic presentation of fkrp 
and the other dystroglycanopathy morphants.  In studies investigating wild type 
embryos the lens is detached up to approximately 2dpf (Dahm et al., 2007), 
suggesting either developmental delay in the morphant eye development or 
disruption to lens adhesion.  In wild type and control MO injected eyes there 
was organised retinal layering ganglion cell layer (GCL), inner plexiform layer 
(IPL), inner nuclear layer (INL) and the photoreceptor layer (PR) could all be 
identified, (Figure 5.2).  Retinal layering in all morphants was disorganised 
(Figure 5.2), with a notably reduced retinal pigmented epithelium layer (RPE) at 
the back of the eye.  The GCL could not be distinguished from IPL or IPL from 
the INL in the morphant fish.  Overall the pathology was consistently most 
severe in the fukutin morphants. 
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Figure 5.2: Transverse sections of the eye at 3dpf, stained with toluidine 
blue 
Toluidine blue stain of sections allows retinal layers to be visualised and basic retinal 
cell morphology to be examined.  Basement membranes are visble however little can 
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be gained about structure at low magnification (40x).  Also visible is the lens and the 
retinal pigmented epithelium.  ILM: inner limiting membrane, GCL: Ganglion Cell Layer, 
IPL: inner plexiform layer, INL: inner nuclear layer, PR: Photo Receptor Layer, BM: 
Bruch’s membrane, scale bar: 20µm. 
5.2.3 Immunohistochemistry of 3dpf Eye 
Immunohistochemistry aided in the determination of whether there is disruption 
to the DGC and ECM proteins in any of the basement membranes in 3dpf 
dystroglycanopathy morphant zebrafish eyes.  A cryosection approach was 
adopted to resolve the precise location of many of the proteins of interest more 
effectively than in wholemount studies.  A minimum of three fish for each data 
point were transversely sectioned at the level of the mid lens.  Morphants were 
all judged to have a moderate phenotype as described in Table 2.2.   
The localisation of β-dystroglycan was used to determine whether there was 
any indication that there might be a mislocalisation of the DGC in the 
dystroglycanopathy morphant fish.  β-Dystroglycan staining was strongest at the 
ILM, with a weaker signal strength at Bruch’s membrane in the wild type fish 
(Figure 5.3).  Specific immunofluorescence was also detected in the retinal 
layers in wild type fish.  The fukutin morphant fish had increased intensity of 
staining for β-dystroglycan at the ILM and Bruch’s membrane when compared 
to controls, a finding not observed in the fkrp morphants.  As expected no 
specific staining was observed in the dystroglycan morphant larvae eye.  
IIH6 was used to detect changes in the levels of glycosylated dystroglycan.  In 
wild type fish IIH6 bound to the same structures as 43DAG indicating that IIH6 
is unlikely to be detecting entirely unknown proteins with similar glyco-epitoptes 
unless the protein has an identical distribution pattern to dystroglycan in the 
eye.  In addition to the ILM and Bruch’s membrane, strong IIH6 staining was 
observed in two examples on the optic nerve of the wild type controls.  Low IIH6 
signal strength was detected in the fukutin and dystroglycan morphants at the 
ILM.  Punctate IIH6 staining was observed in the fkrp morphant fish at the eye 
basement membranes.   
Laminin acts as the key ligand for dystroglycan in muscle, stabilising the 
sarcolemma by connecting it to the ECM.  A similar interaction may also be 
important in the eye, anchoring axons and cells to the three basement 
membranes.  Laminin in the wild type fish was detected with equal signal 
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strength at the ILM and Bruch’s membrane with some signal in retinal layers.  
The lowest signal levels were detected in the wild type embryos, while the 
dystroglycan morphant had the highest signal levels, perhaps suggesting 
laminin overexpression might be a compensatory mechanism for loss of 
dystroglycan in the basement membranes of the eye.  
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Figure 5.3: Immunostaining of cryosectioned 3dpf larval eyes 
3dpf embryos were fixed and embedded in OCT, tranverse sections were cut through the 
eye, sections through the lens were then stained with 43DAG (β-dystroglycan), IIH6 
(glycosylated dystroglycan) or pan-laminin antibody.  fkrp, fukutin and dystroglycan 
morphants were all judged to be in the moderate phenotype group as outlined in Table 2.2.  
Sections were stained with either 43DAG antibody for β-dystroglycan, IIH6 for the 
glycosylated dystroglycan or pan-laminin antibody that predominantly detects laminin-111.  
Green arrows: ILM, blue arrows: Bruch’s membrane and red triangle: optic nerve, scale bar: 
20µm.  
5.2.4 Analysing the Ultrastructure of the Morphant Eye 
TEM was used to investigate the ILM, ELM, RPE and Bruch’s membrane at the 
ultrastructural level in 3dpf larvae.  Large overviews of the eye were imaged to 
assess whether the features observed on histology were still present in the eye on 
TEM (Figure 5.4).  Wild type and control MO injected fish had spherical eyes with a 
round shaped lens positioned towards the front of the eye.  A minimum of six larvae 
from each phenotype category were investigated for each morphant phenotype in 
addition to the controls.  The eye shape in the morphants became progressively less 
spherical with increasing severity of phenotype.  Ectopic lenses were a consistent 
observation in fukutin and dystroglycan morphants across all severities of 
phenotype, a feature only found in the fkrp morphants with the most severe 
phenotype.  Abnormal retinal layering was observed in all morphants with the 
exception of the fkrp mild larvae.  In general, the TEM images show a similar range 
of defects as observed in the toluidine blue stained sections.  
 
 
161 
 
 
Figure 5.4: Transverse sections of the eye at 3dpf on TEM 
Figure highlights similar features to Figure 5.2 including retinal layering, basement 
membranes, lens and retinal pigmented epithelium.  Note particularly the lens dysplasia in 
dystroglycanopathy fish, a feature not seen in the controls.  Green arrow: inner limiting 
membrane, GCL: Ganglion Cell Layer, IPL: inner plexiform layer, INL: inner nuclear layer, 
PR: photo receptor layer & red arrow: external limiting membrane.  Scale bar: 20µm.  
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5.2.5 TEM Analysis of the ILM  
To elucidate a potential mechanism leading to the ectopic lens phenotype in the 
fukutin and dystroglycan morphants, the ILM was investigated using high power TEM.  
The ILM provides a bond between the lens and the retina by connecting to the lens 
to the adjacent GCL.  The ILM in its capacity as a basement membrane is also 
thought to have a role beyond structural integrity.  The ILM can alter cell specification 
(Feitosa et al., 2011), supports the avascular lens with multiple invaginations of small 
blood vessels (Gore et al., 2012) and acts as an anchoring point for the end feet of 
Müller glia.  The Müller glia have the important role of acting as support cells for the 
retinal ganglion cells (RGCs; Bringmann and Wiedemann, 2009).  
The ILM is found between the GCL and lens in controls at 3dpf.  The membrane is a 
continuous regular structure with a smooth surface and occasional invaginations of 
hyaloid vasculature (Figure 5.5).  The small blood vessels of the ILM contain 
presumed blood cell progenitors circulating inside them.  The blood vessels are 
crucial for supplying the lens with all the requirements for correct function, including 
delivery and removal of gases or debris.  In fukutin and dystroglycan morphants the 
ILM is absent across all phenotype groups.  The ILM is present in the fkrp morphant 
mild and moderate phenotypic groups but absent in the larvae with a severe 
phenotype.  The membrane is diminished in the fkrp fish with mild and moderate 
phenotypes, appearing to have a rough surface on the GCL side.  Interestingly, 
despite loss of the ILM in dystroglycan morphant fish with a mild phenotype and fkrp 
morphants with a severe phenotype, there are blood vessels present.  The data 
suggests that despite a close physical association, blood vessel development does 
not depend directly on the ILM (Dahm et al., 2007; Gore et al., 2012).  
163 
 
 
Figure 5.5: Transverse sections of the inner limiting membrane at 3dpf, TEM  
Figure highlights both the ILM and the optic blood vessels that form the inner optic circle 
vessel that is found around the circumference of the lens.  Red arrow: inner limiting 
membrane, Blue triangle: presumed premature erythrocyte, BV: blood vessel, GCL: ganglion 
cell layer, scale bar: 2µm. 
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5.2.6  Analysing the Ultrastructure of the ONL and ELM  
The ELM was investigated because of its role in supporting the photoreceptors 
spanning the entirety of the posterior retina.  The photoreceptors span from the outer 
nuclear layer (ONL) across the ELM to the INL in the control fish.  The ELM in the 
wild type and control MO injected larvae appears as a thickening (darker layer) of the 
ECM that surrounds ONL cells (Figure 5.6).  Unlike the Bruch’s membrane and ILM 
the ELM is not as defined as a membrane, perhaps at 3dpf the membrane is still not 
fully established.  The ELM is of consistent width with a rough surface on the INL 
side observed at the higher magnification in the wild type and control fish.  A 
disrupted, irregular ELM was observed in dystroglycan and FKRP morphants with a 
mild phenotype.  The ELM disruption and membrane surface irregularity increased 
with phenotype severity in the FKRP and dystroglycan morphants with a moderate 
phenotype.  Fukutin morphants and dystroglycan morphants with a severe 
phenotype did not have a visible ELM at TEM level.  ONL and INL were found to be 
poorly ordered in these groups surrounded by presumed oedematous infiltration.  In 
general all morphants had poorly organised cell layering at the back of the retina.   
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Figure 5.6: Perturbations in morphant external limiting membrane 
structure  
TEM images from transverse sections of the eye from FKRP, fukutin, dystroglycan 
morphants, wild type and control injected 3 dpf larvae.  No ELM was found in fukutin 
morphants of any phenotypic group.  Blue triangle: retinal pigmented epithelial layer, 
green arrows: ELM, ONL: outer nuclear layer, INL: inner nuclear layer.  Scale bars 
(bottom left panels) low magnification: 8µm, high magnification: 2µm.  A minimum of 
five embryos for each phenotype were imaged at low and high magnifications.     
5.2.7 Loss of Eye RPE in Morphants 
The retinal pigmented epithelium (RPE) is attached to Bruch’s basement 
membrane, situated between the choroid and the ELM.  The main function of 
the RPE is to support the photoreceptors and provide cues that control the 
process of retinal layering.  To assess the RPE in 3dpf larvae, seven fish from 
each phenotype group were imaged.  Images were taken at three well spaced 
positions at the back of the retina avoiding the optic nerve or proximity to the 
lens.  The RPE were imaged in a manner that centralised the RPE granules in 
the micrograph.  RPE granules were counted in each micrograph and statistical 
analysis was carried out (Young et al., 2006). 
The wild type and control MO injected fish were found to have a dense 
concentration of RPE granules, between the choroid and the ONL (Figure 5.7).  
With increasing severity of the morphant phenotype there was a reduced 
number of RPE granules at the posterior of the eye (p <10-4 in each case; One-
way ANOVA with Tukey analysis; Figure 5.8).  In the morphants with the more 
severe phenotype the RPE granules were found to be variable in size with a 
greater number of smaller granules with rougher edges when compared to the 
smooth edged larger granules found in the controls.  In the most severe 
morphants the choroid appeared to have not formed correctly, suggesting 
FKRP, fukutin and dystroglycan deficiency in the zebrafish disrupts choroid 
formation.  
The RPE is closely associated with a continuous Bruch’s membrane in the wild 
type and control MO injected fish at 3 dpf (Figure 5.7).  Bruch’s membrane was 
found to be thinner with irregular perturbations in fkrp and dystroglycan 
morphants with a mild phenotype, when compared to controls.  The Bruch’s 
membrane is absent at the more severe end of the fkrp and dystroglycan 
morphant spectrum.  In the fukutin morphant across the phenotype range 
Bruch’s membrane was found to be completely abolished.  
167 
 
 
  
Figure 5.7: Disruption to morphant retinal pigmented epithelium layer in 
3dpf larvae 
Black spots (green arrows) are the pigmented granules, counts are shown in Figure 5.8. 
INL: inner nuclear layer, PR: photoreceptor layer, red arrows: Bruch’s membrane, 
Scale Bar: 2µm. 
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                     N          Mean    Grouping 
Wild type            15   152.93            A 
Control MO           21   152.43            A 
FKRP mild             19   106.74      B 
Dystroglycan mild     24    74.63           C 
Fukutin mild         16    38.38               D 
FKRP severe           15    22.80                  D  E 
Dystroglycan severe   15    18.67                     E 
Fukutin severe        15     4.20                       E 
Figure 5.8: Reduced number of pigmented granules at Bruch’s membrane 
in the RPE layer in 3 dpf larvae 
Bars represent 95% confidence interval, results for each phenotype from minimum of 
three images of seven fish from a minimum of two separate experiments.  Tukey 
analysis of the one-way ANOVA is displayed in the table below the graphical 
representation of the data.  Tukey analysis was based on the assumption the data was 
approximately normally distributed and allowed variability to be assessed across 
morphant phenotype groups.  Means that do not share a grouping are significantly 
different.   
5.2.8 Abnormal ILM in 5dpf FKRP Morphant Larvae Eye  
At 5dpf the retinal layering in the wild type fish eyes is fully established.  The 
eye is round and the retinal layering is clearly established with defined borders 
(Figure 5.9).  FKRP morphant fish were the only dystroglycanopathy fish 
investigated at 5dpf because very few fukutin or dystroglycan deficient fish 
survived to 5dpf.  The 5dpf FKRP morphants with mild and severe phenotypes 
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also had round eyes and clearly demarcated retinal layering.  The ILM in wild 
type larvae was smooth with defined membranes surrounding blood vessels 
which were spaced evenly around the lens.  The mild FKRP morphants had no 
marked differences when compared to the controls.  The ILM was disrupted on 
the GCL side in FKRP morphants with a rough surface, interestingly blood 
vessels could not be accurately distinguished from basement membrane on the 
TEM micrographs.  The ELM appeared to be slightly diminished in the FKRP 
morphants, when compared to the controls.  No differences were seen between 
the FKRP morphants and the wild type with respect to Bruch’s membrane.  
There did however appear to be a reduction in number of pigmented granules in 
the RPE in the FKRP morphants when compared to controls.  There was no 
statistical analysis carried out to confirm the assertion because of the limited 
sample size for each phenotype (n=3). 
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Figure 5.9: fkrp Morphant eyes at 5dpf  
Red arrows: inner limiting membrane (ILM), green arrows: external limiting membranes 
(ELM), blue arrows: retinal pigmented epithelium (RPE), blue triangle: presumed erythrocyte, 
BV: Blood vessel, ONL: outer nuclear layer, INL: inner nuclear layer, IPL: inner plexiform 
layer, GCL: ganglion cell layer.  Scale bar (left column): 10µm, scale bar right three columns: 
2µm. 
5.2.9 Perturbation of Eye Vasculature in fukutin and fkrp Morphant Fish  
Changes in vascular development in the myotome of the morphant fish have been 
described in chapter 4 and in WWS patients vascular anomalies were found in the 
brain (Beltran-Valero de Bernabe et al., 2002).  It is reasonable to assume therefore 
that similar vascular developmental problems may persist in the eye.  Similar to the 
previous chapter vasculature was imaged using multiple confocal images through 
the eye to create a projection of all the eye vasculature in a single image.  The inner 
optic circle vessels of the wild type zebrafish form a roughly spherical shape around 
the perimeter of the eye at 1dpf (Figure 5.10).  The inner optic circle vessels within 
the eyes of fkrp and fukutin morphant embryos with a mild phenotype were smaller 
and more oval than those in the eyes of control embryos.  The eye vasculature of the 
fukutin and fkrp morphant zebrafish became increasingly distorted with increasing 
phenotype severity.  In morphant embryos with the most severe phenotypes eye 
vasculature was deformed to an extent which was beyond being clearly identifiable 
as any particular vessel.  Unexpectedly, the eye vasculature in dystroglycan 
morphant fish across all phenotype severity groups had no significant changes when 
compared to the control fish.  
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Figure 5.10: 1dpf eye vasculature of the eye 
The FKRP, fukutin and dystroglycan injected embryos were staged according to phenotype 
at 1dpf.  Micrographs through the eye were obtained on a confocal microscope and images 
were projected together.  White scale bar: 100μm, IOC inner optic circle, MCeV middle 
cerebral vein & NCA naso-cillary vessel.  
The eye vasculature was used as a marker of eye size at 3 dpf in the fish.  The 
areas of control fish eyes were measured and compared to the areas of the eyes of 
the morphants.  A minimum of three independent experiments were carried out for 
each of the phenotypes (Table 2.2), with the exception of dystroglycan where five of 
each mild, moderate and severe were combined, a minimum of ten eyes were 
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scanned for each phenotypic category.  The eyes of control MO injected embryos 
had smaller mean area of eye than in the non-injected embryos however the 
difference was not found to be significant using Tukey analysis, suggesting that the 
MO had minimal non-specific effects that might affect eye development.  The mean 
area of the mild morphant fukutin embryo eyes were significantly, see Tukey’s 
analysis Figure 5.12, smaller than that of the control injected fish eyes (Figure 5.11).  
The eyes of the most severe fukutin and fkrp morphant embryos had the smallest 
areas and were very significantly smaller than eyes of control injected fish.  The eyes 
of the fkrp morphant larvae were significantly larger than those found in the fukutin 
morphants when comparing each phenotype category.  In the dystroglycan morphant 
fish, eye size across each phenotype group was found to be similar to that of the 
control MO injected and wild type fli-1 larvae.  
The vasculature observed in the fli-1 fish (Figure 5.10 & Figure 5.11), can be 
compared to blood vessels in the ultrastructural analysis (Figure 5.1, Figure 5.5 & 
Figure 5.9).  Despite vasculature being visible in the 1dpf fli-1 fish eye when 
examined using confocal microscopy (Figure 5.10), no blood vessels were detected 
by electron microscopy (Figure 5.1), which might indicate correct vascular 
specification with no associated vascular structure formation at this stage of 
development.  By 3dpf the vasculature is visible using both confocal microscopy 
(Figure 5.11) and on TEM micrographs (Figure 5.5).  Only small vessels are present 
on micrographs because the section is very thin in comparison to the confocal 
projections through the entire eye in the confocal micrographs which encompass 
most of the wild type zebrafish eye vasculature at 3dpf.  However vasculature is not 
observed on TEM in the eyes of morphants with a severe phenotype, despite being 
clearly visible on confocal projection.  It is possible that the marker used for 
vasculature (fli-1) is expressed in primordial blood vessels, and detected by 
fluorescence microscopy prior to their development into anatomically recognisable 
structures on TEM and the severe morphants are developmentally delayed.  
Interestingly in 5 dpf fkrp mild and occasionally in severe morphants vasculature is 
visible on TEM micrographs (Figure 5.9).  These findings together suggest there is 
correct specification of vasculature with a delay in the specification of vascular 
epithelium structure in the morphant fish through the first five days of zebrafish 
development. 
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Figure 5.11: 3dpf eye vasculature using projections from confocal microscopy 
through the eye  
Red dots show how area is calculated in Figure 5.12, IOC: inner optic circle DCV: dorsal 
ciliary vein, NCA: naso-cillary vessel & OV: optic vein.  Scale bar: 100μm.  
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                                  N       Mean              Grouping 
Wild Type                21      54812                  A 
Dystroglycan           13      52265                  A 
Control MO              16      46072                  A 
FKRP mild               10      43737                  A  B 
FKRP moderate        8       31892                      B     C 
Fukutin mild             15      27393                             C  D 
Fukutin moderate     15      17673                                  D  E 
FKRP severe            6        16211                             C  D  E 
Fukutin severe         14       9650                                        E 
Figure 5.12: Relative area of 3dpf eye vasculature  
The FKRP and fukutin injected embryos were staged according to Kimmel et al. 1995, Table 
2.1 and morphant severity was judged as in Table 2.2.  Bars represent 95% confidence 
interval, y-axis is in arbitrary units, results for each phenotype from minimum of three 
separate experiments.  One-way ANOVA Tukey analysis is displayed in the table below the 
graphical representation of the data.  Tukey analysis was based on the assumption the data 
was approximately normally distributed and allowed variability to be assessed across 
morphant phenotype groups.  Means that do not share a letter are significantly different.   
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5.3  Summary 
The microphthalmia in the fkrp, fukutin and dystroglycan morphants observed in 
the previous chapter is reminiscent of severe eye pathology observed in WWS.  
By investigating the histology of the eye at 3 dpf it is clear that there is both 
cellular and basement membrane pathology associated with the 
dystroglycanopathy morphants.  Loss of retinal layering was observed in the 
morphant eyes on histological examination.  Perturbations were also found in all 
the major basement membranes of the eye i.e. ILM, ELM and Bruch’s 
membrane at 3dpf.  This raises the important question of whether loss of retinal 
layering and microphthalmia are attributable to the loss of eye basement 
membrane structure.  Interestingly ectopic lens was observed in dystroglycan 
and fukutin morphants which may also be a consequence of disruption to 
basement membranes of the eye, specifically the ILM.  Finally, this data 
provides novel insight into how the loss of eye vascular structure in fkrp and 
fukutin but not dystroglycan morphants links to the ultrastructural and 
immunohistochemical changes. 
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Chapter 6 Discussion 
6.1 Modelling Dystroglycanopathies using Zebrafish 
By comparing dystroglycan to fkrp and fukutin deficiency in zebrafish this thesis 
set out to ascertain the pathological mechanism of dystroglycanopathy.  
Antisense MOs targeting fukutin, fkrp and dystroglycan were used throughout 
the thesis to knock down the fukutin and fkrp pathways to a similar extent in 
order to enable a meaningful comparison between phenotype of the zebrafish 
morphants.  Dystroglycan morphants were a useful model in this study, 
providing confirmation that the pathology resulting from fkrp or fukutin 
knockdown is linked biochemically and phenotypically to dystroglycan in 
zebrafish.  The criteria established to separate the zebrafish into phenotypic 
severity, outlined in Table 2.2, could be applied to other secondary 
dystroglycanopathy models such as POMT1, POMT2, LARGE, POMTGnT1 and 
ISPD in the future.  Evaluating the developmental phenotype of different models 
with comparable severity of morphological defects allowed the identification of 
subtle differences in structural phenotypes by controlling for secondary effects.  
Since defects in primary and secondary dystroglycanopathy genes lead to 
severe developmental abnormalities, study of the zebrafish models, with easily 
accessible embryonic stages, is particularly valuable.  In fact all stages of early 
development can be easily followed in structures of interest such as muscle, 
eye, brain and notochord.  
Zebrafish models for other DGC components such as dystrophin (sapje mutant) 
have muscle fibre detachment from the myoseptum but no eye or brain 
abnormalities (Bassett et al., 2003; Bassett and Currie, 2004; Guyon et al., 
2007).  Those zebrafish mutants with mutations in proteins known to bind to α-
dystroglycan such as laminin-α2 have a phenotype which resembles fukutin 
knockdown in terms of muscle morphology, indicating that the model is 
appropriate for studying fukutin deficiency (Hall et al., 2007; Postel et al., 2008).  
Laminin-α2 is a known ligand of dystroglycan in muscle.  The zebrafish 
candyfloss (caf) mutant which has a mutation in the laminin-α2 gene has a 
degenerative muscle phenotype as a result of muscle detachment from the 
vertical myosepta (Hall et al., 2007) but no observed eye and brain pathology.  
Interestingly the α1, β1 & γ1 laminin mutants, bashful (bal), grumpy (gup) and 
sleepy (sly) respectively have defects in eye development and notochord 
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differentiation (Parsons et al., 2002b).  Based on the phenotype of the fkrp, 
fukutin and dystroglycan morphants the muscle pathology is consistent with a 
failure laminin-α2 dystroglycan interaction, whereas the brain and eye pathology, 
which appeared more severe in fkrp and fukutin morphants than dystroglycan 
morphants, suggests that there may be specific pathways not dependent upon 
dystroglycan in relation to fkrp and fukutin function in eye and brain.  
pomt 1 and pomt2 is another example of MO knock down models for the 
secondary dystroglycanopathy genes that produces a phenotype in zebrafish, 
which is similar to other secondary dystroglycanopathy models (Thornhill et al., 
2008; Avsar-Ban et al., 2010; Kawahara et al., 2010; Lin et al., 2011).  The 
pomt morphants have tail curvature and eye defects similar to that which is 
seen in fkrp, fukutin and dystroglycan MO knock down models.  The 
coexpression of pomt1 and pomt2 is required for the enzymatic O-
mannosylation of dystroglycan, and knock down of both simultaneously 
produces a more severe knockdown than either on their own (Avsar-Ban et al., 
2010).  Recently Kuga et al. and Yoshida-Moriguchi et al.,  showed that FKRP 
in addition to, fukutin and LARGE (Yoshida-Moriguchi et al.; Kuga et al., 2012b) 
are all involved in the phosphorylation of the mannose residue on α-
dystroglycan in muscle, eye and brain, but only to a minimal degree in lung and 
testis.  Therefore FKRP and fukutin may need to be co-expressed for complete 
modification of the mannosyl residues on dystroglycan.  Fukutin has also been 
implicated in a dimerisation with POMGnT1, supporting the theory that the 
secondary dystroglycanopathy proteins act in partnerships (Michele et al., 2002; 
Manya et al., 2004).  Interestingly over-expression of LARGE has previously 
been shown to be capable of functionally bypassing fukutin and FKRP (Barresi 
et al., 2004).  This apparent functional redundancy in the enzymatic pathway for 
post-translational modification of dystroglycan which is not consistent with the 
requirement for these proteins remains intriguing.   
ISPD (isoprenoid domain containing) is the protein most recently found to have 
a role in the modification of dystroglycan (Roscioli et al., 2012; Willer et al., 
2012).  Mutations in ISPD were identified by two groups simultaneously in 
cohorts of WWS syndrome patients whose conditions could not be attributed to 
mutations in the known dystroglycanopathy genes (Willer et al., 2012).  
Knocking down ispd in zebrafish produced morphants with muscle, brain and 
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eye abnormalities (Roscioli et al., 2012).  Interestingly, the observed brain 
malformation (hydrocephalus) could be accentuated by co-injection with either 
fkrp or fukutin MO.  Injection of 3ng each of fukutin and fkrp MO also produced 
hydrocephalus, a feature not seen in our morphants with a knock down of a 
single gene.  This further indicates that the secondary dystroglycanopathy 
proteins may be acting cooperatively. 
6.2 Analysis of the Approach to Modelling FKRP and 
Fukutin Deficiency 
Despite several studies investigating fkrp in zebrafish there is currently no 
stable fkrp mutant fish lines.  An attempt to address the problem using ZFNs 
with the CoDA protocol (Maeder et al., 2009; Sander et al., 2010) proved not to 
be successful in producing a mutant line.  The ZFNs derived from the CoDA 
protocol failed to produce even a low somatic mutation rate in injected fish.  If 
successful, the continuation of use of the ZFN technology to produce a fukutin 
mutant zebrafish line would have been feasible.  Where success could be 
achieved in a relatively short period of time there would have been an attempt 
to create a fukutin morphant line with ZFNs (Porteus and Carroll, 2005). 
There were no mutations reported in any embryos treated with either of the 
CoDA ZFN pairs investigated.  Since the context of the array is only in part 
accounted for by the CoDA protocol, the inference that a particular array will 
function well together remains theoretical and may not be realised when tested.  
It is possible that the somatic mutation rate was too low to be detectable given 
the number of embryos investigated.  A low somatic mutation rate would 
however be difficult to transfer to the next generation due to the large number of 
fish required in the second generation.  A somatic mutation rate of 
approximately 10% is required to move forward with the screening protocol.  No 
mutations were detected in either set of the 95 samples from 10 fish for the two 
ZFN pairs sent for sequencing.  It is therefore concluded the two pairs of ZFNs 
tested were not working with a sufficient efficacy for further use.   
Despite reaching the end of the CoDA protocol, the pairs of ZFNs derived were 
not effective in producing a mutation in the fkrp gene.  CoDA is reported to have 
a 60-75% success rate, and it might therefore be expected that one of the two 
pairs of fingers would produce a mutation.  There still remains a third 
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unexplored set of CoDA zinc fingers for the fkrp gene in zebrafish described by 
ZiFit as 7-1 because of the seven base pair spacer region.  This zinc finger pair 
was not explored because of the requirement for a different pMLM vector.  
Currently only the CoDA zinc fingers with the five base pair spacer region have 
been investigated.  The remaining 7-1 pair would be worth investigating before 
using alternative strategies to develop mutant zebrafish are explored (Maeder et 
al., 2009; Sander et al., 2010). 
The 30-12Apr05B-fukutin MO has been shown to produce an effective knock 
down of fktn gene expression by inducing non-canonical splice variants 
(Nasevicius and Ekker, 2000).  Despite the transient nature of the MO approach 
a range of fukutin morphant phenotypes were observed between 1 & 5dpf.  The 
range of morphants effectively models the spectrum of clinical severity resulting 
from the variety of mutations and splice variants in the fktn gene (Yoshioka and 
Kuroki, 1994).  However it is the range itself and not morphant fish within a 
particular severity category that is of interest, as the mechanisms which 
produce the spectra in fish and humans are not equivalent (Bassett and Currie, 
2003).  
The question of model utility is critical to assess whether any continuation of 
experiments with the 30-12Apr05B-fukutin MO is justified i.e. how useful is the 
fukutin knock down by MO as a model for dystroglycanopathy.  By examining 
the phenotype up to 5dpf it is concluded that the MO is an appropriate tool for 
early developmental questions.  However this model system is less appropriate 
for posing questions about the adult condition.  MOs become diluted with 
increasing number of cells in the zebrafish resulting in re-expression, which 
does not recapitulate the continuing loss of muscle function with ongoing 
Fukutin deficiency observed in the human condition (Chiyonobu et al., 2005; 
Kanagawa et al., 2009a; Taniguchi-Ikeda et al., 2011).   
MO knock down is well suited to the study of congenital disorders (Bassett and 
Currie, 2003; Hall et al., 2007; Thornhill et al., 2008; Kawahara et al., 2010; Lin 
et al., 2011), although a mutant model would simultaneously eliminate non-
specific effects of MO and allow studies to be carried out to investigate adult 
disease, and therefore a mutant line remains an important goal for zebrafish 
dystroglycanopathy research in the future.  The Fkrp-deficient mouse that is not 
embryonic lethal remains the best system to investigate adult Fkrp deficiency 
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(Ackroyd et al., 2009; Ackroyd et al., 2011).  The fukutin chimeric mouse 
remains a good alternative to zebrafish for modelling fukutin deficiency.  The 
final consideration is what would be the best approach to produce a stable 
mutant zebrafish line.  Since there is a range of patient phenotypes from the 
congenital condition to adult onset forms of fukutin associated MD, an allelic 
series of mutants would therefore be desirable.  An allelic series of fish with 
equivalent mutations to those found in the human condition would be the gold 
standard for fukutin associated MD research in zebrafish. 
 In the first chapter different strategies were considered: in the long term the 
zebrafish mutation project will likely produce several lines with mutations in the 
fkrp and fukutin genes.  A mutant line is already being displayed on the ZMP 
website with a confirmed C>T nonsense mutation in the F2 generation in the 
fkrp gene, reported to be available as early as April 2013.  In the short term the 
TALEN system would be a good alternative because of the specific targeted 
nature of the TALENs.  TALENs have recently been shown to produce a higher 
somatic mutation rate >10% in 76% of gene loci tested whereas ZFNs produce 
a somatic mutation rate of <1% in 3.3% of gene loci tested (Moore et al., 2012b).  
Therefore, there is a clear case for switching to a TALEN based approach in the 
future.   
6.3 Mechanisms of Skeletal Muscle Pathology 
The second aim was to investigate the mechanism of muscle pathology in fkrp 
and fukutin knockdown fish.  Ultrastructural analysis revealed that the muscle 
pathology could be associated with both a disruption to the sarcolemma and 
fibre detachment from the vertical myoseptum.  Immunostaining confirmed a 
hypoglycosylation of α-dystroglycan and loss of laminin at the vertical myosepta 
(Thornhill et al., 2008).  Combined with studies investigating laminin-α2 
candyfloss zebrafish (Hall et al., 2007), it was predicted that fibre detachment 
was as a consequence of a disrupted α-dystroglycan laminin-α2 interaction.  
Interestingly, studies that investigated sarcolemmal instability using Evan’s blue 
dye did not find any dye leakage in the laminin-α2 models (Straub and 
Campbell, 1997).  Our findings suggesting sarcolemmal damage may represent 
either a secondary consequence of the severe muscle damage in 
dystroglycanopathy or a developmental delay in the production of sarcolemma.  
The sarcolemmal damage remains intriguing but can be explained by the loss of 
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muscle fibre attachment to the vertical myoseptum.  Utilizing the sapje DMD 
model zebrafish as a comparison would form a good complementary data set, 
since the muscle pathology in this model is thought to be entirely associated 
with sarcolemmal instability (Bassett et al., 2003). 
Interestingly muscle fibres in the lama2 candyfloss fish are known to fuse with 
the vertical myosptum correctly and therefore laminin-α2 is not required for this 
process (Hall et al., 2007).  Recent evidence suggests however that integrin-α7 
is required perhaps with a laminin chain such as laminin- β2 (Jacoby et al., 
2009; Sztal et al., 2012).  Both components are known to be important for 
muscle fibres to form contacts with the vertical myoseptum.  Therefore 
investigating expression and glycosylation of both laminin-β2 and integrin-α7 in 
early zebrafish development in dystroglycanopathy morphant fish would be the 
next logical step to determining the aetiological cause of the muscle pathology 
in fkrp and fukutin deficiency.  Modification of either laminin-β2 or integrin-α7 by 
fkrp and fukutin has currently not been shown.  The post translational 
modification of either component by FKRP or fukutin does not remain outside 
the bounds of possibility, it is however perhaps not important for their function of 
initial adherence of muscle fibre with myoseptum (Postel et al., 2008).  If fkrp 
and fukutin modified either laminin-β2 or integrin-α7 in any way then it would be 
expected that muscle fibres would not adhere to the myoseptum in our fkrp and 
fukutin morphant fish.  Investigating muscle fibre adhesion including laminin-β2 
or integrin-α7 expression to the vertical myoseptum at an earlier time point in 
the dystroglycanopathy fish would prove this hypothesis conclusively.    
6.4 Mechanism of Eye Pathology 
While zebrafish are not the best model system to study brain development since 
they lack much of the complexity found in mammalian brains, they are a good 
model system to study eye development since their eye is structurally similar to 
the mammalian eye.  One aim of this thesis was to understand more about the 
underlying developmental mechanism of the eye pathology found in the fukutin 
and fkrp deficient zebrafish.  Deficiencies in all three eye basement membranes 
were found, providing a basis for eye pathology in dystroglycanopathy.  More 
work will be required to determine what the key interactions are that stabilise 
retinal layering to basement membranes.  Preliminary examination found that a 
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laminin dystroglycan interaction as found in the muscle is unlikely to be 
responsible for maintaining cellular adhesions to basement membranes. 
There is clearly a complex developmental mechanism that is responsible for 
establishing basement membrane structure and retinal layering in mammals 
and fish.  The dystroglycanopathy morphant zebrafish have disrupted basement 
membranes and retinal layering abnormalities.  The observed pathological 
changes in the eyes of the morphant fish may be as a result of a cascade which 
starts with perturbations in the posterior basement membranes i.e. ELM and 
Bruch’s membrane.  The important secondary change attributed to disruptions 
in both of the posterior eye basement membranes, could be the loss of the RPE 
in the morphants.  The final event would be loss of retinal layering organisation 
as a consequence of reduced RPE density.  The RPE is thought to be key in 
driving cellular layer organization, providing molecular cues for differentiation of 
the retinal layers (Strauss, 1995; Martinez-Morales et al., 2004; Bharti et al., 
2006).  Albino animals with no pigment in the RPE illustrates the hypothesised 
mechanism since these mice have disrupted retinal layering but intact 
basement membranes (Al-Hussaini et al., 2008).  Since it is possible to have a 
loss of retinal layering without a loss of basement membrane integrity, it can be 
assumed that disruption to the basement membranes of the eye is not sufficient 
on its own to cause the retinal layering abnormalities.  The implication is 
therefore that a loss of retinal layering in the dystroglycanopathy morphants 
might be a secondary consequence of reduced RPE as a result of the primary 
aetiological perturbation to the posterior basement membranes.  
Perturbations to the anterior basement membrane i.e. the ILM may also 
contribute to the overall poorly differentiated retinal layering in the 
dystroglycanopathy morphant fish.  Recently Randlett and co-workers have 
shown the contact of retinal ganglion cells (RGC) with laminin at the ILM to be 
critical for axon guidance.  Randlett and co-workers propose that axonic 
projections from the RGCs project from Bruch’s membrane during development, 
connecting with the laminin at the ILM, then the axon followed by the cell body 
migrate towards the GCL (Randlett et al., 2011).  The hypothesis in our model is 
that dystroglycanopathy leads to disrupted retinal layering through two 
processes: firstly Müller glia anchoring to the ILM is disrupted as the result of 
loss of the α-dystroglycan laminin interaction.  Secondly a reduction in correctly 
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glycosylated α-dystroglycan in the axonic processes of retinal ganglion cells 
prevents an interaction with laminin in ECM and ILM important in the guidance 
process of cell migration in the eye.  The resultant mis-localised laminin at the 
ILM/ELM and incorrectly glycosylated dystroglycan results in cells failing to 
localise to the correct layers of the retina in fkrp and fukutin morphants.  
Therefore, it is the potentially loss of “driver” function from the posterior retina 
and loss of guidance at the anterior that contribute together to overall 
disorganised retinal layering, as a result of basement membrane disruption in 
the dystroglycanopathy fish. 
The data presented in the vascular section suggests that there may be 
unknown proteins expressed in the eye which are subject to secondary 
modification by fkrp and fukutin.  One potential candidate class of proteins are 
the major basement membrane proteins collagen.  Collagen 4A1 deficiency 
results in iris dysplasia, vascular haemorrhaging, optic nerve cupping, corneal 
opacities, bupthalamos; a condition defined by enlarged eye balls and cataracts 
(Gould et al., 2005; Van Agtmael et al., 2005; Breedveld et al., 2006).  
Mutations in human collagen 8A1-2 are the genetic basis for Fuch’s corneal 
dystrophy (OMIM136800) and result in anterior segment dysgenesis in mice 
(Gottsch et al., 2005; Hopfer et al., 2005).  Retinal detachment, high myopia 
and vitreoretinal degeneration are the key features of mutations in collagen 18, 
referred to as Knobloch syndrome  in humans (OMIM 267750) and mouse 
models deficient in Col18a1 have signs of age related degeneration of the eye 
(Sertie et al., 2000; Fukai et al., 2002; Ylikarppa et al., 2003; Marneros and 
Olsen, 2005).  The specific features of eye pathology associated with fkrp, 
fukutin and dystroglycan deficiency does not correlate with the disturbances to 
the eye in collagen mutant zebrafish.  Despite a clear requirement for collagen 
in the eye the clinical phenotypes are not consistent with those seen in 
secondary dystroglycanopathies, and therefore do not support a collagen-
dystroglycan axis.  Retinal eye pathology might therefore be attributable to a 
more specific component within the basement membrane such as laminin.  
The muscle pathology in fkrp and fukutin deficiency can be attributed to 
disruption to the α-dystroglycan laminin-211 interaction, important for 
maintenance of cell adhesion with basement membrane.  It would therefore be 
logical to hypothesise a similar protein interaction may adhere cells to basement 
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membranes in the eye.  Loss of fkrp and fukutin dependent secondary 
modification of an unknown protein with an alternative laminin chain to laminin-
α2 in the classic interaction might result in loss of cell anchoring to eye 
basement membranes.  This hypothesis is consistent with the vascular findings 
and supported by the nestin-Cre/DG null mouse (Satz et al., 2009).  Studies in 
the nestin-Cre/DG null mouse found that dystroglycan is required for eye 
development but not for the maintenance of anchoring cells at basement 
membranes.  In the zebrafish Laminin-α2 mutant model candyfloss has a 
muscle but no brain or eye phenotype (Hall et al., 2007).  Laminin-α2 is 
therefore an unlikely candidate as an important laminin chain in the eye.  
Laminin-β2 is expressed in the eye in wild type but not the laminin-β2 zebrafish 
mutant softy (Jacoby et al., 2009).  Despite loss of laminin-β2 the softy mutants 
have no discernible eye phenotype.  However patients with mutations in the 
laminin-β2 gene have microcoria-congenital nephrosis, lens, retina, cornea and 
iris abnormalities referred to as Piersons syndrome (OMIM 609049) (Zenker et 
al., 2004; Zenker et al., 2005).  The laminin β1 & γ1 zebrafish mutants showed 
signs of ILM and lens abnormalities, however the only laminin mutant with an 
ectopic lens phenotype was the laminin-α1 mutant zebrafish (Semina et al., 
2006; Lee and Gross, 2007).  Therefore, based on the eye phenotypes of 
patients and animal models, laminin-α1 is the assumed candidate that is 
important for binding dystroglycan in the eye.  The counter argument is laminin-
α1is ubiquitously expressed and is therefore unlikely to be involved in the highly 
specific organisation of the eye.  It is likely that more than one laminin chain 
interacts with dystroglycan and is important for eye development.   
The clear pathology at both the anterior and posterior regions of the eye in the 
dystroglycan morphants, combined with dystroglycan being detectable at both 
the ILM and Bruch’s membrane in wild type fish, suggest a role for dystroglycan 
across the retina.  Immunostaining in the MORE-DG mouse model shows that 
there is role for glycosylated α-dystroglycan in the eye (Satz et al., 2008).  
However, glycosylated α-dystroglycan is neither the most important protein for 
stabilising retinal cells with respect to basement membranes nor a key molecule 
in eye vascular development.  One of the more clearly defined roles of 
dystroglycan is the interaction with pikachurin within ribbon synapses.  Studies 
have shown pikachurin binding of correctly glycosylated α-dystroglycan is 
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important in the formation of ribbon synapses (Sato et al., 2008).  Recently 
dystroglycan clustering at the photoreceptor synaptic terminal has been shown 
to be dependent on pikachurin expression, which is important for proper 
synaptic connectivity (Sato et al., 2008; Bozzi et al., 2009; Omori et al., 2012).  
Basement membrane pathology is, at least in part, a consequence of the loss of 
the interaction between laminin-α1 and α-dystroglycan (Jacoby et al., 2009).  
Based on morphant basement membrane phenotypes on TEM, laminin-α1 is 
clearly important for RGC migration across the retina during development.  
Together with a loss of RPE known to be important for driving retinal layer 
differentiation, laminin-α1 is evidently important in eye basement membranes.  
Lens ablation studies show lens and ILM together are important for invagination 
of vasculature into the optic cup (Semina et al., 2006).  A similar ectopic lens 
and absent ILM phenotype as observed in fkrp/fukutin morphants has been 
reported in laminin-α1deficient zebrafish embryos.  This raises the question of 
whether there is a laminin-α1 interaction with an unknown protein requiring 
fukutin/fkrp for expression which forms the key axis important for driving 
angiogenesis since dystroglycan morphants have a normal eye vascular 
phenotype.  This hypothesis for would support a novel axis i.e. fkrp, fukutin and 
laminin-α1 for vasculogenesis and neurogenesis in zebrafish eye development.  
Laminin-α1 acts as a common receptor within the basement membrane for a 
variety of membrane proteins.  The loss of these interactions in dystroglycan 
morphants may occur as a result of fkrp and fukutin acting as drivers modifying 
independent proteins that bind laminin-α1.  Processes occurring simultaneously 
in the eye such as neurogenesis and angiogenesis can therefore be specifically 
controlled by fkrp and fukutin by glycosylating different laminin binding partners 
at specific time points (Dahm et al., 2007; Randlett et al., 2011).  The multiple 
facets of the eye pathology associated with fkrp and fukutin deficiency suggests 
fundamental roles for proteins modified by fkrp/fukutin in the control of eye 
development. 
Unlike muscle, the eye phenotype cannot be attributed to a loss of α-
dystroglycan interaction with laminin-α2.  However, this phenotype can be 
hypothesised to be caused by a loss of laminin-α1 binding to other receptors 
present in the eye, such as integrin-α6, an integrin known to bind laminin in the 
eye (Hynes, 1992; van der Flier and Sonnenberg, 2001).  The eye is a complex 
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structure and it is likely that laminins, dystroglycan and integrins are involved in 
an intricate interplay with many post translation modifiers such as fkrp and 
fukutin which are important mediators for these interactions.  In conclusion, fkrp 
and fukutin post translational modification of dystroglycan and possibly yet to be 
determined proteins are important in the adherence of cellular components with 
basement membranes (Satz et al., 2008; Bozzi et al., 2009; Satz et al., 2009).  
6.5 Linking Vasculature and Basement Membrane 
Pathology 
Vasculature was studied in this body of work as a hypothesised primary 
aetiology that might contribute to the phenotype in fkrp and fukutin deficiency.  
WWS Patients with POMT1 mutations were observed to have surface vascular 
abnormalities on their brains, forming the initial hypothesis that vascular 
changes may be responsible in part for the dystroglycanopathy phenotype, 
(Beltran-Valero de Bernabe et al., 2002).  Fli-1 fish in conjunction with knock 
down of dystroglycanopathy genes using MOs provided a good model system 
to test this hypothesis. 
Down-regulation of fukutin, fkrp or dystroglycan by MO was found to lead to 
aberrant blood vessel development in the somitic trunk of fli-1 embryos.  Closer 
examination revealed absent or delayed growth of intersegmental vessels in the 
somites of all three morphants at 1dpf.  These findings raised a number of 
questions about the primary origin of this abnormal angiogenesis.  Firstly, was 
the vascular pathology in the dystroglycanopathy knockdown fish secondary to 
the observed changes in the myotome?  Secondly, was myotome degradation a 
secondary effect of aberrant angiogenesis?  A further possibility was raised, 
that muscle necrosis ensued as a consequence of hypoxia in somites?  Finally, 
were both muscle and vascular development independent primary pathologies 
in the morphant fish which may have a currently unknown common mechanism, 
since ECM damage or lack of growth factors from the notochord could equally 
affect both processes?  This raises a further question: are fkrp and fukutin 
involved in more global developmental events and does dystroglycan remain 
the sole receptor for their post translational modification?  
By considering model systems without any muscle pathology and poor 
intersegmental growth such as the endothelial cell-specific molecule 2 (ECSM2) 
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and the netrin receptor UNC5B (Lu et al., 2004; Ma et al., 2009), it is possible to 
make inferences about whether poor angiogenesis is the primary aetiology 
responsible for the muscle damage.  Based on these models it is improbable 
that the poor angiogenesis observed in the dystroglycanopathy models is 
responsible for the muscle necrosis.  An analogous approach found reduced 
segmental vessel development without the curly tail phenotype by knocking 
down the myotubularin family gene Mtmr8 in zebrafish.  Interestingly despite 
Mtmr8 being expressed in the mesoderm, a progenitor tissue of both muscle 
and endothelial cells during embryogenesis, Mtmr8 knockdown only resulted in 
vascular abnormalities (Mei et al., 2010).  Together these findings suggest that 
the muscle phenotype seen in the fukutin, fkrp and dystroglycan morphants was 
unlikely to be a secondary consequence of abnormal angiogenesis in the fish.  
Turning the question around, it is possible to query whether abnormal 
angiogenesis seen in the somites is a secondary consequence of the muscle 
pathology.  Vascularisation has not been studied in other zebrafish models of 
MD to determine whether the described vascular abnormalities are a non-
specific response to muscle pathology.  No vascular phenotype was observed 
in the somites when the ubiquitously expressed gfat1 was down-regulated, 
despite the curly tail phenotype and abnormal muscle fibres.  Generally 
vascularisation is enhanced in regenerating muscle and currently there is no 
evidence from patients or mouse models with MD that might suggest muscle 
pathology affects vascular development (Eguchi et al., 2009; Senderek et al., 
2010).  
This suggests that the disruption of somitic angiogenesis is a primary 
consequence of the knockdown of fukutin, fkrp or dystroglycan, and not a 
secondary outcome of muscle pathology (Lu et al., 2004; Ma et al., 2009).  
Considered the opposite way around aberrant angiogenesis did not result in 
abnormal somite or tail structure in other zebrafish models with early vascular 
defects.  These data combined suggests that vascular and muscle pathology 
observed in the morphants is two distinct pathogenic consequences of 
dystroglycanopathy.  Poor vascularisation of the eye was investigated, as one 
of the possible secondary consequences of loss of eye structure (Gore et al., 
2012).   
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Abnormal eye vasculature development was observed in both fkrp and fukutin 
knockdowns.  Whereas the eyes of dystroglycan morphants had the same 
appearance and were of a similar size to the controls, implying that eye 
vascular development in zebrafish embryos and early larvae is not dependent 
upon dystroglycan expression.  Only fkrp and fukutin morphants were found to 
have aberrant eye vascular development when compared to somitic vascular 
findings, where differences in segmental vessel height was found in all the 
dystroglycanopathy morphants.  The implication is that fkrp and fukutin modify 
yet to be discovered proteins important for eye vasculature development, in 
contrast to vascular development in muscle where correctly glycosylated -
dystroglycan is the most important interaction for angiogenesis.  The findings 
suggest that both fkrp and fukutin are important in vascular development, but 
may have distinct roles in muscle and eye maturation. 
With disrupted vertical myosepta and eye basement membranes it is entirely 
possible that the vascular changes resulted from perturbations in basement 
membranes which are in analogous anatomical locations.  The most likely 
explanation for the eye vasculature not being altered in the dystroglycan 
deficient fish is that FKRP and fukutin have alternative targets in the eye 
important for maintaining the vascular development and maintaining basement 
membrane integrity.  The hypothesis is strengthened by findings in the 
Nestin/Cre DG null mouse dystroglycan mouse that found dystroglycan was 
important for initiating correct eye formation but is not important for its 
maintenance (Satz et al., 2009). 
6.6 Clinical Relevance 
A key requirement was to test whether the MO approach related well to the 
clinical spectrum of disease of FKRP and fukutin deficiency.  Zebrafish allow for 
study of early pathology in muscle and eye, and are well suited to the study of 
congenital conditions such as WWS (Bassett and Currie, 2003).  Without a 
stable mutant line it would be very difficult to make any conclusions about late 
onset or milder conditions such as LGMD2I.  In many senses this is a 
disappointing outcome, since the MO approach is much better system for 
modelling early developmental changes which may not be applicable to the later 
onset LGMDs.  Therapy development for LGMD2I is more likely to be 
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successful than for the CMDs which will be much more difficult to treat due to 
their developmental onset (Brockington et al., 2001a).  
The difficulties in developing therapies for CMDs are a consequence of nature 
of the associated pathology which arises very early during embryonic 
development.  Structures such as eye and brain reach full development at birth 
and defects are irreversible thereafter.  Research into CMDs such as WWS 
should aim to understand the pathogenic mechanisms and to translate the 
findings into therapeutic strategies for milder conditions as a starting point.  
Attention is therefore placed into identifying the remaining causes of WWS that 
will be of use diagnostically.  Indeed, recent findings suggest there are several 
causative genes for WWS that will be identified in the near future, because of 
the rapid progress being made in the field of next generation sequencing 
(Roscioli et al., 2012; Willer et al., 2012).  The ability to diagnose these 
conditions may not aid their treatment but expanding patient registries are in 
place to enable patients to access clinical trials when they become available 
(Bushby et al., 2009).  Accurate and widespread diagnosis also enables bio-
banking, retaining cell lines from these patients to be distributed to researchers 
who may be capable of pioneering new therapeutics.   
6.7 Future Direction   
Overall the project has investigated dystroglycanopathy in zebrafish in detail 
from a histological, ultrastructural and immunohistological perspective in muscle 
and eye.  The notochord is an important developmental structure, clearly 
abnormal on ultrastructural analysis.  The notochord would therefore be worth 
investigating further in the future for the overall understanding of developmental 
disturbances of the fkrp and fukutin deficient zebrafish. 
There are several lines of inquiry the project could move towards.  Firstly, 
gaining a better understanding of the mechanism of disease; finding the key 
proteins for maintaining cellular adhesions at basement membranes and 
investigating any downstream effects of fibres failing to adhere to myoseptum 
such as autophagy (Carmignac et al., 2011).  Secondly, investigating other 
potential targets for FKRP and fukutin; do FKRP and fukutin have any other 
primary targets other than α-dystroglycan?  Thirdly understanding the temporal 
and spatial expression patterns of fkrp and fukutin in zebrafish; which might 
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clarify questions about overall development of muscle, eye and brain in 
dystroglycanopathy.  Finally, developing a pharmaceutical pipeline; since 
adequate treatments do not currently exist for any form of dystroglycanopathy.  
All these approaches overlap and therefore could feed into the central 
understanding of the disease, progressing the overall research forward in each 
of the other areas.  Resource building is often synonymous with progress in 
scientific research and therefore is considered another essential aim of any 
future work that might fall into each of the categories.  
6.7.1 Mechanism  
Understanding more about the disease mechanism of FKRP and fukutin 
deficiency could provide more therapeutic opportunities, such as an autophagic 
response (Carmignac et al., 2011), tying into the translational aims of the 
project.  The unfolded protein response is a mechanism activated to remove 
mis-folded or unfolded proteins by halting translation and upregulating 
chaperones to remove the proteins.  Upregulation of the unfolded protein 
response may account for a part of the mechanism of the disease however it 
does not explain all the aberrant findings in fkrp and fukutin deficiency (Lin et al., 
2011).  The unfolded protein response is perhaps the first attractive therapeutic 
avenue.  However the mechanism is only the beginning of a chain of events that 
includes loss of correctly glycosylated α-dystroglycan binding laminin-211.  How 
a disrupted basement membrane as a result of a reduced dystroglycan laminin 
interaction results in an unfolded protein response and other autophagy 
pathways is of key interest.  It is possible autophagy is induced by either the 
unfolded protein response or loss of structural components.  The full pathways 
and how they link together are currently poorly understood (Benbrook and Long, 
2012).   
6.7.2 Potential Targets of FKRP and Fukutin beyond Dystroglycan  
The work presented in the thesis and in (Lin et al., 2011), provides evidence 
supporting the hypothesis that other targets for FKRP and fukutin might exist.  
Although the brain was not investigated, it is entirely feasible that there are 
novel FKRP and fukutin targets in the cortex, based on the assumption that 
similar mechanisms guide axons through cortical layering as retinal layering.  
These unknown targets outwith dystroglycan may be important, for example in 
processes such as anchoring or guiding the optic neuronal axons.  Studies in 
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the dystroglycan mouse suggest that dystroglycan is redundant after axons are 
guided through the retinal layers and not important for adhering end feet to the 
ILM.  The implication is that FKRP and fukutin may be important for modification 
of the anchor protein in this instance.  Alternatively, the correct glycosylation of 
the novel protein may be involved in providing cues that guide the axon through 
the ECM of the retinal layers.  
The question can therefore be posed, which targets are post-translationally 
modified by FKRP and fukutin?  Hypothetically any protein or lipid with a 
mannose or yet to be determined glycan residue close to its core could be 
phosphorylated by fukutin or FKRP.  It is also not entirely clear if the other 
sugars in the tetramer are essential for fukutin and FKRP to have their 
phosphorylation activity on mannose.  Conversely, the mannose residue alone 
may not be sufficient for phosphoryl modification of α-dystroglycan by FKRP 
and fukutin.  Integrin is one such potential candidate based on it occupying a 
similar position to dystroglycan in the sarcolemma and its ability to bind with 
ECM laminin.  In the eye integrin-α6 is known to bind laminin-111 (Belkin and 
Stepp, 2000), making for an attractive alternative axis to the classic 
dystroglycan laminin-α2 axis in the eye.  The complexity of cellular layering in 
the eye and brain clearly require precisely controlled development, whereas 
muscle in comparison is a relatively simple structure but requires a strong bond 
between basement membrane and sarcolemma, potentially accounting for the 
alternative axes in eye and muscle. 
6.7.3 Developing a Pharmaceutical Pipeline  
Recently zebrafish have been gaining increasing popularity in drug discovery for 
many of their attributes that include optical transparency, low cost and ease of 
genetic manipulation.  The approach currently adopted in MD research is to 
look at changes in birefringence i.e. a relatively fast technique for assessment 
of overall muscle damage, in fish myotome after treatment with chemical 
compound libraries, and the sapje fish is an example of where this technology 
has been employed successfully (Winder et al., 2011).  Normally the chemical 
compound libraries are drug treatments passed for use in humans either by the 
Federal Drug Authority in the United States of America or European Medicines 
Agency.  Other drug screens are based on using high throughput techniques on 
transgenic lines and measure the amount of fluorescence change or overall 
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movement after treatment.  Future work that investigates whether rescuing the 
vascular anomalies is a good assay for the whole muscle disease could 
potentially feed into a pharmaceutical screen for novel compounds that improve 
muscle pathology in dystroglycanopathy.  Stable mutants crossed with 
TG:(Fli1:EGFP) fish could serve as model for dystroglycanopathy since there is 
reduced intersegmental vessel development in the mutant fish.  Recovery of 
muscle structure could be simultaneously assessed using birefringence, 
previously shown in fkrp morphant fish (Thornhill et al., 2008).  Lead 
compounds and successful therapies could then be progressed to being trialled 
in mouse models, an organism physiologically closer to humans. 
6.8 Summary 
By knocking down fkrp and fukutin with MOs to a similar extent in zebrafish, 
with dystroglycan knock down fish used as a comparison it was possible to 
elucidate a great deal more about their roles in development.  Each of the 
dystroglycanopathy morphants had a very similar morphological muscle, eye 
and brain phenotype observed in the fish across the first five days of 
development.  This study was able to comprehensively associate the 
dystroglycanopathy pathology with loss of basement membrane structure in 
muscle, notochord and eye.  The key axis important for maintaining muscle 
integrity was thought to be the α-dystroglycan laminin axis.  Based on previous 
studies laminin-α2 was predicted to be the predominant laminin chain 
responsible for maintaining fibres association with the muscle specific basement 
membranes of the sarcolemma and myosepta.  When vasculature was 
investigated in the eye the loss of vascular structure in the fkrp and fukutin 
morphants but not dystroglycan might suggest the existence of an alternative 
axis to the classical α-dystroglycan laminin-α2 interaction.  In my opinion a 
novel integrin-α6 laminin-111 axis in the eye may be associated with FKRP and 
fukutin.  Laminin and Integrin are therefore novel candidates for post-
translational modification by FKRP and fukutin, currently only known to modify 
mannose on the dystroglycan tetramer.   
  
194 
 
References 
Ackroyd, M.R., Skordis, L., Kaluarachchi, M., Godwin, J., Prior, S., Fidanboylu, 
M., Piercy, R.J., Muntoni, F. and Brown, S.C. (2009) 'Reduced expression of 
fukutin related protein in mice results in a model for fukutin related protein 
associated muscular dystrophies', Brain, 132(Pt 2), pp. 439-51. 
Ackroyd, M.R., Whitmore, C., Prior, S., Kaluarachchi, M., Nikolic, M., Mayer, U., 
Muntoni, F. and Brown, S.C. (2011) 'Fukutin-related protein alters the deposition 
of laminin in the eye and brain', J Neurosci, 31(36), pp. 12927-35. 
Adams, M.E., Kramarcy, N., Fukuda, T., Engel, A.G., Sealock, R. and Froehner, 
S.C. (2004) 'Structural abnormalities at neuromuscular synapses lacking 
multiple syntrophin isoforms', J Neurosci, 24(46), pp. 10302-9. 
Agathon, A., Thisse, C. and Thisse, B. (2003) 'The molecular nature of the 
zebrafish tail organizer', Nature, 424(6947), pp. 448-52. 
Al-Hussaini, H., Kam, J.H., Vugler, A., Semo, M. and Jeffery, G. (2008) 'Mature 
retinal pigment epithelium cells are retained in the cell cycle and proliferate in 
vivo', Mol Vis, 14, pp. 1784-91. 
Aldridge, J., Kunkel, L., Bruns, G., Tantravahi, U., Lalande, M., Brewster, T., 
Moreau, E., Wilson, M., Bromley, W., Roderick, T. and et al. (1984) 'A strategy 
to reveal high-frequency RFLPs along the human X chromosome', Am J Hum 
Genet, 36(3), pp. 546-64. 
Alvarez, Y., Cederlund, M.L., Cottell, D.C., Bill, B.R., Ekker, S.C., Torres-
Vazquez, J., Weinstein, B.M., Hyde, D.R., Vihtelic, T.S. and Kennedy, B.N. 
(2007) 'Genetic determinants of hyaloid and retinal vasculature in zebrafish', 
BMC Dev Biol, 7, p. 114. 
Amsterdam, A., Varshney, G.K. and Burgess, S.M. (2011) 'Retroviral-mediated 
Insertional Mutagenesis in Zebrafish', Methods Cell Biol, 104, pp. 59-82. 
Anderson, J.E. (1991) 'Dystrophic changes in mdx muscle regenerating from 
denervation and devascularization', Muscle Nerve, 14(3), pp. 268-79. 
Aravind, L. and Koonin, E.V. (1999) 'The fukutin protein family--predicted 
enzymes modifying cell-surface molecules', Curr Biol, 9(22), pp. R836-7. 
Aumailley, M., Bruckner-Tuderman, L., Carter, W.G., Deutzmann, R., Edgar, D., 
Ekblom, P., Engel, J., Engvall, E., Hohenester, E., Jones, J.C., Kleinman, H.K., 
Marinkovich, M.P., Martin, G.R., Mayer, U., Meneguzzi, G., Miner, J.H., 
Miyazaki, K., Patarroyo, M., Paulsson, M., Quaranta, V., Sanes, J.R., Sasaki, T., 
Sekiguchi, K., Sorokin, L.M., Talts, J.F., Tryggvason, K., Uitto, J., Virtanen, I., 
von der Mark, K., Wewer, U.M., Yamada, Y. and Yurchenco, P.D. (2005) 'A 
simplified laminin nomenclature', Matrix Biol, 24(5), pp. 326-32. 
195 
 
Avanesov, A. and Malicki, J. (2004) 'Approaches to study neurogenesis in the 
zebrafish retina', Methods Cell Biol, 76, pp. 333-84. 
Avsar-Ban, E., Ishikawa, H., Manya, H., Watanabe, M., Akiyama, S., Miyake, H., 
Endo, T. and Tamaru, Y. (2010) 'Protein O-mannosylation is necessary for 
normal embryonic development in zebrafish', Glycobiology, 20(9), pp. 1089-102. 
Bach, J.R. (2000) 'The Duchenne de Boulogne-Meryon controversy and 
pseudohypertrophic muscular dystrophy', J Hist Med Allied Sci, 55(2), pp. 158-
78. 
Bajanca, F. and Thorsteinsdottir, S. (2002) 'Integrin expression patterns during 
early limb muscle development in the mouse', Gene Expr Patterns, 2(1-2), pp. 
133-6. 
Balci, B., Uyanik, G., Dincer, P., Gross, C., Willer, T., Talim, B., Haliloglu, G., 
Kale, G., Hehr, U., Winkler, J. and Topaloglu, H. (2005) 'An autosomal 
recessive limb girdle muscular dystrophy (LGMD2) with mild mental retardation 
is allelic to Walker-Warburg syndrome (WWS) caused by a mutation in the 
POMT1 gene', Neuromuscul Disord, 15(4), pp. 271-5. 
Banks, G.B. and Chamberlain, J.S. (2008) 'The value of mammalian models for 
duchenne muscular dystrophy in developing therapeutic strategies', Curr Top 
Dev Biol, 84, pp. 431-53. 
Barresi, R. and Campbell, P. (2005) 'Dystroglycan: from biosynthesis to 
pathogenesis of human disease', Journal of Cell Science, 119(2), pp. 199-2007. 
Barresi, R., Michele, D.E., Kanagawa, M., Harper, H.A., Dovico, S.A., Satz, J.S., 
Moore, S.A., Zhang, W., Schachter, H., Dumanski, J.P., Cohn, R.D., Nishino, I. 
and Campbell, K.P. (2004) 'LARGE can functionally bypass alpha-dystroglycan 
glycosylation defects in distinct congenital muscular dystrophies', Nat Med, 
10(7), pp. 696-703. 
Bassett, D. and Currie, P.D. (2004) 'Identification of a zebrafish model of 
muscular dystrophy', Clin Exp Pharmacol Physiol, 31(8), pp. 537-40. 
Bassett, D.I., Bryson-Richardson, R.J., Daggett, D.F., Gautier, P., Keenan, D.G. 
and Currie, P.D. (2003) 'Dystrophin is required for the formation of stable 
muscle attachments in the zebrafish embryo', Development, 130(23), pp. 5851-
60. 
Bassett, D.I. and Currie, P.D. (2003) 'The zebrafish as a model for muscular 
dystrophy and congenital myopathy', Hum Mol Genet, 12 Spec No 2, pp. R265-
70. 
Bedell, V.M., Wang, Y., Campbell, J.M., Poshusta, T.L., Starker, C.G., Krug Ii, 
R.G., Tan, W., Penheiter, S.G., Ma, A.C., Leung, A.Y., Fahrenkrug, S.C., 
196 
 
Carlson, D.F., Voytas, D.F., Clark, K.J., Essner, J.J. and Ekker, S.C. (2012) 'In 
vivo genome editing using a high-efficiency TALEN system', Nature. 
Belkin, A.M. and Stepp, M.A. (2000) 'Integrins as receptors for laminins', 
Microsc Res Tech, 51(3), pp. 280-301. 
Beltran-Valero de Bernabe, D., Currier, S., Steinbrecher, A., Celli, J., van 
Beusekom, E., van der Zwaag, B., Kayserili, H., Merlini, L., Chitayat, D., Dobyns, 
W.B., Cormand, B., Lehesjoki, A.E., Cruces, J., Voit, T., Walsh, C.A., van 
Bokhoven, H. and Brunner, H.G. (2002) 'Mutations in the O-
mannosyltransferase gene POMT1 give rise to the severe neuronal migration 
disorder Walker-Warburg syndrome', Am J Hum Genet, 71(5), pp. 1033-43. 
Beltran-Valero de Bernabe, D., Voit, T., Longman, C., Steinbrecher, A., Straub, 
V., Yuva, Y., Herrmann, R., Sperner, J., Korenke, C., Diesen, C., Dobyns, W.B., 
Brunner, H.G., van Bokhoven, H., Brockington, M. and Muntoni, F. (2004) 
'Mutations in the FKRP gene can cause muscle-eye-brain disease and Walker-
Warburg syndrome', J Med Genet, 41(5), p. e61. 
Benbrook, D.M. and Long, A. (2012) 'Integration of autophagy, proteasomal 
degradation, unfolded protein response and apoptosis', Exp Oncol, 34(3), pp. 
286-97. 
Bertini, E., D'Amico, A., Gualandi, F. and Petrini, S. (2011) 'Congenital muscular 
dystrophies: a brief review', Semin Pediatr Neurol, 18(4), pp. 277-88. 
Bharti, K., Nguyen, M.T., Skuntz, S., Bertuzzi, S. and Arnheiter, H. (2006) 'The 
other pigment cell: specification and development of the pigmented epithelium 
of the vertebrate eye', Pigment Cell Res, 19(5), pp. 380-94. 
Bill, B.R., Petzold, A.M., Clark, K.J., Schimmenti, L.A. and Ekker, S.C. (2009) 'A 
primer for morpholino use in zebrafish', Zebrafish, 6(1), pp. 69-77. 
Boettiger, D. (2012) 'Mechanical control of integrin-mediated adhesion and 
signaling', Curr Opin Cell Biol. 
Bogdanik, L., Framery, B., Frolich, A., Franco, B., Mornet, D., Bockaert, J., 
Sigrist, S.J., Grau, Y. and Parmentier, M.L. (2008) 'Muscle dystroglycan 
organizes the postsynapse and regulates presynaptic neurotransmitter release 
at the Drosophila neuromuscular junction', PLoS One, 3(4), p. e2084. 
Bohm, S.V. and Roberts, R.G. (2009) 'Expression of members of the dystrophin, 
dystrobrevin, and dystrotelin superfamily', Crit Rev Eukaryot Gene Expr, 19(2), 
pp. 89-108. 
Boncinelli, E. and Morgan, R. (2001) 'Downstream of Otx2, or how to get a 
head', Trends Genet, 17(11), pp. 633-6. 
197 
 
Bork, P., Downing, A.K., Kieffer, B. and Campbell, I.D. (1996) 'Structure and 
distribution of modules in extracellular proteins', Q Rev Biophys, 29(2), pp. 119-
67. 
Bourteel, H., Vermersch, P., Cuisset, J.M., Maurage, C.A., Laforet, P., Richard, 
P. and Stojkovic, T. (2009) 'Clinical and mutational spectrum of limb-girdle 
muscular dystrophy type 2I in 11 French patients', J Neurol Neurosurg 
Psychiatry, 80(12), pp. 1405-8. 
Bowe, M.A., Mendis, D.B. and Fallon, J.R. (2000) 'The Small Leucine-rich 
Repeat Proteoglycan Biglycan Binds to α-Dystroglycan and Is Upregulated in 
Dystrophic Muscle' J Cell Biology, 148(4), pp. 801-10. 
Boyd, Y. and Buckle, V.J. (1986) 'Cytogenetic heterogeneity of translocations 
associated with Duchenne muscular dystrophy', Clin Genet, 29(2), pp. 108-15. 
Bozic, D., Sciandra, F., Lamba, D. and Brancaccio, A. (2004) 'The Structure of 
the N-terminal Region of Murine Skeletal Muscle a-Dystroglycan Discloses a 
Modular Architecture', The Journal of Biological Chemistry, 279(43), pp. 44812-
44816. 
Bozzi, M., Bianchi, M., Sciandra, F., Paci, M., Giardina, B., Brancaccio, A. and 
Cicero, D.O. (2003) 'Structural characterization by NMR of the natively unfolded 
extracellular domain of beta-dystroglycan: toward the identification of the 
binding epitope for alpha-dystroglycan', Biochemistry, 42(46), pp. 13717-24. 
Bozzi, M., Morlacchi, S., Bigotti, M.G., Sciandra, F. and Brancaccio, A. (2009) 
'Functional diversity of dystroglycan', Matrix Biol, 28(4), pp. 179-87. 
Bozzi, M., Sciandra, F., Ferri, L., Torreri, P., Pavoni, E., Petrucci, T.C., Giardina, 
B. and Brancaccio, A. (2006) 'Concerted mutation of Phe residues belonging to 
the beta-dystroglycan ectodomain strongly inhibits the interaction with alpha-
dystroglycan in vitro', Febs J, 273(21), pp. 4929-43. 
Brancaccio, A., Schulthess, T., Gesemann, M. and Engel, J. (1995) 'Electron 
microscopic evidence for a mucin-like region in chick muscle alpha-
dystroglycan', FEBS Lett, 368(1), pp. 139-42. 
Brancaccio, A., Schulthess, T., Gesemann, M. and Engel, J. (1997) 'The N-
terminal region of alpha-dystroglycan is an autonomous globular domain', Eur J 
Biochem, 246(1), pp. 166-72. 
Breedveld, G., de Coo, I.F., Lequin, M.H., Arts, W.F., Heutink, P., Gould, D.B., 
John, S.W., Oostra, B. and Mancini, G.M. (2006) 'Novel mutations in three 
families confirm a major role of COL4A1 in hereditary porencephaly', J Med 
Genet, 43(6), pp. 490-5. 
Breton, C. and Imberty, A. (1999) 'Structure/function studies of 
glycosyltransferases', Curr Opin Struct Biol, 9(5), pp. 563-71. 
198 
 
Bringmann, A. and Wiedemann, P. (2009) 'Involvement of Muller glial cells in 
epiretinal membrane formation', Graefes Arch Clin Exp Ophthalmol, 247(7), pp. 
865-83. 
Brockdorff, N., Cross, G.S., Cavanna, J.S., Fisher, E.M., Lyon, M.F., Davies, 
K.E. and Brown, S.D. (1987) 'The mapping of a cDNA from the human X-linked 
Duchenne muscular dystrophy gene to the mouse X chromosome', Nature, 
328(6126), pp. 166-8. 
Brockington, M., Blake, D.J., Brown, S.C. and Muntoni, F. (2002) 'The gene for 
a novel glycosyltransferase is mutated in congenital muscular dystrophy 
MDC1C and limb girdle muscular dystrophy 2I', Neuromuscul Disord, 12(3), pp. 
233-4. 
Brockington, M., Blake, D.J., Prandini, P., Brown, S.C., Torelli, S., Benson, M.A., 
Ponting, C.P., Estournet, B., Romero, N.B., Mercuri, E., Voit, T., Sewry, C.A., 
Guicheney, P. and Muntoni, F. (2001a) 'Mutations in the fukutin-related protein 
gene (FKRP) cause a form of congenital muscular dystrophy with secondary 
laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan', 
Am J Hum Genet, 69(6), pp. 1198-209. 
Brockington, M., Torelli, S., Prandini, P., Boito, C., Dolatshad, N.F., Longman, 
C., Brown, S.C. and Muntoni, F. (2005) 'Localization and functional analysis of 
the LARGE family of glycosyltransferases: significance for muscular dystrophy', 
Hum Mol Genet, 14(5), pp. 657-65. 
Brockington, M., Yuva, Y., Prandini, P., Brown, S.C., Torelli, S., Benson, M.A., 
Herrmann, R., Anderson, L.V., Bashir, R., Burgunder, J.M., Fallet, S., Romero, 
N., Fardeau, M., Straub, V., Storey, G., Pollitt, C., Richard, I., Sewry, C.A., 
Bushby, K., Voit, T., Blake, D.J. and Muntoni, F. (2001b) 'Mutations in the 
fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I 
as a milder allelic variant of congenital muscular dystrophy MDC1C', Hum Mol 
Genet, 10(25), pp. 2851-9. 
Broglio, L., Tentorio, M., Cotelli, M.S., Mancuso, M., Vielmi, V., Gregorelli, V., 
Padovani, A. and Filosto, M. (2010) 'Limb-girdle muscular dystrophy-associated 
protein diseases', Neurologist, 16(6), pp. 340-52. 
Brown, C.S., Pearson, P.L., Thomas, N.S., Sarfarazi, M., Harper, P.S. and 
Shaw, D.J. (1985) 'Linkage analysis of a DNA polymorphism proximal to the 
Duchenne and Becker muscular dystrophy loci on the short arm of the X 
chromosome', J Med Genet, 22(3), pp. 179-81. 
Brown, D.D. (1984) 'The role of stable complexes that repress and activate 
eucaryotic genes', Cell, 37(2), pp. 359-65. 
Bulfield, G., Siller, W.G., Wight, P.A. and Moore, K.J. (1984) 'X chromosome-
linked muscular dystrophy (mdx) in the mouse', Proc Natl Acad Sci U S A, 81(4), 
pp. 1189-92. 
199 
 
Burda, P. and Aebi, M. (1999) 'The dolichol pathway of N-linked glycosylation', 
Biochim Biophys Acta, 1426(2), pp. 239-57. 
Burkin, D.J. and Kaufman, S.J. (1999) 'The alpha7beta1 integrin in muscle 
development and disease', Cell Tissue Res, 296(1), pp. 183-90. 
Bushby, K. (2009) 'Diagnosis and management of the limb girdle muscular 
dystrophies', Pract Neurol, 9(6), pp. 314-23. 
Bushby, K., Lynn, S. and Straub, T. (2009) 'Collaborating to bring new therapies 
to the patient--the TREAT-NMD model', Acta Myol, 28(1), pp. 12-5. 
Bushby, K.M. (1994) 'The muscular dystrophies', Baillieres Clin Neurol, 3(2), pp. 
407-30. 
Calderwood, D.A., Huttenlocher, A., Kiosses, W.B., Rose, D.M., Woodside, 
D.G., Schwartz, M.A. and Ginsberg, M.H. (2001) 'Increased filamin binding to 
beta-integrin cytoplasmic domains inhibits cell migration', Nat Cell Biol, 3(12), 
pp. 1060-8. 
Campanelli, J.T., Roberds, S.L., Campbell, K.P. and Scheller, R.H. (1994) 'A 
role for dystrophin-associated glycoproteins and utrophin in agrin-induced 
AChR clustering', Cell, 77(5), pp. 663-74. 
Campbell, K.P. and Kahl, S.D. (1989) 'Association of dystrophin and an integral 
membrane glycoprotein', Nature, 338(6212), pp. 259-62. 
Cao, W., Henry, M.D., Borrow, P., Yamada, H., Elder, J.H., Ravkov, E.V., 
Nichol, S.T., Compans, R.W., Campbell, K.P. and Oldstone, M.B. (1998) 
'Identification of alpha-dystroglycan as a receptor for lymphocytic 
choriomeningitis virus and Lassa fever virus', Science, 282(5396), pp. 2079-81. 
Carmignac, V., Svensson, M., Korner, Z., Elowsson, L., Matsumura, C., Gawlik, 
K.I., Allamand, V. and Durbeej, M. (2011) 'Autophagy is increased in laminin 
alpha2 chain-deficient muscle and its inhibition improves muscle morphology in 
a mouse model of MDC1A', Hum Mol Genet, 20(24), pp. 4891-902. 
Carson, J.A. and Wei, L. (2000) 'Integrin signaling's potential for mediating gene 
expression in hypertrophying skeletal muscle', J Appl Physiol, 88(1), pp. 337-43. 
Cazzato, G. (1968) 'Considerations about a possible role played by connective 
tissue proliferation and vascular disturbances in the pathogenesis of 
progressive muscular dystrophy', Eur Neurol, 1(3), pp. 158-79. 
Cha, Y.R. and Weinstein, B.M. (2007) 'Visualization and experimental analysis 
of blood vessel formation using transgenic zebrafish', Birth Defects Res C 
Embryo Today, 81(4), pp. 286-96. 
200 
 
Chamberlain, J.S. and Benian, G.M. (2000) 'Muscular dystrophy: the worm 
turns to genetic disease', Curr Biol, 10(21), pp. R795-7. 
Chiba, A., Matsumura, K., Yamada, H., Inazu, T., Shimizu, T., Kusunoki, S., 
Kanazawa, I., Kobata, A. and Endo, T. (1997) 'Structures of sialylated O-linked 
oligosaccharides of bovine peripheral nerve alpha-dystroglycan. The role of a 
novel O-mannosyl-type oligosaccharide in the binding of alpha-dystroglycan 
with laminin', J Biol Chem, 272(4), pp. 2156-62. 
Childs, S., Chen, J.N., Garrity, D.M. and Fishman, M.C. (2002) 'Patterning of 
angiogenesis in the zebrafish embryo', Development, 129(4), pp. 973-82. 
Chiyonobu, T., Sasaki, J., Nagai, Y., Takeda, S., Funakoshi, H., Nakamura, T., 
Sugimoto, T. and Toda, T. (2005) 'Effects of fukutin deficiency in the developing 
mouse brain', Neuromuscul Disord, 15(6), pp. 416-26. 
Choo, Y., Sanchez-Garcia, I. and Klug, A. (1994) 'In vivo repression by a site-
specific DNA-binding protein designed against an oncogenic sequence', Nature, 
372(6507), pp. 642-5. 
Chow, R.L. and Lang, R.A. (2001) 'Early eye development in vertebrates', Annu 
Rev Cell Dev Biol, 17, pp. 255-96. 
Chuang, J.C. and Raymond, P.A. (2002) 'Embryonic origin of the eyes in teleost 
fish', Bioessays, 24(6), pp. 519-29. 
Clark, M.D., Guryev, V., Bruijn, E., Nijman, I.J., Tada, M., Wilson, C., Deloukas, 
P., Postlethwait, J.H., Cuppen, E. and Stemple, D.L. (2011) 'Single nucleotide 
polymorphism (SNP) panels for rapid positional cloning in zebrafish', Methods 
Cell Biol, 104, pp. 219-35. 
Cohn, R.D. and Campbell, K.P. (2000) 'Molecular basis of muscular 
dystrophies', Muscle Nerve, 23(10), pp. 1456-71. 
Cohn, R.D., Henry, M.D., Michele, D.E., Barresi, R., Saito, F., Moore, S.A., 
Flanagan, J.D., Skwarchuk, M.W., Robbins, M.E., Mendell, J.R., Williamson, 
R.A. and Campbell, K.P. (2002) 'Disruption of DAG1 in differentiated skeletal 
muscle reveals a role for dystroglycan in muscle regeneration', Cell, 110(5), pp. 
639-48. 
Colombo, R., Bignamini, A.A., Carobene, A., Sasaki, J., Tachikawa, M., 
Kobayashi, K. and Toda, T. (2000) 'Age and origin of the FCMD 3'-untranslated-
region retrotransposal insertion mutation causing Fukuyama-type congenital 
muscular dystrophy in the Japanese population', Hum Genet, 107(6), pp. 559-
67. 
Conte G, G.L. (1836) Annali Clinici dell’Ospedale degl’Incurabili di Napoli. 
201 
 
Corbi, N., Libri, V., Onori, A. and Passananti, C. (2004) 'Synthetic zinc finger 
peptides: old and novel applications', Biochem Cell Biol, 82(4), pp. 428-36. 
Cote, P.D., Moukhles, H., Lindenbaum, M. and Carbonetto, S. (1999) 
'Chimaeric mice deficient in dystroglycans develop muscular dystrophy and 
have disrupted myoneural synapses', Nat Genet, 23(3), pp. 338-42. 
Cowan, J., Macdessi, J., Stark, A. and Morgan, G. (1980) 'Incidence of 
Duchenne muscular dystrophy in New South Wales and Australian Capital 
Territory', J Med Genet, 17(4), pp. 245-9. 
Cox, G.A., Phelps, S.F., Chapman, V.M. and Chamberlain, J.S. (1993) 'New 
mdx mutation disrupts expression of muscle and nonmuscle isoforms of 
dystrophin', Nat Genet, 4(1), pp. 87-93. 
Crosbie, R.H. (2001) 'NO vascular control in Duchenne muscular dystrophy', 
Nat Med, 7(1), pp. 27-9. 
Crosbie, R.H., Lebakken, C.S., Holt, K.H., Venzke, D.P., Straub, V., Lee, J.C., 
Grady, R.M., Chamberlain, J.S., Sanes, J.R. and Campbell, K.P. (1999) 
'Membrane targeting and stabilization of sarcospan is mediated by the 
sarcoglycan subcomplex', J Cell Biol, 145(1), pp. 153-65. 
Dabire, H., Barthelemy, I., Blanchard-Gutton, N., Sambin, L., Sampedrano, C.C., 
Gouni, V., Unterfinger, Y., Aguilar, P., Thibaud, J.L., Ghaleh, B., Bize, A., 
Pouchelon, J.L., Blot, S., Berdeaux, A., Hittinger, L., Chetboul, V. and Su, J.B. 
(2012) 'Vascular endothelial dysfunction in Duchenne muscular dystrophy is 
restored by bradykinin through upregulation of eNOS and nNOS', Basic Res 
Cardiol, 107(1), p. 240. 
Dahm, R., Schonthaler, H.B., Soehn, A.S., van Marle, J. and Vrensen, G.F. 
(2007) 'Development and adult morphology of the eye lens in the zebrafish', 
Exp Eye Res, 85(1), pp. 74-89. 
Davies, K.E., Pearson, P.L., Harper, P.S., Murray, J.M., O'Brien, T., Sarfarazi, 
M. and Williamson, R. (1983) 'Linkage analysis of two cloned DNA sequences 
flanking the Duchenne muscular dystrophy locus on the short arm of the human 
X chromosome', Nucleic Acids Res, 11(8), pp. 2303-12. 
de Bernabe, D.B., van Bokhoven, H., van Beusekom, E., Van den Akker, W., 
Kant, S., Dobyns, W.B., Cormand, B., Currier, S., Hamel, B., Talim, B., 
Topaloglu, H. and Brunner, H.G. (2003) 'A homozygous nonsense mutation in 
the fukutin gene causes a Walker-Warburg syndrome phenotype', J Med Genet, 
40(11), pp. 845-8. 
De la Porte, S., Morin, S. and Koenig, J. (1999) 'Characteristics of skeletal 
muscle in mdx mutant mice', Int Rev Cytol, 191, pp. 99-148. 
202 
 
Deconinck, A.E., Rafael, J.A., Skinner, J.A., Brown, S.C., Potter, A.C., 
Metzinger, L., Watt, D.J., Dickson, J.G., Tinsley, J.M. and Davies, K.E. (1997) 
'Utrophin-dystrophin-deficient mice as a model for Duchenne muscular 
dystrophy', Cell, 90(4), pp. 717-27. 
Demany, M.A. and Zimmerman, H.A. (1969) 'Progressive muscular dystrophy. 
Hemodynamic, angiographic, and pathologic study of a patient with myocardial 
involvement', Circulation, 40(3), pp. 377-84. 
Denzer, A.J., Brandenberger, R., Gesemann, M., Chiquet, M. and Ruegg, M.A. 
(1997) 'Agrin binds to the nerve-muscle basal lamina via laminin', J Cell Biol, 
137(3), pp. 671-83. 
Deufel, T. and Gerbitz, K.D. (1991) 'Biochemistry and molecular genetics of 
muscle diseases', Eur J Clin Chem Clin Biochem, 29(1), pp. 13-38. 
Dong, J. and Stuart, G.W. (2004) 'Transgene manipulation in zebrafish by using 
recombinases', Methods Cell Biol, 77, pp. 363-79. 
Dowling, J.J., Vreede, A.P., Low, S.E., Gibbs, E.M., Kuwada, J.Y., Bonnemann, 
C.G. and Feldman, E.L. (2009) 'Loss of myotubularin function results in T-tubule 
disorganization in zebrafish and human myotubular myopathy', PLoS Genet, 
5(2), p. e1000372. 
Draper, B.W., Morcos, P.A. and Kimmel, C.B. (2001) 'Inhibition of zebrafish fgf8 
pre-mRNA splicing with morpholino oligos: a quantifiable method for gene 
knockdown', Genesis, 30(3), pp. 154-6. 
Drummond AJ, A.B., Buxton S, Cheung M, Cooper A, Duran C, Field M, Heled 
J, Kearse M, Markowitz S, Moir R, Stones-Havas S, Sturrock S, Thierer T, 
Wilson  (2011 ) 'A Geneious v5.4,'. 
Durbeej, M. (2010) 'Laminins', Cell Tissue Res, 339(1), pp. 259-68. 
Durbeej, M. and Campbell, K.P. (2002) 'Muscular dystrophies involving the 
dystrophin-glycoprotein complex: an overview of current mouse models', Curr 
Opin Genet Dev, 12(3), pp. 349-61. 
Durbeej, M., Cohn, R.D., Hrstka, R.F., Moore, S.A., Allamand, V., Davidson, 
B.L., Williamson, R.A. and Campbell, K.P. (2000) 'Disruption of the beta-
sarcoglycan gene reveals pathogenetic complexity of limb-girdle muscular 
dystrophy type 2E', Mol Cell, 5(1), pp. 141-51. 
Eguchi, S., Oshiro, N., Miyamoto, T., Yoshino, K., Okamoto, S., Ono, T., 
Kikkawa, U. and Yonezawa, K. (2009) 'AMP-activated protein kinase 
phosphorylates glutamine : fructose-6-phosphate amidotransferase 1 at Ser243 
to modulate its enzymatic activity', Genes Cells, 14(2), pp. 179-89. 
203 
 
Ellertsdottir, E., Lenard, A., Blum, Y., Krudewig, A., Herwig, L., Affolter, M. and 
Belting, H.G. (2010) 'Vascular morphogenesis in the zebrafish embryo', Dev 
Biol, 341(1), pp. 56-65. 
Emery, A.E. (1993) 'Duchenne muscular dystrophy--Meryon's disease', 
Neuromuscul Disord, 3(4), pp. 263-6. 
Endo, T. (1999) 'O-mannosyl glycans in mammals', Biochim Biophys Acta, 
1473(1), pp. 237-46. 
Ervasti, J.M. and Campbell, K.P. (1991) 'Membrane organization of the 
dystrophin-glycoprotein complex', Cell, 66(6), pp. 1121-31. 
Ervasti, J.M. and Campbell, K.P. (1993) 'A role for the dystrophin-glycoprotein 
complex as a transmembrane linker between laminin and actin', J Cell Biol, 
122(4), pp. 809-23. 
Esapa, C.T., Benson, M.A., Schroder, J.E., Martin-Rendon, E., Brockington, M., 
Brown, S.C., Muntoni, F., Kroger, S. and Blake, D.J. (2002) 'Functional 
requirements for fukutin-related protein in the Golgi apparatus', Hum Mol Genet, 
11(26), pp. 3319-31. 
Fadool, J.M. and Dowling, J.E. (2008) 'Zebrafish: a model system for the study 
of eye genetics', Prog Retin Eye Res, 27(1), pp. 89-110. 
Fan, L. and Collodi, P. (2006) 'Zebrafish embryonic stem cells', Methods 
Enzymol, 418, pp. 64-77. 
Favreau, C., Delbarre, E., Courvalin, J.C. and Buendia, B. (2008) 'Differentiation 
of C2C12 myoblasts expressing lamin A mutated at a site responsible for 
Emery-Dreifuss muscular dystrophy is improved by inhibition of the MEK-ERK 
pathway and stimulation of the PI3-kinase pathway', Exp Cell Res, 314(6), pp. 
1392-405. 
Feitosa, N.M., Richardson, R., Bloch, W. and Hammerschmidt, M. (2011) 
'Basement membrane diseases in zebrafish', Methods Cell Biol, 105, pp. 191-
222. 
Foley, J.E., Maeder, M.L., Pearlberg, J., Joung, J.K., Peterson, R.T. and Yeh, 
J.R. (2009) 'Targeted mutagenesis in zebrafish using customized zinc-finger 
nucleases', Nat Protoc, 4(12), pp. 1855-67. 
Forsberg, H., Crozet, F. and Brown, N.A. (1998) 'Waves of mouse Lunatic fringe 
expression, in four-hour cycles at two-hour intervals, precede somite boundary 
formation', Curr Biol, 8(18), pp. 1027-30. 
Foster, H., Popplewell, L. and Dickson, G. (2012) 'Genetic therapeutic 
approaches for duchenne muscular dystrophy', Hum Gene Ther, 23(7), pp. 676-
87. 
204 
 
Fouquet, B., Weinstein, B.M., Serluca, F.C. and Fishman, M.C. (1997) 'Vessel 
patterning in the embryo of the zebrafish: guidance by notochord', Dev Biol, 
183(1), pp. 37-48. 
Francke, U., Ochs, H.D., de Martinville, B., Giacalone, J., Lindgren, V., Disteche, 
C., Pagon, R.A., Hofker, M.H., van Ommen, G.J., Pearson, P.L. and et al. (1985) 
'Minor Xp21 chromosome deletion in a male associated with expression of 
Duchenne muscular dystrophy, chronic granulomatous disease, retinitis 
pigmentosa, and McLeod syndrome', Am J Hum Genet, 37(2), pp. 250-67. 
Froehner, S.C., Adams, M.E., Peters, M.F. and Gee, S.H. (1997) 'Syntrophins: 
modular adapter proteins at the neuromuscular junction and the sarcolemma', 
Soc Gen Physiol Ser, 52, pp. 197-207. 
Frosk, P., Greenberg, C.R., Tennese, A.A., Lamont, R., Nylen, E., Hirst, C., 
Frappier, D., Roslin, N.M., Zaik, M., Bushby, K., Straub, V., Zatz, M., de Paula, 
F., Morgan, K., Fujiwara, T.M. and Wrogemann, K. (2005) 'The most common 
mutation in FKRP causing limb girdle muscular dystrophy type 2I (LGMD2I) 
may have occurred only once and is present in Hutterites and other populations', 
Hum Mutat, 25(1), pp. 38-44. 
Fu, G., Wang, W. and Luo, B.H. (2012) 'Overview: structural biology of integrins', 
Methods Mol Biol, 757, pp. 81-99. 
Fuentes-Mera, L., Rodriguez-Munoz, R., Gonzalez-Ramirez, R., Garcia-Sierra, 
F., Gonzalez, E., Mornet, D. and Cisneros, B. (2006) 'Characterization of a 
novel Dp71 dystrophin-associated protein complex (DAPC) present in the 
nucleus of HeLa cells: members of the nuclear DAPC associate with the nuclear 
matrix', Exp Cell Res, 312(16), pp. 3023-35. 
Fuhrmann, S. (2008) 'Wnt signaling in eye organogenesis', Organogenesis, 4(2), 
pp. 60-7. 
Fuhrmann, S. (2010) 'Eye morphogenesis and patterning of the optic vesicle', 
Curr Top Dev Biol, 93, pp. 61-84. 
Fukai, N., Eklund, L., Marneros, A.G., Oh, S.P., Keene, D.R., Tamarkin, L., 
Niemela, M., Ilves, M., Li, E., Pihlajaniemi, T. and Olsen, B.R. (2002) 'Lack of 
collagen XVIII/endostatin results in eye abnormalities', EMBO J, 21(7), pp. 
1535-44. 
Fukuyama, Y., Osawa, M. and Suzuki, H. (1981) 'Congenital progressive 
muscular dystrophy of the Fukuyama type - clinical, genetic and pathological 
considerations', Brain Dev, 3(1), pp. 1-29. 
Gee, S.H., Montanaro, F., Lindenbaum, M.H. and Carbonetto, S. (1994) 
'Dystroglycan-alpha, a dystrophin-associated glycoprotein, is a functional agrin 
receptor', Cell, 77(5), pp. 675-86. 
205 
 
Gillies, A.R. and Lieber, R.L. (2011) 'Structure and function of the skeletal 
muscle extracellular matrix', Muscle Nerve, 44(3), pp. 318-31. 
Gillis, J.M. (2000) 'An attempt of gene therapy in Duchenne muscular dystrophy: 
overexpression of utrophin in transgenic mdx mice', Acta Neurol Belg, 100(3), 
pp. 146-50. 
Goder, V. and Melero, A. (2011) 'Protein O-mannosyltransferases participate in 
ER protein quality control', J Cell Sci, 124(Pt 1), pp. 144-53. 
Godfrey, C., Escolar, D., Brockington, M., Clement, E.M., Mein, R., Jimenez-
Mallebrera, C., Torelli, S., Feng, L., Brown, S.C., Sewry, C.A., Rutherford, M., 
Shapira, Y., Abbs, S. and Muntoni, F. (2006) 'Fukutin gene mutations in steroid-
responsive limb girdle muscular dystrophy', Ann Neurol, 60(5), pp. 603-10. 
Godfrey, C., Foley, A.R., Clement, E. and Muntoni, F. (2011) 
'Dystroglycanopathies: coming into focus', Curr Opin Genet Dev, 21(3), pp. 278-
85. 
Gore, A.V., Monzo, K., Cha, Y.R., Pan, W. and Weinstein, B.M. (2012) 
'Vascular development in the zebrafish', Cold Spring Harb Perspect Med, 2(5), 
p. a006684. 
Gorecki, D.C., Derry, J.M. and Barnard, E.A. (1994) 'Dystroglycan: brain 
localisation and chromosome mapping in the mouse', Hum Mol Genet, 3(9), pp. 
1589-97. 
Gossen, M. and Bujard, H. (1992) 'Tight control of gene expression in 
mammalian cells by tetracycline-responsive promoters', Proc Natl Acad Sci U S 
A, 89(12), pp. 5547-51. 
Gottsch, J.D., Zhang, C., Sundin, O.H., Bell, W.R., Stark, W.J. and Green, W.R. 
(2005) 'Fuchs corneal dystrophy: aberrant collagen distribution in an L450W 
mutant of the COL8A2 gene', Invest Ophthalmol Vis Sci, 46(12), pp. 4504-11. 
Gould, D.B., Phalan, F.C., Breedveld, G.J., van Mil, S.E., Smith, R.S., 
Schimenti, J.C., Aguglia, U., van der Knaap, M.S., Heutink, P. and John, S.W. 
(2005) 'Mutations in Col4a1 cause perinatal cerebral hemorrhage and 
porencephaly', Science, 308(5725), pp. 1167-71. 
Grady, R.M., Teng, H., Nichol, M.C., Cunningham, J.C., Wilkinson, R.S. and 
Sanes, J.R. (1997) 'Skeletal and cardiac myopathies in mice lacking utrophin 
and dystrophin: a model for Duchenne muscular dystrophy', Cell, 90(4), pp. 
729-38. 
Grewal, P.K., Holzfeind, P.J., Bittner, R.E. and Hewitt, J.E. (2001) 'Mutant 
glycosyltransferase and altered glycosylation of alpha-dystroglycan in the 
myodystrophy mouse', Nat Genet, 28(2), pp. 151-4. 
206 
 
Grindley, J.C., Davidson, D.R. and Hill, R.E. (1995) 'The role of Pax-6 in eye 
and nasal development', Development, 121(5), pp. 1433-42. 
Gumerson, J.D. and Michele, D.E. (2011) 'The dystrophin-glycoprotein complex 
in the prevention of muscle damage', J Biomed Biotechnol, 2011, p. 210797. 
Gupta, V., Kawahara, G., Gundry, S.R., Chen, A.T., Lencer, W.I., Zhou, Y., Zon, 
L.I., Kunkel, L.M. and Beggs, A.H. (2011) 'The zebrafish dag1 mutant: A novel 
genetic model for dystroglycanopathies', Hum Mol Genet. 
Guyon, J.R., Mosley, A.N., Zhou, Y., O'Brien, K.F., Sheng, X., Chiang, K., 
Davidson, A.J., Volinski, J.M., Zon, L.I. and Kunkel, L.M. (2003) 'The dystrophin 
associated protein complex in zebrafish', Hum Mol Genet, 12(6), pp. 601-15. 
Guyon, J.R., Steffen, L.S., Howell, M.H., Pusack, T.J., Lawrence, C. and Kunkel, 
L.M. (2007) 'Modeling human muscle disease in zebrafish', Biochim Biophys 
Acta, 1772(2), pp. 205-15. 
Haenggi, T. and Fritschy, J.M. (2006) 'Role of dystrophin and utrophin for 
assembly and function of the dystrophin glycoprotein complex in non-muscle 
tissue', Cell Mol Life Sci, 63(14), pp. 1614-31. 
Halfter, W., Willem, M. and Mayer, U. (2005) 'Basement membrane-dependent 
survival of retinal ganglion cells', Invest Ophthalmol Vis Sci, 46(3), pp. 1000-9. 
Hall, H., Bozic, D., Michel, K. and Hubell, J. (2003) 'N-terminal alpha-
dystroglycan binds to different extracellular matrix molecules expressed in 
regenerating peripheral nerves in a protein-mediated manner and promotes 
neurite extension of PC12 cells.', Molecular Nueroscience, 24, pp. 1062-1073. 
Hall, T.E., Bryson-Richardson, R.J., Berger, S., Jacoby, A.S., Cole, N.J., 
Hollway, G.E., Berger, J. and Currie, P.D. (2007) 'The zebrafish candyfloss 
mutant implicates extracellular matrix adhesion failure in laminin alpha2-
deficient congenital muscular dystrophy', Proc Natl Acad Sci U S A, 104(17), pp. 
7092-7. 
Hansen, K., Coussens, M.J., Sago, J., Subramanian, S., Gjoka, M. and Briner, 
D. (2012) 'Genome editing with CompoZr custom zinc finger nucleases (ZFNs)', 
J Vis Exp, (64), p. e3304. 
Hara, Y., Balci-Hayta, B., Yoshida-Moriguchi, T., Kanagawa, M., Beltran-Valero 
de Bernabe, D., Gundesli, H., Willer, T., Satz, J.S., Crawford, R.W., Burden, 
S.J., Kunz, S., Oldstone, M.B., Accardi, A., Talim, B., Muntoni, F., Topaloglu, H., 
Dincer, P. and Campbell, K.P. (2011) 'A dystroglycan mutation associated with 
limb-girdle muscular dystrophy', N Engl J Med, 364(10), pp. 939-46. 
Harland, R. and Gerhart, J. (1997) 'Formation and function of Spemann's 
organizer', Annu Rev Cell Dev Biol, 13, pp. 611-67. 
207 
 
Harper, S.Q., Crawford, R.W., DelloRusso, C. and Chamberlain, J.S. (2002) 
'Spectrin-like repeats from dystrophin and alpha-actinin-2 are not functionally 
interchangeable', Hum Mol Genet, 11(16), pp. 1807-15. 
Heasman, J. (2002) 'Morpholino oligos: making sense of antisense?', Dev Biol, 
243(2), pp. 209-14. 
Hehr, U., Uyanik, G., Gross, C., Walter, M.C., Bohring, A., Cohen, M., Oehl-
Jaschkowitz, B., Bird, L.M., Shamdeen, G.M., Bogdahn, U., Schuierer, G., 
Topaloglu, H., Aigner, L., Lochmuller, H. and Winkler, J. (2007) 'Novel 
POMGnT1 mutations define broader phenotypic spectrum of muscle-eye-brain 
disease', Neurogenetics, 8(4), pp. 279-88. 
Herson, S., Hentati, F., Rigolet, A., Behin, A., Romero, N.B., Leturcq, F., Laforet, 
P., Maisonobe, T., Amouri, R., Haddad, H., Audit, M., Montus, M., Masurier, C., 
Gjata, B., Georger, C., Cherai, M., Carlier, P., Hogrel, J.Y., Herson, A., 
Allenbach, Y., Lemoine, F.M., Klatzmann, D., Sweeney, H.L., Mulligan, R.C., 
Eymard, B., Caizergues, D., Voit, T. and Benveniste, O. (2012) 'A phase I trial 
of adeno-associated virus serotype 1-gamma-sarcoglycan gene therapy for limb 
girdle muscular dystrophy type 2C', Brain, 135(Pt 2), pp. 483-92. 
Hewitt, J.E. (2009) 'Abnormal glycosylation of dystroglycan in human genetic 
disease', Biochim Biophys Acta, 1792(9), pp. 853-61. 
Hino, N., Kobayashi, M., Shibata, N., Yamamoto, T., Saito, K. and Osawa, M. 
(2001) 'Clinicopathological study on eyes from cases of Fukuyama type 
congenital muscular dystrophy', Brain Dev, 23(2), pp. 97-107. 
Hoffman, E.P., Brown, R.H., Jr. and Kunkel, L.M. (1987) 'Dystrophin: the protein 
product of the Duchenne muscular dystrophy locus', Cell, 51(6), pp. 919-28. 
Hogan, B.L., Barlow, D.P. and Kurkinen, M. (1984) 'Reichert's membrane as a 
model for studying the biosynthesis and assembly of basement membrane 
components', Ciba Found Symp, 108, pp. 60-74. 
Hogan, B.L., Cooper, A.R. and Kurkinen, M. (1980) 'Incorporation into 
Reichert's membrane of laminin-like extracellular proteins synthesized by 
parietal endoderm cells of the mouse embryo', Dev Biol, 80(2), pp. 289-300. 
Hohenester, E., Tisi, D., Talts, J.F. and Timpl, R. (1999) 'The crystal structure of 
a laminin G-like module reveals the molecular basis of alpha-dystroglycan 
binding to laminins, perlecan, and agrin', Mol Cell, 4(5), pp. 783-92. 
Holley, S.A., Geisler, R. and Nusslein-Volhard, C. (2000) 'Control of her1 
expression during zebrafish somitogenesis by a delta-dependent oscillator and 
an independent wave-front activity', Genes Dev, 14(13), pp. 1678-90. 
Holley, S.A. and Nusslein-Volhard, C. (2000) 'Somitogenesis in zebrafish', Curr 
Top Dev Biol, 47, pp. 247-77. 
208 
 
Holt, K.H., Crosbie, R.H., Venzke, D.P. and Campbell, K.P. (2000) 'Biosynthesis 
of dystroglycan: processing of a precursor propeptide', FEBS Lett, 468(1), pp. 
79-83. 
Hopfer, U., Fukai, N., Hopfer, H., Wolf, G., Joyce, N., Li, E. and Olsen, B.R. 
(2005) 'Targeted disruption of Col8a1 and Col8a2 genes in mice leads to 
anterior segment abnormalities in the eye', FASEB J, 19(10), pp. 1232-44. 
Horie, M., Kobayashi, K., Takeda, S., Nakamura, Y., Lyons, G.E. and Toda, T. 
(2002) 'Isolation and characterization of the mouse ortholog of the Fukuyama-
type congenital muscular dystrophy gene', Genomics, 80(5), pp. 482-6. 
Hosokawa, H., Ninomiya, H., Kitamura, Y., Fujiwara, K. and Masaki, T. (2002) 
'Vascular endothelial cells that express dystroglycan are involved in 
angiogenesis', J Cell Sci, 115(Pt 7), pp. 1487-96. 
Huang, P., Xiao, A., Zhou, M., Zhu, Z., Lin, S. and Zhang, B. (2011) 'Heritable 
gene targeting in zebrafish using customized TALENs', Nat Biotechnol, 29(8), 
pp. 699-700. 
Hynes, R.O. (1992) 'Integrins: versatility, modulation, and signaling in cell 
adhesion', Cell, 69(1), pp. 11-25. 
Ibraghimov-Beskrovnaya, O., Ervasti, J.M., Leveille, C.J., Slaughter, C.A., 
Sernett, S.W. and Campbell, K.P. (1992) 'Primary structure of dystrophin-
associated glycoproteins linking dystrophin to the extracellular matrix', Nature, 
355(6362), pp. 696-702. 
Ibraghimov-Beskrovnaya, O., Milatovich, A., Ozcelik, T., Yang, B., Koepnick, K., 
Francke, U. and Campbell, K.P. (1993) 'Human dystroglycan: skeletal muscle 
cDNA, genomic structure, origin of tissue specific isoforms and chromosomal 
localization', Hum Mol Genet, 2(10), pp. 1651-7. 
Imperiali, M., Thoma, C., Pavoni, E., Brancaccio, A., Callewaert, N. and 
Oxenius, A. (2005) 'O Mannosylation of alpha-dystroglycan is essential for 
lymphocytic choriomeningitis virus receptor function', J Virol, 79(22), pp. 14297-
308. 
Inamori, K., Yoshida-Moriguchi, T., Hara, Y., Anderson, M.E., Yu, L. and 
Campbell, K.P. (2012) 'Dystroglycan function requires xylosyl- and 
glucuronyltransferase activities of LARGE', Science, 335(6064), pp. 93-6. 
Inoue, S., Leblond, C.P. and Laurie, G.W. (1983) 'Ultrastructure of Reichert's 
membrane, a multilayered basement membrane in the parietal wall of the rat 
yolk sac', J Cell Biol, 97(5 Pt 1), pp. 1524-37. 
Ishikawa-Sakurai, M., Yoshida, M., Imamura, M., Davies, K.E. and Ozawa, E. 
(2004) 'ZZ domain is essentially required for the physiological binding of 
209 
 
dystrophin and utrophin to beta-dystroglycan', Hum Mol Genet, 13(7), pp. 693-
702. 
Isogai, S., Horiguchi, M. and Weinstein, B.M. (2001) 'The vascular anatomy of 
the developing zebrafish: an atlas of embryonic and early larval development', 
Dev Biol, 230(2), pp. 278-301. 
Jacoby, A.S., Busch-Nentwich, E., Bryson-Richardson, R.J., Hall, T.E., Berger, 
J., Berger, S., Sonntag, C., Sachs, C., Geisler, R., Stemple, D.L. and Currie, 
P.D. (2009) 'The zebrafish dystrophic mutant softy maintains muscle fibre 
viability despite basement membrane rupture and muscle detachment', 
Development, 136(19), pp. 3367-76. 
Jarvinen, T.A., Jozsa, L., Kannus, P., Jarvinen, T.L. and Jarvinen, M. (2002) 
'Organization and distribution of intramuscular connective tissue in normal and 
immobilized skeletal muscles. An immunohistochemical, polarization and 
scanning electron microscopic study', J Muscle Res Cell Motil, 23(3), pp. 245-54. 
Jayasinha, V., Nguyen, H.H., Xia, B., Kammesheidt, A., Hoyte, K. and Martin, 
P.T. (2003) 'Inhibition of dystroglycan cleavage causes muscular dystrophy in 
transgenic mice', Neuromuscul Disord, 13(5), pp. 365-75. 
Jerusalem, F., Engel, A.G. and Gomez, M.R. (1974) 'Duchenne dystrophy. I. 
Morphometric study of the muscle microvasculature', Brain, 97(1), pp. 115-22. 
Jin, E.J., Erickson, C.A., Takada, S. and Burrus, L.W. (2001) 'Wnt and BMP 
signaling govern lineage segregation of melanocytes in the avian embryo', Dev 
Biol, 233(1), pp. 22-37. 
Johnson, R.P. and Kramer, J.M. (2012) 'Neural maintenance roles for the matrix 
receptor dystroglycan and the nuclear anchorage complex in Caenorhabditis 
elegans', Genetics, 190(4), pp. 1365-77. 
Jung, D., Yang, B., Meyer, J., Chamberlain, J.S. and Campbell, K.P. (1995) 
'Identification and characterization of the dystrophin anchoring site on beta-
dystroglycan', J Biol Chem, 270(45), pp. 27305-10. 
Justice, M.J., Zheng, B., Woychik, R.P. and Bradley, A. (1997) 'Using targeted 
large deletions and high-efficiency N-ethyl-N-nitrosourea mutagenesis for 
functional analyses of the mammalian genome', Methods, 13(4), pp. 423-36. 
Kanagawa, M., Nishimoto, A., Chiyonobu, T., Takeda, S., Miyagoe-Suzuki, Y., 
Wang, F., Fujikake, N., Taniguchi, M., Lu, Z., Tachikawa, M., Nagai, Y., Tashiro, 
F., Miyazaki, J., Tajima, Y., Endo, T., Kobayashi, K., Campbell, K.P. and Toda, 
T. (2009a) 'Residual laminin-binding activity and enhanced dystroglycan 
glycosylation by LARGE in novel model mice to dystroglycanopathy', Hum Mol 
Genet, 18(4), pp. 621-31. 
Kanagawa, M., Nishimoto, A., Chiyonobu, T., Takeda, S., Miyagoe-Suzuki, Y., 
Wang, F., Fujikake, N., Taniguchi, M., Lu, Z., Tachikawa, M., Nagai, Y., Tashiro, 
210 
 
F., Miyazaki, J., Tajima, Y., Takeda, S., Endo, T., Kobayashi, K., Campbell, K.P. 
and Toda, T. (2009b) 'Residual laminin-binding activity and enhanced 
dystroglycan glycosylation by LARGE in novel model mice to 
dystroglycanopathy', Hum Mol Genet, 18(4), pp. 621-31. 
Kanoff, R.J., Curless, R.G., Petito, C., Falcone, S., Siatkowski, R.M. and 
Pegoraro, E. (1998) 'Walker-Warburg syndrome: neurologic features and 
muscle membrane structure', Pediatr Neurol, 18(1), pp. 76-80. 
Kaplan, J.C. (2011) 'The 2012 version of the gene table of monogenic 
neuromuscular disorders', Neuromuscul Disord, 21(12), pp. 833-61. 
Kawahara, G., Guyon, J.R., Nakamura, Y. and Kunkel, L.M. (2010) 'Zebrafish 
models for human FKRP muscular dystrophies', Hum Mol Genet, 19(4), pp. 
623-33. 
Kelly, D., Chancellor, K., Milatovich, A., Francke, U., Suzuki, K. and Popko, B. 
(1994) 'Autosomal recessive neuromuscular disorder in a transgenic line of 
mice', J Neurosci, 14(1), pp. 198-207. 
Kelsh, R.N., Brand, M., Jiang, Y.J., Heisenberg, C.P., Lin, S., Haffter, P., 
Odenthal, J., Mullins, M.C., van Eeden, F.J., Furutani-Seiki, M., Granato, M., 
Hammerschmidt, M., Kane, D.A., Warga, R.M., Beuchle, D., Vogelsang, L. and 
Nusslein-Volhard, C. (1996) 'Zebrafish pigmentation mutations and the 
processes of neural crest development', Development, 123, pp. 369-89. 
Keramaris-Vrantsis, E., Lu, P.J., Doran, T., Zillmer, A., Ashar, J., Esapa, C.T., 
Benson, M.A., Blake, D.J., Rosenfeld, J. and Lu, Q.L. (2007) 'Fukutin-related 
protein localizes to the Golgi apparatus and mutations lead to mislocalization in 
muscle in vivo', Muscle Nerve, 36(4), pp. 455-65. 
Kettleborough, R.N., Bruijn, E., Eeden, F., Cuppen, E. and Stemple, D.L. (2011) 
'High-throughput target-selected gene inactivation in zebrafish', Methods Cell 
Biol, 104, pp. 121-7. 
Kim, D.S., Hayashi, Y.K., Matsumoto, H., Ogawa, M., Noguchi, S., Murakami, 
N., Sakuta, R., Mochizuki, M., Michele, D.E., Campbell, K.P., Nonaka, I. and 
Nishino, I. (2004) 'POMT1 mutation results in defective glycosylation and loss of 
laminin-binding activity in alpha-DG', Neurology, 62(6), pp. 1009-11. 
Kim, Y.G., Cha, J. and Chandrasegaran, S. (1996) 'Hybrid restriction enzymes: 
zinc finger fusions to Fok I cleavage domain', Proc Natl Acad Sci U S A, 93(3), 
pp. 1156-60. 
Kimmel, C., Ballard, W., Kimmel, S., Ullmann, B. and Schilling, T. (1995) 
'Stages of embryonic development of the zebrafish', Developmental Dynamics, 
203, pp. 253-310. 
211 
 
Kimmel, C.B., Warga, R.M. and Schilling, T.F. (1990) 'Origin and organization of 
the zebrafish fate map', Development, 108(4), pp. 581-94. 
Kinali, M., Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., Adkin, C., 
Guglieri, M., Ashton, E., Abbs, S., Nihoyannopoulos, P., Garralda, M.E., 
Rutherford, M., McCulley, C., Popplewell, L., Graham, I.R., Dickson, G., Wood, 
M.J., Wells, D.J., Wilton, S.D., Kole, R., Straub, V., Bushby, K., Sewry, C., 
Morgan, J.E. and Muntoni, F. (2009) 'Local restoration of dystrophin expression 
with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a 
single-blind, placebo-controlled, dose-escalation, proof-of-concept study', 
Lancet Neurol, 8(10), pp. 918-28. 
Kipling, D. (1997) 'Telomere structure and telomerase expression during mouse 
development and tumorigenesis', Eur J Cancer, 33(5), pp. 792-800. 
Klug, A. (2010a) 'The discovery of zinc fingers and their applications in gene 
regulation and genome manipulation', Annu Rev Biochem, 79, pp. 213-31. 
Klug, A. (2010b) 'The discovery of zinc fingers and their development for 
practical applications in gene regulation and genome manipulation', Q Rev 
Biophys, 43(1), pp. 1-21. 
Knapik, E.W. (2000) 'ENU mutagenesis in zebrafish--from genes to complex 
diseases', Mamm Genome, 11(7), pp. 511-9. 
Knopf, F., Schnabel, K., Haase, C., Pfeifer, K., Anastassiadis, K. and Weidinger, 
G. (2010) 'Dually inducible TetON systems for tissue-specific conditional gene 
expression in zebrafish', Proc Natl Acad Sci U S A, 107(46), pp. 19933-8. 
Kobayashi, K., Nakahori, Y., Miyake, M., Matsumura, K., Kondo-Iida, E., 
Nomura, Y., Segawa, M., Yoshioka, M., Saito, K., Osawa, M., Hamano, K., 
Sakakihara, Y., Nonaka, I., Nakagome, Y., Kanazawa, I., Nakamura, Y., 
Tokunaga, K. and Toda, T. (1998) 'An ancient retrotransposal insertion causes 
Fukuyama-type congenital muscular dystrophy', Nature, 394(6691), pp. 388-92. 
Kobayashi, Y.M., Rader, E.P., Crawford, R.W., Iyengar, N.K., Thedens, D.R., 
Faulkner, J.A., Parikh, S.V., Weiss, R.M., Chamberlain, J.S., Moore, S.A. and 
Campbell, K.P. (2008) 'Sarcolemma-localized nNOS is required to maintain 
activity after mild exercise', Nature, 456(7221), pp. 511-5. 
Koch, M., Olson, P.F., Albus, A., Jin, W., Hunter, D.D., Brunken, W.J., 
Burgeson, R.E. and Champliaud, M.F. (1999) 'Characterization and expression 
of the laminin gamma3 chain: a novel, non-basement membrane-associated, 
laminin chain', J Cell Biol, 145(3), pp. 605-18. 
Koenig, M. and Kunkel, L.M. (1990) 'Detailed analysis of the repeat domain of 
dystrophin reveals four potential hinge segments that may confer flexibility', J 
Biol Chem, 265(8), pp. 4560-6. 
212 
 
Kohling, R., Nischt, R., Vasudevan, A., Ho, M., Weiergraber, M., Schneider, T. 
and Smyth, N. (2006) 'Nidogen and nidogen-associated basement membrane 
proteins and neuronal plasticity', Neurodegener Dis, 3(1-2), pp. 56-61. 
Kornegay, J.N., Childers, M.K., Bogan, D.J., Bogan, J.R., Nghiem, P., Wang, J., 
Fan, Z., Howard, J.F., Jr., Schatzberg, S.J., Dow, J.L., Grange, R.W., Styner, 
M.A., Hoffman, E.P. and Wagner, K.R. (2012) 'The paradox of muscle 
hypertrophy in muscular dystrophy', Phys Med Rehabil Clin N Am, 23(1), pp. 
149-72, xii. 
Kuang, W., Xu, H., Vachon, P.H. and Engvall, E. (1998) 'Disruption of the lama2 
gene in embryonic stem cells: laminin alpha 2 is necessary for sustenance of 
mature muscle cells', Exp Cell Res, 241(1), pp. 117-25. 
Kuga, A., Kanagawa, M., Sudo, A., Chan, Y.M., Tajiri, M., Manya, H., Kikkawa, 
Y., Nomizu, M., Kobayashi, K., Endo, T., Lu, Q.L., Wada, Y. and Toda, T. 
(2012a) 'Absence of post-phosphoryl modification in dystroglycanopathy mouse 
models and wild-type tissues expressing a non-laminin binding form of alpha-
dystroglycan', J Biol Chem. 
Kuga, A., Kanagawa, M., Sudo, A., Chan, Y.M., Tajiri, M., Manya, H., Kikkawa, 
Y., Nomizu, M., Kobayashi, K., Endo, T., Lu, Q.L., Wada, Y. and Toda, T. 
(2012b) 'Absence of post-phosphoryl modification in dystroglycanopathy mouse 
models and wild-type tissues expressing non-laminin binding form of alpha-
dystroglycan', J Biol Chem, 287(12), pp. 9560-7. 
Kuga, A., Kanagawa, M. and Toda, T. (2011) '[Recent Advances in alpha-
dystroglycanopathy]', Brain Nerve, 63(11), pp. 1189-95. 
Kunz, S., Rojek, J.M., Kanagawa, M., Spiropoulou, C.F., Barresi, R., Campbell, 
K.P. and Oldstone, M.B. (2005) 'Posttranslational modification of alpha-
dystroglycan, the cellular receptor for arenaviruses, by the glycosyltransferase 
LARGE is critical for virus binding', J Virol, 79(22), pp. 14282-96. 
Kurahashi, H., Taniguchi, M., Meno, C., Taniguchi, Y., Takeda, S., Horie, M., 
Otani, H. and Toda, T. (2005) 'Basement membrane fragility underlies 
embryonic lethality in fukutin-null mice', Neurobiol Dis, 19(1-2), pp. 208-17. 
Kuru, S. (2011) '[Respiratory management in muscular dystrophies]', Brain 
Nerve, 63(11), pp. 1229-36. 
Kwon, S.W., Kang, S.W., Kim, J.Y., Choi, E.Y., Yoon, Y.W., Park, Y.M., Ma, 
D.W., Chung, H., Kwon, H.M. and Rim, S.J. (2012) 'Outcomes of cardiac 
involvement in patients with late-stage Duchenne muscular dystrophy under 
management in the pulmonary rehabilitation center of a tertiary referral hospital', 
Cardiology, 121(3), pp. 186-93. 
213 
 
Lapidos, K.A., Kakkar, R. and McNally, E.M. (2004) 'The dystrophin 
glycoprotein complex: signaling strength and integrity for the sarcolemma', Circ 
Res, 94(8), pp. 1023-31. 
Law, D.J., Caputo, A. and Tidball, J.G. (1995) 'Site and mechanics of failure in 
normal and dystrophin-deficient skeletal muscle', Muscle Nerve, 18(2), pp. 216-
23. 
Law, D.J. and Tidball, J.G. (1993) 'Dystrophin deficiency is associated with 
myotendinous junction defects in prenecrotic and fully regenerated skeletal 
muscle', Am J Pathol, 142(5), pp. 1513-23. 
Lawson, N.D. and Weinstein, B.M. (2002) 'In vivo imaging of embryonic 
vascular development using transgenic zebrafish', Dev Biol, 248(2), pp. 307-18. 
Le Rumeur, E., Winder, S.J. and Hubert, J.F. (2010) 'Dystrophin: more than just 
the sum of its parts', Biochim Biophys Acta, 1804(9), pp. 1713-22. 
LeBleu, V.S., Macdonald, B. and Kalluri, R. (2007) 'Structure and function of 
basement membranes', Exp Biol Med (Maywood), 232(9), pp. 1121-9. 
Lee, J. and Gross, J.M. (2007) 'Laminin beta1 and gamma1 containing laminins 
are essential for basement membrane integrity in the zebrafish eye', Invest 
Ophthalmol Vis Sci, 48(6), pp. 2483-90. 
Lefeber, D.J., Schonberger, J., Morava, E., Guillard, M., Huyben, K.M., Verrijp, 
K., Grafakou, O., Evangeliou, A., Preijers, F.W., Manta, P., Yildiz, J., Grunewald, 
S., Spilioti, M., van den Elzen, C., Klein, D., Hess, D., Ashida, H., Hofsteenge, 
J., Maeda, Y., van den Heuvel, L., Lammens, M., Lehle, L. and Wevers, R.A. 
(2009) 'Deficiency of Dol-P-Man synthase subunit DPM3 bridges the congenital 
disorders of glycosylation with the dystroglycanopathies', Am J Hum Genet, 
85(1), pp. 76-86. 
Lessman, C.A. (2011) 'The developing zebrafish (Danio rerio): a vertebrate 
model for high-throughput screening of chemical libraries', Birth Defects Res C 
Embryo Today, 93(3), pp. 268-80. 
Liesi, P. (1990) 'Extracellular matrix and neuronal movement', Experientia, 46(9), 
pp. 900-7. 
Lim, L.E. and Campbell, K.P. (1998) 'The sarcoglycan complex in limb-girdle 
muscular dystrophy', Curr Opin Neurol, 11(5), pp. 443-52. 
Lin, Y.Y., White, R.J., Torelli, S., Cirak, S., Muntoni, F. and Stemple, D.L. (2011) 
'Zebrafish Fukutin family proteins link the unfolded protein response with 
dystroglycanopathies', Hum Mol Genet. 20 (9) pp. 1763-75. 
Liu, J., Ball, S.L., Yang, Y., Mei, P., Zhang, L., Shi, H., Kaminski, H.J., Lemmon, 
V.P. and Hu, H. (2006) 'A genetic model for muscle-eye-brain disease in mice 
214 
 
lacking protein O-mannose 1,2-N-acetylglucosaminyltransferase (POMGnT1)', 
Mech Dev, 123(3), pp. 228-40. 
Lombard, J.H. (2011) 'Microcirculation in a mouse model of Duchenne muscular 
dystrophy: another blow to the vascular hypothesis?', J Appl Physiol, 110(3), pp. 
587-8. 
Longman, C., Brockington, M., Torelli, S., Jimenez-Mallebrera, C., Kennedy, C., 
Khalil, N., Feng, L., Saran, R.K., Voit, T., Merlini, L., Sewry, C.A., Brown, S.C. 
and Muntoni, F. (2003) 'Mutations in the human LARGE gene cause MDC1D, a 
novel form of congenital muscular dystrophy with severe mental retardation and 
abnormal glycosylation of alpha-dystroglycan', Hum Mol Genet, 12(21), pp. 
2853-61. 
Lu, X., Le Noble, F., Yuan, L., Jiang, Q., De Lafarge, B., Sugiyama, D., Breant, 
C., Claes, F., De Smet, F., Thomas, J.L., Autiero, M., Carmeliet, P., Tessier-
Lavigne, M. and Eichmann, A. (2004) 'The netrin receptor UNC5B mediates 
guidance events controlling morphogenesis of the vascular system', Nature, 
432(7014), pp. 179-86. 
Lynch, T.A., Lam, L.T., Man, N.T., Kobayashi, K., Toda, T. and Morris, G.E. 
(2012) 'Detection of the dystroglycanopathy protein, fukutin, using a new panel 
of site-specific monoclonal antibodies', Biochem Biophys Res Commun. 
Ma, F., Zhang, D., Yang, H., Sun, H., Wu, W., Gan, Y., Balducci, J., Wei, Y.Q., 
Zhao, X. and Huang, Y. (2009) 'Endothelial cell-specific molecule 2 (ECSM2) 
modulates actin remodeling and epidermal growth factor receptor signaling', 
Genes Cells, 14(3), pp. 281-93. 
Maeda, Y. and Kinoshita, T. (2008) 'Dolichol-phosphate mannose synthase: 
structure, function and regulation', Biochim Biophys Acta, 1780(6), pp. 861-8. 
Maeder, M.L., Thibodeau-Beganny, S., Sander, J.D., Voytas, D.F. and Joung, 
J.K. (2009) 'Oligomerized pool engineering (OPEN): an 'open-source' protocol 
for making customized zinc-finger arrays', Nat Protoc, 4(10), pp. 1471-501. 
Mann, C.J., Honeyman, K., Cheng, A.J., Ly, T., Lloyd, F., Fletcher, S., Morgan, 
J.E., Partridge, T.A. and Wilton, S.D. (2001) 'Antisense-induced exon skipping 
and synthesis of dystrophin in the mdx mouse', Proc Natl Acad Sci U S A, 98(1), 
pp. 42-7. 
Mann, C.J., Perdiguero, E., Kharraz, Y., Aguilar, S., Pessina, P., Serrano, A.L. 
and Munoz-Canoves, P. (2011) 'Aberrant repair and fibrosis development in 
skeletal muscle', Skelet Muscle, 1(1), p. 21. 
Manya, H., Chiba, A., Yoshida, A., Wang, X., Chiba, Y., Jigami, Y., Margolis, 
R.U. and Endo, T. (2004) 'Demonstration of mammalian protein O-
mannosyltransferase activity: coexpression of POMT1 and POMT2 required for 
enzymatic activity', Proc Natl Acad Sci U S A, 101(2), pp. 500-5. 
215 
 
Manzur, A.Y. and Muntoni, F. (2009) 'Diagnosis and new treatments in 
muscular dystrophies', J Neurol Neurosurg Psychiatry, 80(7), pp. 706-14. 
Marneros, A.G. and Olsen, B.R. (2005) 'Physiological role of collagen XVIII and 
endostatin', FASEB J, 19(7), pp. 716-28. 
Martin-Blanco, E. and Garcia-Bellido, A. (1996) 'Mutations in the rotated 
abdomen locus affect muscle development and reveal an intrinsic asymmetry in 
Drosophila', Proc Natl Acad Sci U S A, 93(12), pp. 6048-52. 
Martinez-Morales, J.R., Rodrigo, I. and Bovolenta, P. (2004) 'Eye development: 
a view from the retina pigmented epithelium', Bioessays, 26(7), pp. 766-77. 
Mayer, U. (2003) 'Integrins: redundant or important players in skeletal muscle?', 
J Biol Chem, 278(17), pp. 14587-90. 
Mayer, U., Saher, G., Fassler, R., Bornemann, A., Echtermeyer, F., von der 
Mark, H., Miosge, N., Poschl, E. and von der Mark, K. (1997) 'Absence of 
integrin alpha 7 causes a novel form of muscular dystrophy', Nat Genet, 17(3), 
pp. 318-23. 
McDearmon, E.L., Combs, A.C. and Ervasti, J.M. (2001) 'Differential Vicia 
villosa agglutinin reactivity identifies three distinct dystroglycan complexes in 
skeletal muscle', J Biol Chem, 276(37), pp. 35078-86. 
McGrew, M.J., Dale, J.K., Fraboulet, S. and Pourquie, O. (1998) 'The lunatic 
fringe gene is a target of the molecular clock linked to somite segmentation in 
avian embryos', Curr Biol, 8(17), pp. 979-82. 
Mei, J., Liu, S., Li, Z. and Gui, J.F. (2010) 'Mtmr8 is essential for vasculature 
development in zebrafish embryos', BMC Dev Biol, 10(1), p. 96. 
Mendell, J.R., Boue, D.R. and Martin, P.T. (2006) 'The congenital muscular 
dystrophies: recent advances and molecular insights', Pediatr Dev Pathol, 9(6), 
pp. 427-43. 
Mendell, J.R., Engel, W.K. and Derrer, E.C. (1972) 'Increased plasma enzyme 
concentrations in rats with functional ischaemia of muscle provide a possible 
model of Duchenne muscular dystrophy', Nature, 239(5374), pp. 522-4. 
Mercuri, E., Brockington, M., Straub, V., Quijano-Roy, S., Yuva, Y., Herrmann, 
R., Brown, S.C., Torelli, S., Dubowitz, V., Blake, D.J., Romero, N.B., Estournet, 
B., Sewry, C.A., Guicheney, P., Voit, T. and Muntoni, F. (2003) 'Phenotypic 
spectrum associated with mutations in the fukutin-related protein gene', Ann 
Neurol, 53(4), pp. 537-42. 
Mercuri, E., Topaloglu, H., Brockington, M., Berardinelli, A., Pichiecchio, A., 
Santorelli, F., Rutherford, M., Talim, B., Ricci, E., Voit, T. and Muntoni, F. (2006) 
216 
 
'Spectrum of brain changes in patients with congenital muscular dystrophy and 
FKRP gene mutations', Arch Neurol, 63(2), pp. 251-7. 
Michele, D.E., Barresi, R., Kanagawa, M., Saito, F., Cohn, R.D., Satz, J.S., 
Dollar, J., Nishino, I., Kelley, R.I., Somer, H., Straub, V., Mathews, K.D., Moore, 
S.A. and Campbell, K.P. (2002) 'Post-translational disruption of dystroglycan-
ligand interactions in congenital muscular dystrophies', Nature, 418(6896), pp. 
417-22. 
Miller, J., McLachlan, A.D. and Klug, A. (1985) 'Repetitive zinc-binding domains 
in the protein transcription factor IIIA from Xenopus oocytes', EMBO J, 4(6), pp. 
1609-14. 
Miyagoe-Suzuki, Y., Nakagawa, M. and Takeda, S. (2000) 'Merosin and 
congenital muscular dystrophy', Microsc Res Tech, 48(3-4), pp. 181-91. 
Mohideen, M.A., Beckwith, L.G., Tsao-Wu, G.S., Moore, J.L., Wong, A.C., 
Chinoy, M.R. and Cheng, K.C. (2003) 'Histology-based screen for zebrafish 
mutants with abnormal cell differentiation', Dev Dyn, 228(3), pp. 414-23. 
Moiseeva, E.P. (2001) 'Adhesion receptors of vascular smooth muscle cells and 
their functions', Cardiovasc Res, 52(3), pp. 372-86. 
Monaco, A.P., Bertelson, C.J., Middlesworth, W., Colletti, C.A., Aldridge, J., 
Fischbeck, K.H., Bartlett, R., Pericak-Vance, M.A., Roses, A.D. and Kunkel, L.M. 
(1985) 'Detection of deletions spanning the Duchenne muscular dystrophy locus 
using a tightly linked DNA segment', Nature, 316(6031), pp. 842-5. 
Monaco, A.P., Neve, R.L., Colletti-Feener, C., Bertelson, C.J., Kurnit, D.M. and 
Kunkel, L.M. (1986) 'Isolation of candidate cDNAs for portions of the Duchenne 
muscular dystrophy gene', Nature, 323(6089), pp. 646-50. 
Moore, C.J., Goh, H.T. and Hewitt, J.E. (2008) 'Genes required for functional 
glycosylation of dystroglycan are conserved in zebrafish', Genomics, 92(3), pp. 
159-67. 
Moore, D.T., Nygren, P., Jo, H., Boesze-Battaglia, K., Bennett, J.S. and 
DeGrado, W.F. (2012a) 'Affinity of talin-1 for the beta3-integrin cytosolic domain 
is modulated by its phospholipid bilayer environment', Proc Natl Acad Sci U S A, 
109(3), pp. 793-8. 
Moore, F.E., Reyon, D., Sander, J.D., Martinez, S.A., Blackburn, J.S., Khayter, 
C., Ramirez, C.L., Joung, J.K. and Langenau, D.M. (2012b) 'Improved somatic 
mutagenesis in zebrafish using transcription activator-like effector nucleases 
(TALENs)', PLoS One, 7(5), p. e37877. 
Moore, S.A., Saito, F., Chen, J., Michele, D.E., Henry, M.D., Messing, A., Cohn, 
R.D., Ross-Barta, S.E., Westra, S., Williamson, R.A., Hoshi, T. and Campbell, 
217 
 
K.P. (2002) 'Deletion of brain dystroglycan recapitulates aspects of congenital 
muscular dystrophy', Nature, 418(6896), pp. 422-5. 
Moremen, K.W., Tiemeyer, M. and Nairn, A.V. (2012) 'Vertebrate protein 
glycosylation: diversity, synthesis and function', Nat Rev Mol Cell Biol, 13(7), pp. 
448-62. 
Moukhles, H., Roque, R. and Carbonetto, S. (2000) 'alpha-dystroglycan 
isoforms are differentially distributed in adult rat retina', J Comp Neurol, 420(2), 
pp. 182-94. 
Munoz, I., Carrillo, M., Zanuy, S. and Gomez, A. (2005) 'Regulation of 
exogenous gene expression in fish cells: an evaluation of different versions of 
the tetracycline-regulated system', Gene, 363, pp. 173-82. 
Muntoni, F., Torelli, S., Wells, D.J. and Brown, S.C. (2011) 'Muscular 
dystrophies due to glycosylation defects: diagnosis and therapeutic strategies', 
Curr Opin Neurol, 24(5), pp. 437-42. 
Muntoni, F. and Voit, T. (2004) 'The congenital muscular dystrophies in 2004: a 
century of exciting progress', Neuromuscul Disord, 14(10), pp. 635-49. 
Nakanishi, T., Sakauchi, M., Kaneda, Y., Tomimatsu, H., Saito, K., Nakazawa, 
M. and Osawa, M. (2006) 'Cardiac involvement in Fukuyama-type congenital 
muscular dystrophy', Pediatrics, 117(6), pp. e1187-92. 
Nance, J.R., Dowling, J.J., Gibbs, E.M. and Bonnemann, C.G. (2012) 
'Congenital myopathies: an update', Curr Neurol Neurosci Rep, 12(2), pp. 165-
74. 
Nasevicius, A. and Ekker, S.C. (2000) 'Effective targeted gene 'knockdown' in 
zebrafish', Nat Genet, 26(2), pp. 216-20. 
Nechiporuk, A., Finney, J.E., Keating, M.T. and Johnson, S.L. (1999) 
'Assessment of polymorphism in zebrafish mapping strains', Genome Res, 
9(12), pp. 1231-8. 
Negroni, E., Vallese, D., Vilquin, J.T., Butler-Browne, G., Mouly, V. and Trollet, 
C. (2011) 'Current advances in cell therapy strategies for muscular dystrophies', 
Expert Opin Biol Ther, 11(2), pp. 157-76. 
Nicholson, L.V., Johnson, M.A., Bushby, K.M., Gardner-Medwin, D., Curtis, A., 
Ginjaar, I.B., den Dunnen, J.T., Welch, J.L., Butler, T.J., Bakker, E. and et al. 
(1993) 'Integrated study of 100 patients with Xp21 linked muscular dystrophy 
using clinical, genetic, immunochemical, and histopathological data. Part 2. 
Correlations within individual patients', J Med Genet, 30(9), pp. 737-44. 
Nicole, S., Davoine, C.S., Topaloglu, H., Cattolico, L., Barral, D., Beighton, P., 
Hamida, C.B., Hammouda, H., Cruaud, C., White, P.S., Samson, D., Urtizberea, 
218 
 
J.A., Lehmann-Horn, F., Weissenbach, J., Hentati, F. and Fontaine, B. (2000) 
'Perlecan, the major proteoglycan of basement membranes, is altered in 
patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia)', Nat 
Genet, 26(4), pp. 480-3. 
Nieves, B., Jones, C.W., Ward, R., Ohta, Y., Reverte, C.G. and LaFlamme, S.E. 
(2010) 'The NPIY motif in the integrin beta1 tail dictates the requirement for 
talin-1 in outside-in signaling', J Cell Sci, 123(Pt 8), pp. 1216-26. 
Nishiuchi, R., Takagi, J., Hayashi, M., Ido, H., Yagi, Y., Sanzen, N., Tsuji, T., 
Yamada, M. and Sekiguchi, K. (2006) 'Ligand-binding specificities of laminin-
binding integrins: a comprehensive survey of laminin-integrin interactions using 
recombinant alpha3beta1, alpha6beta1, alpha7beta1 and alpha6beta4 integrins', 
Matrix Biol, 25(3), pp. 189-97. 
Noonan, D.M., Fulle, A., Valente, P., Cai, S., Horigan, E., Sasaki, M., Yamada, 
Y. and Hassell, J.R. (1991) 'The complete sequence of perlecan, a basement 
membrane heparan sulfate proteoglycan, reveals extensive similarity with 
laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion 
molecule', J Biol Chem, 266(34), pp. 22939-47. 
North, K.N. (2011) 'Clinical approach to the diagnosis of congenital myopathies', 
Semin Pediatr Neurol, 18(4), pp. 216-20. 
Norwood, F.M., Harling, C., Chinnery. P.F., Eagle, M., Bushby, K. and Straub, V. 
(2009) 'Prevalence of genetic muscle disease in Northern England: in-depth 
analysis of a muscle clinic population' Brain, 132(11), pp. 3175-3186. 
Norwood, F.L., Sutherland-Smith, A.J., Keep, N.H. and Kendrick-Jones, J. 
(2000) 'The structure of the N-terminal actin-binding domain of human 
dystrophin and how mutations in this domain may cause Duchenne or Becker 
muscular dystrophy', Structure, 8(5), pp. 481-91. 
Odenthal, J., Haffter, P., Vogelsang, E., Brand, M., van Eeden, F.J., Furutani-
Seiki, M., Granato, M., Hammerschmidt, M., Heisenberg, C.P., Jiang, Y.J., 
Kane, D.A., Kelsh, R.N., Mullins, M.C., Warga, R.M., Allende, M.L., Weinberg, 
E.S. and Nusslein-Volhard, C. (1996) 'Mutations affecting the formation of the 
notochord in the zebrafish, Danio rerio', Development, 123, pp. 103-15. 
Olsen, B.R. (1999) 'Life without perlecan has its problems', J Cell Biol, 147(5), 
pp. 909-12. 
Omori, Y., Araki, F., Chaya, T., Kajimura, N., Irie, S., Terada, K., Muranishi, Y., 
Tsujii, T., Ueno, S., Koyasu, T., Tamaki, Y., Kondo, M., Amano, S. and 
Furukawa, T. (2012) 'Presynaptic dystroglycan-pikachurin complex regulates 
the proper synaptic connection between retinal photoreceptor and bipolar cells', 
J Neurosci, 32(18), pp. 6126-37. 
219 
 
Opat, A.S., van Vliet, C. and Gleeson, P.A. (2001) 'Trafficking and localisation 
of resident Golgi glycosylation enzymes', Biochimie, 83(8), pp. 763-73. 
Palmeirim, I., Henrique, D., Ish-Horowicz, D. and Pourquie, O. (1997) 'Avian 
hairy gene expression identifies a molecular clock linked to vertebrate 
segmentation and somitogenesis', Cell, 91(5), pp. 639-48. 
Parichy, D.M. (2006) 'Evolution of danio pigment pattern development', Heredity 
(Edinb), 97(3), pp. 200-10. 
Parsons, M.J., Campos, I., Hirst, E.M. and Stemple, D.L. (2002a) 'Removal of 
dystroglycan causes severe muscular dystrophy in zebrafish embryos', 
Development, 129(14), pp. 3505-12. 
Parsons, M.J., Pollard, S.M., Saude, L., Feldman, B., Coutinho, P., Hirst, E.M. 
and Stemple, D.L. (2002b) 'Zebrafish mutants identify an essential role for 
laminins in notochord formation', Development, 129(13), pp. 3137-46. 
Patton, B.L., Wang, B., Tarumi, Y.S., Seburn, K.L. and Burgess, R.W. (2008) 'A 
single point mutation in the LN domain of LAMA2 causes muscular dystrophy 
and peripheral amyelination', J Cell Sci, 121(Pt 10), pp. 1593-604. 
Paulk, A., Millard, S.S. and van Swinderen, B. (2012) 'Vision in Drosophila: 
Seeing the World Through a Models Eyes', Annu Rev Entomol.  [Epub ahead of 
print]. 
Pelham, H.R. and Brown, D.D. (1980) 'A specific transcription factor that can 
bind either the 5S RNA gene or 5S RNA', Proc Natl Acad Sci U S A, 77(7), pp. 
4170-4. 
Persengiev, S.P., Zhu, X. and Green, M.R. (2004) 'Nonspecific, concentration-
dependent stimulation and repression of mammalian gene expression by small 
interfering RNAs (siRNAs)', RNA, 10(1), pp. 12-8. 
Petrof, B.J., Shrager, J.B., Stedman, H.H., Kelly, A.M. and Sweeney, H.L. (1993) 
'Dystrophin protects the sarcolemma from stresses developed during muscle 
contraction', Proc Natl Acad Sci U S A, 90(8), pp. 3710-4. 
Picard, B. and Wegnez, M. (1979) 'Isolation of a 7S particle from Xenopus 
laevis oocytes: a 5S RNA-protein complex', Proc Natl Acad Sci U S A, 76(1), pp. 
241-5. 
Pollard, S.M., Parsons, M.J., Kamei, M., Kettleborough, R.N., Thomas, K.A., 
Pham, V.N., Bae, M.K., Scott, A., Weinstein, B.M. and Stemple, D.L. (2006) 
'Essential and overlapping roles for laminin alpha chains in notochord and blood 
vessel formation', Dev Biol, 289(1), pp. 64-76. 
220 
 
Pons, F., Augier, N., Heilig, R., Leger, J., Mornet, D. and Leger, J.J. (1990) 
'Isolated dystrophin molecules as seen by electron microscopy', Proc Natl Acad 
Sci U S A, 87(20), pp. 7851-5. 
Porteus, M.H. and Carroll, D. (2005) 'Gene targeting using zinc finger 
nucleases', Nat Biotechnol, 23(8), pp. 967-73. 
Poschl, E., Schlotzer-Schrehardt, U., Brachvogel, B., Saito, K., Ninomiya, Y. 
and Mayer, U. (2004) 'Collagen IV is essential for basement membrane stability 
but dispensable for initiation of its assembly during early development', 
Development, 131(7), pp. 1619-28. 
Postel, R., Vakeel, P., Topczewski, J., Knoll, R. and Bakkers, J. (2008) 
'Zebrafish integrin-linked kinase is required in skeletal muscles for strengthening 
the integrin-ECM adhesion complex', Dev Biol, 318(1), pp. 92-101. 
Potter, C.J. and Luo, L. (2011) 'Using the Q system in Drosophila melanogaster', 
Nat Protoc, 6(8), pp. 1105-20. 
Prockop, D.J. and Kivirikko, K.I. (1995) 'Collagens: molecular biology, diseases, 
and potentials for therapy', Annu Rev Biochem, 64, pp. 403-34. 
Purcell, P., Oliver, G., Mardon, G., Donner, A.L. and Maas, R.L. (2005) 'Pax6-
dependence of Six3, Eya1 and Dach1 expression during lens and nasal 
placode induction', Gene Expr Patterns, 6(1), pp. 110-8. 
Purslow, P.P. (2010) 'Muscle fascia and force transmission', J Bodyw Mov Ther, 
14(4), pp. 411-7. 
Purslow, P.P. and Trotter, J.A. (1994) 'The morphology and mechanical 
properties of endomysium in series-fibred muscles: variations with muscle 
length', J Muscle Res Cell Motil, 15(3), pp. 299-308. 
Radecke, S., Radecke, F., Cathomen, T. and Schwarz, K. (2010) 'Zinc-finger 
nuclease-induced gene repair with oligodeoxynucleotides: wanted and 
unwanted target locus modifications', Mol Ther, 18(4), pp. 743-53. 
Rambukkana, A., Yamada, H., Zanazzi, G., Mathus, T., Salzer, J.L., Yurchenco, 
P.D., Campbell, K.P. and Fischetti, V.A. (1998) 'Role of alpha-dystroglycan as a 
Schwann cell receptor for Mycobacterium leprae', Science, 282(5396), pp. 
2076-9. 
Ramirez, C.L., Foley, J.E., Wright, D.A., Muller-Lerch, F., Rahman, S.H., Cornu, 
T.I., Winfrey, R.J., Sander, J.D., Fu, F., Townsend, J.A., Cathomen, T., Voytas, 
D.F. and Joung, J.K. (2008) 'Unexpected failure rates for modular assembly of 
engineered zinc fingers', Nat Methods, 5(5), pp. 374-5. 
221 
 
Randlett, O., Poggi, L., Zolessi, F.R. and Harris, W.A. (2011) 'The oriented 
emergence of axons from retinal ganglion cells is directed by laminin contact in 
vivo', Neuron, 70(2), pp. 266-80. 
Razin, S.V., Borunova, V.V., Maksimenko, O.G. and Kantidze, O.L. (2012) 
'Cys2His2 Zinc Finger Protein Family: Classification, Functions, and Major 
Members', Biochemistry (Mosc), 77(3), pp. 217-26. 
Reed, P.W., Mathews, K.D., Mills, K.A. and Bloch, R.J. (2004) 'The sarcolemma 
in the Large(myd) mouse', Muscle Nerve, 30(5), pp. 585-95. 
Reid, M.B. (1998) 'Role of nitric oxide in skeletal muscle: synthesis, distribution 
and functional importance', Acta Physiol Scand, 162(3), pp. 401-9. 
Reifer, H. and Sobel, E. (1998) 'Contrasts in clinical presentation and genetic 
transmission of myotonic dystrophy', J Am Podiatr Med Assoc, 88(7), pp. 313-
22. 
Reilich, P., Krause, S., Schramm, N., Klutzny, U., Bulst, S., Zehetmayer, B., 
Schneiderat, P., Walter, M.C., Schoser, B. and Lochmuller, H. (2011) 'A novel 
mutation in the myotilin gene (MYOT) causes a severe form of limb girdle 
muscular dystrophy 1A (LGMD1A)', J Neurol, 258(8), pp. 1437-44. 
Rembold, M., Loosli, F., Adams, R.J. and Wittbrodt, J. (2006) 'Individual cell 
migration serves as the driving force for optic vesicle evagination', Science, 
313(5790), pp. 1130-4. 
Remy, S., Tesson, L., Menoret, S., Usal, C., Scharenberg, A.M. and Anegon, I. 
(2010) 'Zinc-finger nucleases: a powerful tool for genetic engineering of animals', 
Transgenic Res, 19(3), pp. 363-71. 
Rentschler, S., Linn, H., Deininger, K., Bedford, M.T., Espanel, X. and Sudol, M. 
(1999) 'The WW domain of dystrophin requires EF-hands region to interact with 
beta-dystroglycan', Biol Chem, 380(4), pp. 431-42. 
Ribeiro, I., Yuan, L., Tanentzapf, G., Dowling, J.J. and Kiger, A. (2011) 
'Phosphoinositide regulation of integrin trafficking required for muscle 
attachment and maintenance', PLoS Genet, 7(2), p. e1001295. 
Richards, J.B. and Hemming, F.W. (1972) 'The transfer of mannose from 
guanosine diphosphate mannose to dolichol phosphate and protein by pig liver 
endoplasmic reticulum', Biochem J, 130(1), pp. 77-93. 
Ridge, J.C., Tidball, J.G., Ahl, K., Law, D.J. and Rickoll, W.L. (1994) 
'Modifications in myotendinous junction surface morphology in dystrophin-
deficient mouse muscle', Exp Mol Pathol, 61(1), pp. 58-68. 
222 
 
Rocha, C.T. and Hoffman, E.P. (2010) 'Limb-girdle and congenital muscular 
dystrophies: current diagnostics, management, and emerging technologies', 
Curr Neurol Neurosci Rep, 10(4), pp. 267-76. 
Rojek, J.M., Spiropoulou, C.F., Campbell, K.P. and Kunz, S. (2007) 'Old World 
and clade C New World arenaviruses mimic the molecular mechanism of 
receptor recognition used by alpha-dystroglycan's host-derived ligands', J Virol, 
81(11), pp. 5685-95. 
Roscioli, T., Kamsteeg, E.J., Buysse, K., Maystadt, I., van Reeuwijk, J., van den 
Elzen, C., van Beusekom, E., Riemersma, M., Pfundt, R., Vissers, L.E., 
Schraders, M., Altunoglu, U., Buckley, M.F., Brunner, H.G., Grisart, B., Zhou, H., 
Veltman, J.A., Gilissen, C., Mancini, G.M., Delree, P., Willemsen, M.A., 
Ramadza, D.P., Chitayat, D., Bennett, C., Sheridan, E., Peeters, E.A., Tan-
Sindhunata, G.M., de Die-Smulders, C.E., Devriendt, K., Kayserili, H., El-
Hashash, O.A., Stemple, D.L., Lefeber, D.J., Lin, Y.Y. and van Bokhoven, H. 
(2012) 'Mutations in ISPD cause Walker-Warburg syndrome and defective 
glycosylation of alpha-dystroglycan', Nat Genet. 
Rosen, J.N., Sweeney, M.F. and Mably, J.D. (2009) 'Microinjection of zebrafish 
embryos to analyze gene function', J Vis Exp, (25). 
Rowe, R.W. (1981) 'Morphology of perimysial and endomysial connective tissue 
in skeletal muscle', Tissue Cell, 13(4), pp. 681-90. 
Rubenstein, J.L. and Beachy, P.A. (1998) 'Patterning of the embryonic 
forebrain', Curr Opin Neurobiol, 8(1), pp. 18-26. 
Ruparelia, A.A., Zhao, M., Currie, P.D. and Bryson-Richardson, R.J. (2012) 
'Characterization and investigation of zebrafish models of filamin-related 
myofibrillar myopathy', Hum Mol Genet. [Epub ahead of print]. 
Rush, J.S. and Waechter, C.J. (1995) 'Transmembrane movement of a water-
soluble analogue of mannosylphosphoryldolichol is mediated by an 
endoplasmic reticulum protein', J Cell Biol, 130(3), pp. 529-36. 
Rybakova, I.N., Amann, K.J. and Ervasti, J.M. (1996) 'A new model for the 
interaction of dystrophin with F-actin', J Cell Biol, 135(3), pp. 661-72. 
Sadoulet-Puccio, H.M., Rajala, M. and Kunkel, L.M. (1997) 'Dystrobrevin and 
dystrophin: an interaction through coiled-coil motifs', Proc Natl Acad Sci U S A, 
94(23), pp. 12413-8. 
Saint-Amant, L., Sprague, S.M., Hirata, H., Li, Q., Cui, W.W., Zhou, W., Poudou, 
O., Hume, R.I. and Kuwada, J.Y. (2008) 'The zebrafish ennui behavioral 
mutation disrupts acetylcholine receptor localization and motor axon stability', 
Dev Neurobiol, 68(1), pp. 45-61. 
223 
 
Salamat, M., Gotz, W., Horster, A., Janotte, B. and Herken, R. (1993) 
'Ultrastructural localization of carbohydrates in Reichert's membrane of the 
mouse', Cell Tissue Res, 272(2), pp. 375-81. 
Salamat, M., Miosge, N. and Herken, R. (1995) 'Development of Reichert's 
membrane in the early mouse embryo', Anat Embryol (Berl), 192(3), pp. 275-81. 
Sander, J.D., Dahlborg, E.J., Goodwin, M.J., Cade, L., Zhang, F., Cifuentes, D., 
Curtin, S.J., Blackburn, J.S., Thibodeau-Beganny, S., Qi, Y., Pierick, C.J., 
Hoffman, E., Maeder, M.L., Khayter, C., Reyon, D., Dobbs, D., Langenau, D.M., 
Stupar, R.M., Giraldez, A.J., Voytas, D.F., Peterson, R.T., Yeh, J.R. and Joung, 
J.K. (2010) 'Selection-free zinc-finger-nuclease engineering by context-
dependent assembly (CoDA)', Nat Methods, 8(1), pp. 67-9. 
Sasaki, T., Yamada, H., Matsumura, K., Shimizu, T., Kobata, A. and Endo, T. 
(1998) 'Detection of O-mannosyl glycans in rabbit skeletal muscle alpha-
dystroglycan', Biochim Biophys Acta, 1425(3), pp. 599-606. 
Sato, S., Omori, Y., Katoh, K., Kondo, M., Kanagawa, M., Miyata, K., Funabiki, 
K., Koyasu, T., Kajimura, N., Miyoshi, T., Sawai, H., Kobayashi, K., Tani, A., 
Toda, T., Usukura, J., Tano, Y., Fujikado, T. and Furukawa, T. (2008) 
'Pikachurin, a dystroglycan ligand, is essential for photoreceptor ribbon synapse 
formation', Nat Neurosci, 11(8), pp. 923-31. 
Satz, J.S., Barresi, R., Durbeej, M., Willer, T., Turner, A., Moore, S.A. and 
Campbell, K.P. (2008) 'Brain and eye malformations resembling Walker-
Warburg syndrome are recapitulated in mice by dystroglycan deletion in the 
epiblast', J Neurosci, 28(42), pp. 10567-75. 
Satz, J.S., Philp, A.R., Nguyen, H., Kusano, H., Lee, J., Turk, R., Riker, M.J., 
Hernandez, J., Weiss, R.M., Anderson, M.G., Mullins, R.F., Moore, S.A., Stone, 
E.M. and Campbell, K.P. (2009) 'Visual impairment in the absence of 
dystroglycan', J Neurosci, 29(42), pp. 13136-46. 
Saude, L., Woolley, K., Martin, P., Driever, W. and Stemple, D.L. (2000) 'Axis-
inducing activities and cell fates of the zebrafish organizer', Development, 
127(16), pp. 3407-17. 
Schier, A.F. (2001) 'Axis formation and patterning in zebrafish', Curr Opin Genet 
Dev, 11(4), pp. 393-404. 
Schier, A.F. and Talbot, W.S. (2005) 'Molecular genetics of axis formation in 
zebrafish', Annu Rev Genet, 39, pp. 561-613. 
Schwander, M., Shirasaki, R., Pfaff, S.L. and Muller, U. (2004) 'Beta1 integrins 
in muscle, but not in motor neurons, are required for skeletal muscle 
innervation', J Neurosci, 24(37), pp. 8181-91. 
224 
 
Schwarz, F. and Aebi, M. (2011) 'Mechanisms and principles of N-linked protein 
glycosylation', Curr Opin Struct Biol, 21(5), pp. 576-82. 
Sciandra, F., Bozzi, M., Bianchi, M., Pavoni, E., Giardina, B. and Brancaccio, A. 
(2003) 'Dystroglycan and muscular dystrophies related to the dystrophin-
glycoprotein complex', Ann Ist Super Sanita, 39(2), pp. 173-81. 
Sejerson, T. and Bushby, K. (2009) 'Standards of care for Duchenne muscular 
dystrophy: brief TREAT-NMD recommendations', Adv Exp Med Biol, 652, pp. 
13-21. 
Semina, E.V., Bosenko, D.V., Zinkevich, N.C., Soules, K.A., Hyde, D.R., Vihtelic, 
T.S., Willer, G.B., Gregg, R.G. and Link, B.A. (2006) 'Mutations in laminin alpha 
1 result in complex, lens-independent ocular phenotypes in zebrafish', Dev Biol, 
299(1), pp. 63-77. 
Semmola, S. (1834) Filiatre-Sebezio Giornale delle scienze mediche. ch. 8, pp. 
58-68. 
Senderek, J., Muller, J.S., Dusl, M., Strom, T.M., Guergueltcheva, V., Diepolder, 
I., Laval, S.H., Maxwell, S., Cossins, J., Krause, S., Muelas, N., Vilchez, J.J., 
Colomer, J., Mallebrera, C.J., Nascimento, A., Nafissi, S., Kariminejad, A., 
Nilipour, Y., Bozorgmehr, B., Najmabadi, H., Rodolico, C., Sieb, J.P., Steinlein, 
O.K., Schlotter, B., Schoser, B., Kirschner, J., Herrmann, R., Voit, T., Oldfors, A., 
Lindbergh, C., Urtizberea, A., von der Hagen, M., Hubner, A., Palace, J., 
Bushby, K., Straub, V., Beeson, D., Abicht, A. and Lochmuller, H. (2010) 
'Hexosamine biosynthetic pathway mutations cause neuromuscular 
transmission defect', Am J Hum Genet, 88(2), pp. 162-72. 
Sertie, A.L., Sossi, V., Camargo, A.A., Zatz, M., Brahe, C. and Passos-Bueno, 
M.R. (2000) 'Collagen XVIII, containing an endogenous inhibitor of 
angiogenesis and tumor growth, plays a critical role in the maintenance of 
retinal structure and in neural tube closure (Knobloch syndrome)', Hum Mol 
Genet, 9(13), pp. 2051-8. 
Sewry, C.A., Philpot, J., Mahony, D., Wilson, L.A., Muntoni, F. and Dubowitz, V. 
(1995) 'Expression of laminin subunits in congenital muscular dystrophy', 
Neuromuscul Disord, 5(4), pp. 307-16. 
Sharma, A., Yu, C., Leung, C., Trane, A., Lau, M., Utokaparch, S., Shaheen, F., 
Sheibani, N. and Bernatchez, P. (2010) 'A new role for the muscle repair protein 
dysferlin in endothelial cell adhesion and angiogenesis', Arterioscler Thromb 
Vasc Biol, 30(11), pp. 2196-204. 
Shih, J. and Fraser, S.E. (1996) 'Characterizing the zebrafish organizer: 
microsurgical analysis at the early-shield stage', Development, 122(4), pp. 
1313-22. 
225 
 
Smalheiser, N. and Schwartz, N. (1987) 'Cranin: A laminin-binding protein of 
cell membranes', Cell Biology, 84, pp. 6457-6461. 
Smith, K.K. and Strickland, S. (1981) 'Structural components and characteristics 
of Reichert's membrane, an extra-embryonic basement membrane', J Biol 
Chem, 256(9), pp. 4654-61. 
Snobl, D., Binaghi, L.E. and Zenker, W. (1998) 'Microarchitecture and 
innervation of the human latissimus dorsi muscle', J Reconstr Microsurg, 14(3), 
pp. 171-7. 
Solnica-Krezel, L. (2005) 'Conserved patterns of cell movements during 
vertebrate gastrulation', Curr Biol, 15(6), pp. R213-28. 
Soules, K.A. and Link, B.A. (2005) 'Morphogenesis of the anterior segment in 
the zebrafish eye', BMC Dev Biol, 5, p. 12. 
Sparks, S.E. and Escolar, D.M. (2011) 'Congenital muscular dystrophies', 
Handb Clin Neurol, 101, pp. 47-79. 
Spence, H.J., Dhillon, A.S., James, M. and Winder, S.J. (2004) 'Dystroglycan, a 
scaffold for the ERK-MAP kinase cascade', EMBO Rep, 5(5), pp. 484-9. 
Spiro, R.G. (1973) 'Glycoproteins', Adv Protein Chem, 27, pp. 349-467. 
Spiro, R.G. (2002) 'Protein glycosylation: nature, distribution, enzymatic 
formation, and disease implications of glycopeptide bonds', Glycobiology, 12(4), 
pp. 43R-56R. 
Stalnaker, S.H., Stuart, R. and Wells, L. (2011) 'Mammalian O-mannosylation: 
unsolved questions of structure/function', Curr Opin Struct Biol, 21(5), pp. 603-9. 
Steffen, L.S., Guyon, J.R., Vogel, E.D., Howell, M.H., Zhou, Y., Weber, G.J., 
Zon, L.I. and Kunkel, L.M. (2007) 'The zebrafish runzel muscular dystrophy is 
linked to the titin gene', Dev Biol, 309(2), pp. 180-92. 
Stemple, D.L. (2005) 'Structure and function of the notochord: an essential 
organ for chordate development', Development, 132(11), pp. 2503-12. 
Stemple, D.L. (2011) ZMP. Available at: 
http://www.sanger.ac.uk/Projects/D_rerio/zmp/ (Accessed: 051211). 
Stemple, D.L., Solnica-Krezel, L., Zwartkruis, F., Neuhauss, S.C., Schier, A.F., 
Malicki, J., Stainier, D.Y., Abdelilah, S., Rangini, Z., Mountcastle-Shah, E. and 
Driever, W. (1996) 'Mutations affecting development of the notochord in 
zebrafish', Development, 123, pp. 117-28. 
226 
 
Stickney, H.L., Barresi, M.J. and Devoto, S.H. (2000) 'Somite development in 
zebrafish', Dev Dyn, 219(3), pp. 287-303. 
Straub, V. and Campbell, K.P. (1997) 'Muscular dystrophies and the dystrophin-
glycoprotein complex', Curr Opin Neurol, 10(2), pp. 168-75. 
Straub, V., Rafael, J.A., Chamberlain, J.S. and Campbell, K.P. (1997) 'Animal 
models for muscular dystrophy show different patterns of sarcolemmal 
disruption', J Cell Biol, 139(2), pp. 375-85. 
Strauss, O. (1995) 'The Retinal Pigment Epithelium'. ch. 3, [available online: 
http://www.ncbi.nlm.nih.gov/books/NBK54392/, accesed 04/01/12]   
Sugita, S., Saito, F., Tang, J., Satz, J., Campbell, K. and Sudhof, T.C. (2001) 'A 
stoichiometric complex of neurexins and dystroglycan in brain', J Cell Biol, 
154(2), pp. 435-45. 
Sugiyama, J., Bowen, D.C. and Hall, Z.W. (1994) 'Dystroglycan binds nerve and 
muscle agrin', Neuron, 13(1), pp. 103-15. 
Summerton, J. (1999) 'Morpholino antisense oligomers: the case for an RNase 
H-independent structural type', Biochim Biophys Acta, 1489(1), pp. 141-58. 
Summerton, J. and Weller, D. (1997) 'Morpholino antisense oligomers: design, 
preparation, and properties', Antisense Nucleic Acid Drug Dev, 7(3), pp. 187-95. 
Summerton, J.E. (2007) 'Morpholino, siRNA, and S-DNA compared: impact of 
structure and mechanism of action on off-target effects and sequence 
specificity', Curr Top Med Chem, 7(7), pp. 651-60. 
Sumoy, L., Keasey, J.B., Dittman, T.D. and Kimelman, D. (1997) 'A role for 
notochord in axial vascular development revealed by analysis of phenotype and 
the expression of VEGR-2 in zebrafish flh and ntl mutant embryos', Mech Dev, 
63(1), pp. 15-27. 
Sunada, Y., Bernier, S.M., Kozak, C.A., Yamada, Y. and Campbell, K.P. (1994) 
'Deficiency of merosin in dystrophic dy mice and genetic linkage of laminin M 
chain gene to dy locus', J Biol Chem, 269(19), pp. 13729-32. 
Sveen, M.L., Schwartz, M. and Vissing, J. (2006) 'High prevalence and 
phenotype-genotype correlations of limb girdle muscular dystrophy type 2I in 
Denmark', Ann Neurol, 59(5), pp. 808-15. 
Svoboda, J., Hejnar, J., Geryk, J., Elleder, D. and Vernerova, Z. (2000) 
'Retroviruses in foreign species and the problem of provirus silencing', Gene, 
261(1), pp. 181-8. 
227 
 
Sztal, T.E., Sonntag, C., Hall, T.E. and Currie, P.D. (2012) 'Epistatic dissection 
of laminin-receptor interactions in dystrophic zebrafish muscle', Hum Mol Genet. 
[Epub ahead of print].  
Takada, K., Nakamura, H. and Takashima, S. (1988) 'Cortical dysplasia in 
Fukuyama congenital muscular dystrophy (FCMD): a Golgi and 
angioarchitectonic analysis', Acta Neuropathologica, 76(2), pp. 170-8. 
Takeda, S., Kondo, M., Sasaki, J., Kurahashi, H., Kano, H., Arai, K., Misaki, K., 
Fukui, T., Kobayashi, K., Tachikawa, M., Imamura, M., Nakamura, Y., Shimizu, 
T., Murakami, T., Sunada, Y., Fujikado, T., Matsumura, K., Terashima, T. and 
Toda, T. (2003) 'Fukutin is required for maintenance of muscle integrity, cortical 
histiogenesis and normal eye development', Hum Mol Genet, 12(12), pp. 1449-
59. 
Takke, C. and Campos-Ortega, J.A. (1999) 'her1, a zebrafish pair-rule like gene, 
acts downstream of notch signalling to control somite development', 
Development, 126(13), pp. 3005-14. 
Tallquist, M.D. and Soriano, P. (2000) 'Epiblast-restricted Cre expression in 
MORE mice: a tool to distinguish embryonic vs. extra-embryonic gene function', 
Genesis, 26(2), pp. 113-5. 
Tanabe, Y., Esaki, K. and Nomura, T. (1986) 'Skeletal muscle pathology in X 
chromosome-linked muscular dystrophy (mdx) mouse', Acta Neuropathol, 69(1-
2), pp. 91-5. 
Taniguchi-Ikeda, M., Kobayashi, K., Kanagawa, M., Yu, C.C., Mori, K., Oda, T., 
Kuga, A., Kurahashi, H., Akman, H.O., DiMauro, S., Kaji, R., Yokota, T., Takeda, 
S. and Toda, T. (2011) 'Pathogenic exon-trapping by SVA retrotransposon and 
rescue in Fukuyama muscular dystrophy', Nature, 478(7367), pp. 127-31. 
Tawil, R. and Van Der Maarel, S.M. (2006) 'Facioscapulohumeral muscular 
dystrophy', Muscle Nerve, 34(1), pp. 1-15. 
Thanh, L.T., Nguyen, T.M., Helliwell, T.R. and Morris, G.E. (1995) 
'Characterization of revertant muscle fibers in Duchenne muscular dystrophy, 
using exon-specific monoclonal antibodies against dystrophin', Am J Hum 
Genet, 56(3), pp. 725-31. 
Thomas, G.D., Shaul, P.W., Yuhanna, I.S., Froehner, S.C. and Adams, M.E. 
(2003) 'Vasomodulation by skeletal muscle-derived nitric oxide requires alpha-
syntrophin-mediated sarcolemmal localization of neuronal Nitric oxide synthase', 
Circ Res, 92(5), pp. 554-60. 
Thornhill, P., Basset, D., Lochmüller, H., Bushby, K. and Straub, V. (2008) 
'Developmental defects in a zebrafish model for muscular dystrophies 
associated with the loss of fukutin-related protein (FKRP)', Brain, 131, pp. 1551-
1561. 
228 
 
Timpl, R., Tisi, D., Talts, J.F., Andac, Z., Sasaki, T. and Hohenester, E. (2000) 
'Structure and function of laminin LG modules', Matrix Biol, 19(4), pp. 309-17. 
Tisi, D., Talts, J.F., Timpl, R. and Hohenester, E. (2000) 'Structure of the C-
terminal laminin G-like domain pair of the laminin alpha2 chain harbouring 
binding sites for alpha-dystroglycan and heparin', EMBO J, 19(7), pp. 1432-40. 
Toda, T. (2009) '[Pathomechanism and therapeutic strategy of Fukuyama 
congenital muscular dystrophy and related disorders]', Rinsho Shinkeigaku, 
49(11), pp. 859-62. 
Toda, T. and Kobayashi, K. (1999) 'Fukuyama-type congenital muscular 
dystrophy: the first human disease to be caused by an ancient retrotransposal 
integration', J Mol Med (Berl), 77(12), pp. 816-23. 
Toda, T., Segawa, M., Nomura, Y., Nonaka, I., Masuda, K., Ishihara, T., Sakai, 
M., Tomita, I., Origuchi, Y., Suzuki, M. and et al. (1993) 'Localization of a gene 
for Fukuyama type congenital muscular dystrophy to chromosome 9q31-33', 
Nat Genet, 5(3), pp. 283-6. 
Trotter, J.A. (1993) 'Functional morphology of force transmission in skeletal 
muscle. A brief review', Acta Anat (Basel), 146(4), pp. 205-22. 
Trotter, J.A. and Purslow, P.P. (1992) 'Functional morphology of the 
endomysium in series fibered muscles', J Morphol, 212(2), pp. 109-22. 
Tuckwell, D.S., Weston, S.A. and Humphries, M.J. (1993) 'Integrins: a review of 
their structure and mechanisms of ligand binding', Symp Soc Exp Biol, 47, pp. 
107-36. 
Vachon, P.H., Xu, H., Liu, L., Loechel, F., Hayashi, Y., Arahata, K., Reed, J.C., 
Wewer, U.M. and Engvall, E. (1997) 'Integrins (alpha7beta1) in muscle function 
and survival. Disrupted expression in merosin-deficient congenital muscular 
dystrophy', J Clin Invest, 100(7), pp. 1870-81. 
Van Agtmael, T., Schlotzer-Schrehardt, U., McKie, L., Brownstein, D.G., Lee, 
A.W., Cross, S.H., Sado, Y., Mullins, J.J., Poschl, E. and Jackson, I.J. (2005) 
'Dominant mutations of Col4a1 result in basement membrane defects which 
lead to anterior segment dysgenesis and glomerulopathy', Hum Mol Genet, 
14(21), pp. 3161-8. 
van der Flier, A. and Sonnenberg, A. (2001) 'Function and interactions of 
integrins', Cell Tissue Res, 305(3), pp. 285-98. 
van Reeuwijk, J., Janssen, M., van den Elzen, C., Beltran-Valero de Bernabe, 
D., Sabatelli, P., Merlini, L., Boon, M., Scheffer, H., Brockington, M., Muntoni, F., 
Huynen, M.A., Verrips, A., Walsh, C.A., Barth, P.G., Brunner, H.G. and van 
Bokhoven, H. (2005) 'POMT2 mutations cause alpha-dystroglycan 
229 
 
hypoglycosylation and Walker-Warburg syndrome', J Med Genet, 42(12), pp. 
907-12. 
Van Reeuwijk, J., Olderode-Berends, M.J., Van den Elzen, C., Brouwer, O.F., 
Roscioli, T., Van Pampus, M.G., Scheffer, H., Brunner, H.G., Van Bokhoven, H. 
and Hol, F.A. (2010) 'A homozygous FKRP start codon mutation is associated 
with Walker-Warburg syndrome, the severe end of the clinical spectrum', Clin 
Genet, 78(3), pp. 275-81. 
Verma, M., Asakura, Y., Hirai, H., Watanabe, S., Tastad, C., Fong, G.H., Ema, 
M., Call, J.A., Lowe, D.A. and Asakura, A. (2010) 'Flt-1 haploinsufficiency 
ameliorates muscular dystrophy phenotype by developmentally increased 
vasculature in mdx mice', Hum Mol Genet, 19(21), pp. 4145-59. 
Vuillaumier-Barrot, S., Quijano-Roy, S., Bouchet-Seraphin, C., Maugenre, S., 
Peudenier, S., Van den Bergh, P., Marcorelles, P., Avila-Smirnow, D., Chelbi, 
M., Romero, N.B., Carlier, R.Y., Estournet, B., Guicheney, P. and Seta, N. 
(2009) 'Four Caucasian patients with mutations in the fukutin gene and variable 
clinical phenotype', Neuromuscul Disord, 19(3), pp. 182-8. 
Walsh, M.P. (1994) 'Calmodulin and the regulation of smooth muscle 
contraction', Mol Cell Biochem, 135(1), pp. 21-41. 
Walton, J.N. and Nattrass, F.J. (1954) 'On the classification, natural history and 
treatment of the myopathies', Brain, 77(2), pp. 169-231. 
Wang, M.X., Murrell, D.F., Szabo, C., Warren, R.F., Sarris, M. and Murrell, G.A. 
(2001) 'Nitric oxide in skeletal muscle: inhibition of nitric oxide synthase inhibits 
walking speed in rats', Nitric Oxide, 5(3), pp. 219-32. 
Welser, J.V., Rooney, J.E., Cohen, N.C., Gurpur, P.B., Singer, C.A., Evans, 
R.A., Haines, B.A. and Burkin, D.J. (2009) 'Myotendinous junction defects and 
reduced force transmission in mice that lack alpha7 integrin and utrophin', Am J 
Pathol, 175(4), pp. 1545-54. 
Westerfield, M. (2000) The zebrafish book. A guide for the laboratory use of 
zebrafish (Danio rerio). Eugene: Univ. of Oregon Press. 
Willer, T., Lee, H., Lommel, M., Yoshida-Moriguchi, T., de Bernabe, D.B., 
Venzke, D., Cirak, S., Schachter, H., Vajsar, J., Voit, T., Muntoni, F., Loder, 
A.S., Dobyns, W.B., Winder, T.L., Strahl, S., Mathews, K.D., Nelson, S.F., 
Moore, S.A. and Campbell, K.P. (2012) 'ISPD loss-of-function mutations disrupt 
dystroglycan O-mannosylation and cause Walker-Warburg syndrome', Nat 
Genet. 44(5), pp. 575-80. 
Willer, T., Prados, B., Falcon-Perez, J.M., Renner-Muller, I., Przemeck, G.K., 
Lommel, M., Coloma, A., Valero, M.C., de Angelis, M.H., Tanner, W., Wolf, E., 
Strahl, S. and Cruces, J. (2004) 'Targeted disruption of the Walker-Warburg 
230 
 
syndrome gene Pomt1 in mouse results in embryonic lethality', Proc Natl Acad 
Sci U S A, 101(39), pp. 14126-31. 
Williamson, R.A., Henry, M.D., Daniels, K.J., Hrstka, R.F., Lee, J.C., Sunada, Y., 
Ibraghimov-Beskrovnaya, O. and Campbell, K.P. (1997) 'Dystroglycan is 
essential for early embryonic development: disruption of Reichert's membrane 
in Dag1-null mice', Hum Mol Genet, 6(6), pp. 831-41. 
Wilson, S.W. and Rubenstein, J.L. (2000) 'Induction and dorsoventral patterning 
of the telencephalon', Neuron, 28(3), pp. 641-51. 
Winder, S.J., Hemmings, L., Maciver, S.K., Bolton, S.J., Tinsley, J.M., Davies, 
K.E., Critchley, D.R. and Kendrick-Jones, J. (1995) 'Utrophin actin binding 
domain: analysis of actin binding and cellular targeting', J Cell Sci, 108 ( Pt 1), 
pp. 63-71. 
Winder, S.J., Lipscomb, L., Angela Parkin, C. and Juusola, M. (2011) 'The 
proteasomal inhibitor MG132 prevents muscular dystrophy in zebrafish', PLoS 
Curr, 3, p. RRN1286. 
Wood, A.J., Lo, T.W., Zeitler, B., Pickle, C.S., Ralston, E.J., Lee, A.H., Amora, 
R., Miller, J.C., Leung, E., Meng, X., Zhang, L., Rebar, E.J., Gregory, P.D., 
Urnov, F.D. and Meyer, B.J. (2011a) 'Targeted genome editing across species 
using ZFNs and TALENs', Science, 333(6040), p. 307. 
Wood, A.J., Muller, J.S., Jepson, C.D., Laval, S.H., Lochmuller, H., Bushby, K., 
Barresi, R. and Straub, V. (2011b) 'Abnormal vascular development in zebrafish 
models for fukutin and FKRP deficiency', Hum Mol Genet, 20(24), pp. 4879-90. 
Xie, L., Palmsten, K., MacDonald, B., Kieran, M.W., Potenta, S., Vong, S. and 
Kalluri, R. (2008) 'Basement membrane derived fibulin-1 and fibulin-5 function 
as angiogenesis inhibitors and suppress tumor growth', Exp Biol Med 
(Maywood), 233(2), pp. 155-62. 
Xu, H., Christmas, P., Wu, X.R., Wewer, U.M. and Engvall, E. (1994) 'Defective 
muscle basement membrane and lack of M-laminin in the dystrophic dy/dy 
mouse', Proc Natl Acad Sci U S A, 91(12), pp. 5572-6. 
Yatsenko, A.S., Gray, E.E., Shcherbata, H.R., Patterson, L.B., Sood, V.D., 
Kucherenko, M.M., Baker, D. and Ruohola-Baker, H. (2007) 'A putative Src 
homology 3 domain binding motif but not the C-terminal dystrophin WW domain 
binding motif is required for dystroglycan function in cellular polarity in 
Drosophila', J Biol Chem, 282(20), pp. 15159-69. 
Ylikarppa, R., Eklund, L., Sormunen, R., Kontiola, A.I., Utriainen, A., Maatta, M., 
Fukai, N., Olsen, B.R. and Pihlajaniemi, T. (2003) 'Lack of type XVIII collagen 
results in anterior ocular defects', FASEB J, 17(15), pp. 2257-9. 
231 
 
Yokota, T., Lu, Q.L., Morgan, J.E., Davies, K.E., Fisher, R., Takeda, S. and 
Partridge, T.A. (2006) 'Expansion of revertant fibers in dystrophic mdx muscles 
reflects activity of muscle precursor cells and serves as an index of muscle 
regeneration', J Cell Sci, 119(Pt 13), pp. 2679-87. 
York, J. and Nunberg, J.H. (2006) 'Role of the stable signal peptide of Junin 
arenavirus envelope glycoprotein in pH-dependent membrane fusion', J Virol, 
80(15), pp. 7775-80. 
Yoshida-Moriguchi, T., Yu, L., Stalnaker, S.H., Davis, S., Kunz, S., Madson, M., 
Oldstone, M.B., Schachter, H., Wells, L. and Campbell, K.P. (2010) 'O-
mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding', 
Science, 327(5961), pp. 88-92. 
Yoshioka, M. and Kuroki, S. (1994) 'Clinical spectrum and genetic studies of 
Fukuyama congenital muscular dystrophy', Am J Med Genet, 53(3), pp. 245-50. 
Young, B., Lowe, J.S., Stevens, A. and Heath, J.W. (eds.) (2006) Wheater's 
Functional Histology. 5 edn. Elsevier. 
Yurchenco, P.D. and Cheng, Y.S. (1994) 'Laminin self-assembly: a three-arm 
interaction hypothesis for the formation of a network in basement membranes', 
Contrib Nephrol, 107, pp. 47-56. 
Yurchenco, P.D. and Patton, B.L. (2009) 'Developmental and pathogenic 
mechanisms of basement membrane assembly', Curr Pharm Des, 15(12), pp. 
1277-94. 
Zenker, M., Aigner, T., Wendler, O., Tralau, T., Muntefering, H., Fenski, R., Pitz, 
S., Schumacher, V., Royer-Pokora, B., Wuhl, E., Cochat, P., Bouvier, R., Kraus, 
C., Mark, K., Madlon, H., Dotsch, J., Rascher, W., Maruniak-Chudek, I., Lennert, 
T., Neumann, L.M. and Reis, A. (2004) 'Human laminin beta2 deficiency causes 
congenital nephrosis with mesangial sclerosis and distinct eye abnormalities', 
Hum Mol Genet, 13(21), pp. 2625-32. 
Zenker, M., Pierson, M., Jonveaux, P. and Reis, A. (2005) 'Demonstration of 
two novel LAMB2 mutations in the original Pierson syndrome family reported 42 
years ago', Am J Med Genet A, 138(1), pp. 73-4. 
Zhang, J.R., Idanpaan-Heikkila, I., Fischer, W. and Tuomanen, E.I. (1999) 
'Pneumococcal licD2 gene is involved in phosphorylcholine metabolism', Mol 
Microbiol, 31(5), pp. 1477-88. 
Zhang, W., Betel, D. and Schachter, H. (2002) 'Cloning and expression of a 
novel UDP-GlcNAc:alpha-D-mannoside beta1,2-N-
acetylglucosaminyltransferase homologous to UDP-GlcNAc:alpha-3-D-
mannoside beta1,2-N-acetylglucosaminyltransferase I', Biochem J, 361(Pt 1), 
pp. 153-62. 
232 
 
Zhang, Z., Zhang, P. and Hu, H. (2011) 'LARGE expression augments the 
glycosylation of glycoproteins in addition to alpha-dystroglycan conferring 
laminin binding', PLoS One, 6(4), p. e19080. 
  
233 
 
Publications Arising From this Work 
Wood, A.J., Muller, J.S., Jepson, C.D., Laval, S.H., Lochmuller, H., Bushby, K., 
Barresi, R. and Straub, V. (2011b) 'Abnormal vascular development in zebrafish 
models for fukutin and FKRP deficiency', Hum Mol Genet, 20(24), pp. 4879-90. 
 
